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Abstract 
Respiratory failure, due to infection and concomitant inflammation is the major cause of 
morbidity and mortality in people suffering from the genetic disorder, cystic fibrosis (CF). 
Consequently, the CF Foundation currently estimates that patients with CF have a median 
predicted life expectancy of only 41.1 years. Understanding the relationship between the 
complex and diverse bacterial community present within the lower respiratory tract and 
patient outcomes has therefore become a top priority. Through the use of next generation 
sequencing technologies (Roche 454 and Illumina MiSeq) and ecological statistics and 
modelling, the complex relationships between the bacterial community within the CF lung 
and host related clinical factors were investigated.  
By first establishing guideline methodologies for the reduction of bias in the collection, 
storage and treatment of respiratory samples, this thesis aimed to use large scale spatial 
and longitudinal studies to investigate key relationships between the bacterial community 
and clinical factors. 
It has been well established that a complex and diverse bacterial community exists within the 
CF lung. Spatial sampling revealed key relationships between the bacterial community and 
other diagnostic parameters including, FEV1, gender, and clinic location.   
Longitudinal sampling aimed principally to investigate CF pulmonary exacerbations (CFPE), 
implicated in the progressive loss of lung function associated with CF lung disease. Over the 
course of a CFPE the common bacterial taxa show resistance to perturbations while the rare 
taxa show resilience. Through this investigation, Veillonella parvula was identified as a 
potential bioindicator of CFPE, introducing the potential for a rapidly testable parameter for 
clinicians to identify a CFPE. This finding could provide one of the most important recent 
developments in CF therapy. 
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1.1 Introduction 
Lower respiratory tract infections (LRTI) are a considerable burden to human health and 
healthcare organisations. These infections represent a wide range of conditions, which 
include both, acute, short lived infections such as pneumonia and respiratory syncytial virus 
(RSV), as well as more chronic conditions, including chronic obstructive pulmonary disease 
(COPD) and the infections associated with cystic fibrosis (CF). The World Health 
Organisation (WHO) ranks LRTI as the leading cause of death due to infection (1) and as a 
result, the costs of LRTI economically, and in terms of morbidity and mortality, are immense 
(2).  
Pulmonary failure as a result of progressive lung damage from chronic infection and 
concomitant inflammation is the primary cause of morbidity and mortality in CF patients (3). 
Given the influence of infection on clinical outcome, it is by extension important to 
characterise the species in the CF airways.  In recent years advances in culture independent 
methodologies have revealed that CF lung infections are not, as previously considered, the 
result of a single or few pathogenic organism but rather comprise a complex and diverse 
microbial community (4). It is therefore important to fully understand the relationship between 
the microbial community and disease progression. To achieve this, changes in the bacterial 
community along with the factors that influence this, have to be investigated.  
The aim of this dissertation was to investigate how bacterial community composition within 
the lungs of individuals with CF relates to disease state. By employing a multidisciplinary 
approach combining medical and ecological methodologies, it was possible to investigate the 
relationship between the bacterial community and disease state. 
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1.2 The microbial world 
Microorganisms, including bacteria, archaea, viruses and fungi, are some of the most 
abundant forms of life on the planet. Current estimates suggest there are between 9.2-
31.7x1029 bacterial and archaeal cells (5), about 1031 viral particles (6). Due to the 
multicellular nature of some fungal species, no approximation of the numbers of individual 
fungal organisms exists however, it is estimated that there are around 1.5x106 species on 
Earth (7). Despite associations with health and disease, microorganisms are essential for 
maintaining the planet’s ability to sustain life through essential roles in biogeochemical 
cycling (8). Concentrations of oxygen, carbon dioxide and methane in the atmosphere are 
influenced by microbes, which regulate functions such as the global hydrogen, carbon, 
nitrogen, oxygen and sulphur cycles (8).  
Improvements to the microscope around 300 years ago opened up a new world of 
microorganisms. Robert Hooke, who published the first depiction of “microfungus” in 1665, 
stated “...in every little particle of its matter, we now behold almost as great a variety of 
Creatures, as we were able before to reckon up in the whole Universe itself.”(9). Later in 
1676, van Leeuwenhoek, using a microscope of his own design which magnified up to 250 
times, visualised and described the first bacterial cells (10).  
It was not till the 19th century that major leaps forward in the understanding of 
microorganisms and their role in disease were made. Robert Koch, considered by many to 
be the founder of modern medical bacteriology, laid out guidelines to establish the microbial 
cause of infectious diseases, known as Koch’s postulates (11, 12). These guidelines state 
that:  
1. The microorganism must be found in abundance in all organisms suffering from the 
disease, but should not be found in healthy organisms.  
2. The microorganism must be isolated from a diseased organism and grown in pure 
culture.  
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3. The cultured microorganism should cause disease when introduced into a healthy 
organism.  
4. The microorganism must be reisolated from the inoculated, disease experimental 
host and identified as being identical to the original specific causative agent.  
To do this he developed methods for the pure culture of bacterial species, which allowed 
microbes to be classified into taxonomic groups by appearance and nutritional requirements. 
These methodologies are still widely used in diagnostic microbiology, however, with 
advances in diagnostic methodologies modification to the original Koch’s postulates have 
been suggested by Fredricks and Relman (1996) (13); 
1. A nucleic acid sequence belonging to a putative pathogen should be present in most 
cases of an infectious disease. Microbial nucleic acids should be found preferentially 
in those organs or gross anatomic sites known to be diseased, and not in those 
organs that lack pathology.  
2. Fewer, or no copies of pathogen-associated nucleic acid sequences should occur in 
hosts or tissues without disease.  
3. With resolution of disease, the copy number of pathogen-associated nucleic acid 
sequences should decrease or become undetectable. With clinical relapse, the 
opposite should occur.  
4. When sequence detectiomn predates disease, or sequence copy number correlates 
with severity of disease or pathology, the sequence-disease association is more 
likely to be a causal relationship.  
5. The nature of the microorganism inferred from the available sequence should be 
consistent with the known biological characteristics of that group of organisms.  
6. Tissue-sequence correlates should be sought at the cellular level: efforts should be 
made to demonstrate specific in situ hybridisation of microbial sequence to areas of 
tissue pathology and to visible microorganisms or to areas where microorganisms 
are presumed to be located.  
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7. These sequence-based forms of evidence for microbial causation should be 
reproducible.  
While the modified poslulates are useful they do not account for established disease 
association, such as papillomavirus and cervical cancer or prion disease (13).  
DNA was first discovered in 1869 by Freidrich Miescher as a microscopic substance located 
in the nuclei of cells. Watson and Crick’s work on the structure and function of DNA (14) and 
the subsequent understanding of the role of DNA in an organisms evolutionary history (15), 
led to Carl Woese proposing the use of ribosomal RNA (rRNA) sequences to classify the 
taxonomy of microorganisms (16). The use of rRNA for the investigation of microbes began 
to reveal the enormous genetic diversity present in the microbial world (17). As work 
continued in this area it became apparent that only a fraction of the bacteria from the 
environment had been grown in the laboratory (18). 
The vast genetic diversity of microorganism is still being revealed. The Approved Lists of 
Bacterial Names (http://www.bacterio.net/-number.html) as of August 2013, included 10,599 
published species names, a more than 500% increase from those listed in 1980. This 
increase in recognised taxa is attributed largely to advances in DNA sequencing 
technologies.  
The 16S rRNA gene codes for part of the ribosomal RNA which makes up the 30S 
prokaryotic ribosomal subunit. The S in 16S refers to the Svedberg unit, which is a non-SI 
unit for sedimentation rate. The 16S rRNA gene is the most commonly sequenced section of 
the bacterial (or archaeal) genome used for identification (19). It is around 1,500 bp in length 
and contains highly conserved regions of the rRNA gene, present within different species of 
bacteria and archaea, and has nine hypervariable regions (20, 21). The conserved regions 
allow the design of universal primers that will amplify “all” bacterial or archaeal species while 
the hypervariable regions that can provide species-specific signature sequences important in 
allowing species identification (20, 21).  
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For similar reasons, the internal transcribed spacer (ITS) regions of the rRNA gene are the 
most widely used for the identification of fungal species (22). The ITS regions are lengths of 
non-functional RNA, interspersed along the conserved rRNA gene 
(18S_ITS1_5.8S_ITS2_28S). These areas have been widely sequenced due to their high 
copy number, allowing amplification from small quantities of DNA, and their high variability 
compared to other genetic regions of ribosomal DNA, thereby allowing identification of even 
closely related fungi to the species level (23).  
Unfortunately, no universal primer equivalent exists for the molecular identification of viruses 
due mainly to the variation in genetic material, single stranded DNA, single stranded RNA, 
double stranded DNA or double stranded RNA. Therefore the diagnosis of viral infections 
has relied heavily on the use of multiplex PCR, developed for panels of known viruses (24). 
In recent years however, methods have been developed using metagenomics, viral particle 
purification followed by shotgun sequencing, to identify unknown and previously 
uncharacterised viral particles from a variety of sample types (25).  
 
1.3 Microbial ecology 
Despite the diversity, ubiquity and importance of microorganisms, microbial communities are 
still poorly understood. The discipline of microbial ecology aims to address this by 
investigating microbes and their interactions with the environment. This is arguably one of 
the most important challenges for ecologists today, as understanding these communities 
may have major impacts on some of the fundamental trials facing society, such as the 
management of natural ecosystems and the mitigation of climate change (26).    
 Ecological theory is essential in order to interpret and predict interactions between species 
in a shared environment (27). However, the abundance, diversity and actions of 
microorganisms make it challenging to apply theories developed for the study of plants and 
animals to microbial communities. This is mainly due to the challenges associated with 
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assigning microorganisms to species. The traditional definition of species involves the ability 
to produce viable offspring from sexual reproduction, the biological species concept (28). 
Therefore, this cannot be applied to organisms that reproduce asexually, and hence in order 
to apply ecological theory to microorganisms it became important to determine a new 
method to differentiate between microbial species, this is explored further in Chapter 1.4.  
Despite some challenges in applying ecological theory to microbial populations, ecology has 
been able to generate predications of practical value for social, political and business needs. 
An example of this included the application of epidemiological models in predicting the 
spread of pathogens (29).  Quantitative theory has also been employed to optimise operating 
conditions for the efficienct running of wastewater treatment plants (30). On a wider scale it 
is hoped that quantitative information on microbial community structure and population 
dynamics will help assess the impact of climate change on microbial ecosystem processes.  
The challenge facing microbial ecologists is to match the appropriate theoretical approach to 
the organism, system, scale and question of interest. Until recent years lack of available 
information about the microbial community was a limiting factor of these studies, however 
the development of high throughput sequencing platforms has lead to greater use of 
ecological theories.   
In the inverstigation of human microbiota, each individual can be considered an island 
habitat, containing a diverse microbial assembalage (31). As a result ecological theories 
such as the community assembly theory (32) and metacommunity theory (33) can be 
utalised to help understand the community dynamica and variability in the human microbial 
community (31).  
1.4 Identifying bacteria 
Traditionally, microbes were clustered using phenotypic characteristics, subsequently these 
methods were soon overtaken by the use of genotypic approaches. Whole genome methods 
such as DNA-DNA hybridisation (DDH), currently considered the gold standard for species 
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identification, and average nucleotide identity (ANI), a more recent technique that uses a pair 
wise comparison of all shared sequences between two strains, are widely used. However, 
these methods are time consuming and technically demanding, compared to rapid and easy 
sequencing of signature sequences such as the 16S rRNA genes (34, 35). It is not surprising 
therefore that 16S rRNA amplicons are commonly sequenced to investigate the phylogeny 
and taxonomy of bacterial species (36). When comparing full length 16S rRNA gene 
sequencing, two microorganisms are defined as the same species if their ribosomal RNA 
gene sequences show over 98.7% similarity (37).  
The 98.7% cut off is considered appropriate for bacterial species identification as it accounts 
for a certain amount of within species variation. Variation is observed within nine 
hypervariable regions (V1-V9) found interspersed with conserved areas of the 16S rRNA 
gene. As sequencing of the entire 16S rRNA gene is not always practical, smaller regions of 
the gene may also be used for species identification. As such, the V1-V2 or the V3 to V5 
regions of the gene can be used for the taxonomic classification of bacterial sequences. By 
covering more than one hypervariable region, sensitivity, specificity and reliability are 
increased. Even so, due to reduction in the conserved areas being covered in these shorter 
reads, a 97% similarity cut off can be used as an approximation for species.  
Our ability to amplify and sequence rRNA genes is important in enabling species diversity to 
be estimated. This approach can have limitations; a study by Hong et al, 2009, using clone 
libraries of marine sediment, found that polymerase chain reaction (PCR) of 16S rRNA 
genes with ‘universal’ primers failed to amplify at least half of the microbial diversity 
regardless of taxonomic level (38). Further, Gans et al (2005) calculated that in order to 
estimate 80% of the diversity within a soil sample, containing an estimated billion bacterial 
cells, at least 1 million 16S rRNA gene reads would be required (39). Although, this may 
have previously seemed unachievable, recent technological improvements are now making 
such assessments feasible, as reviewed by Shendure and Aiden, 2012 (40). 
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DNA profiling methodologies such as Terminal Restriction Fragment Length Polymorphism 
(T-RFLP) have, and continue to, allow microbial ecologists to monitor changes in the 
structure and composition of microbial communities. T-RFLP is one of the most frequently 
used profiling techniques for culture independent studies of bacteria and fungi due to its 
speed, simplicity and reproducibility (41). T-RFLP is based on PCR amplification of a target 
gene with fluorescent labelled primers; amplicons are then digested with restriction enzymes 
to create fragments, which can be separated and detected using a DNA sequencer, thereby 
creating a profile of the community. These profiles are shown graphically as peaks, where 
the X-axis represents the fragment size and the Y-axis, the fluorescence intensity. Each 
peak is associated with a genetic variant within the original sample, while the intensity 
indicates the relative abundance within the community. The profiles created can be used to 
compare communities, by peak presence or absence, while clone libraries or peak resolving 
databases can be used to identify the species associated with each peak. This process was 
carried out by Rogers et al 2003, for the investigation of the bacterial community within the 
CF lung (42). Despite the frequency of use, T-RFLP has been criticised for its lack of 
resolution (43, 44) and therefore in recent years there has been a drive towards the use of 
high throughput or next generation sequencing technologies (45).  
The move towards next generation sequencing has not been without challenges, particularly 
as early technologies were hampered by the short read length produced, limiting taxonomic 
resolution (46). However, as technologies have improved so have read lengths, and 
therefore the use of next generation sequencing has increased exponentially. Technologies 
such as Roche 454 (47) or Illumina MiSeq (48) are now widely used and capable of 
producing hundreds of thousands of sequence reads per sample. These can be directly 
clustered into operational taxonomic units (OTU, an operational definition of species used in 
the analysis of DNA sequencing data) thereby allowing better estimates of community 
diversity to be calculated.  
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1.4.1 Human microbiota 
Humans are superorganisms composed of both human and microbial components (49). As 
more is understood about the microbiota associated with the human body, the importance of 
microbes in human health is being increasingly recognised. In fact, it is estimated that the 
microbes associated with the human body outnumber our cells by 10-fold (50).  
Since the 19th century, culture based analysis has been the principle method for the 
investigation of human associated microbes (51). However, with the vast number of 
microbes present on and within the human body, the use of culture for the investigation of 
these dense and complex microbial communities can be problematic (50). The introduction 
of DNA based analyses, in particular next generation sequencing technologies, has given us 
the ability to create vast quantities of data that can be used to investigate the composition 
and function of microbial communities associated with the humans. 
In 2008, The International Human Microbiome Consortium (IHMC) was officially launched, 
with the aim to study and understand the role of human associated microbes in the 
preservation of health and the causation of disease (http://www.human-microbiome.org). 
This work has revealed a complex community of microorganisms, where community 
composition primarily varies by anatomical site (51). Understanding the complex microbial 
community associated with the healthy individual is the first step in understanding the 
complex relationship between the microbial population and human health.   
To fully understand the relationship between the microbial community and human health 
understanding colonisation and succession is key. Inside the amniontic sac the faetus is 
considered essentially sterile, however, after vaginal delivery the microbial community is 
found to closely resemble that of the mother’s vagina (52). The predominant organisms in 
the vagina are Lactobacilli, therefore it is unsurprising that this is the first organism found in 
the gastrointestinal (GI) tract of newborn babies (52). This initial colonisation is considered to 
prepare the GI tract for further microbial colonisation and succession (52). Over time a 
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densely populated microbial community develops over the body, with changes occurring due 
to changes in the body, the eruption of teeth (53), as well as external environmental factors. 
Cho et al (2012) has been hypothesised that changes in the microbiotia in early life can 
affect host immunological, metabolic, cognative and reproductive development (52).  
A wide variety of studies have been published examining the link between microbial 
populations and disease states. These have revealed changes in the microbial community 
associated with, for example; psoriasis (54), obesity (55), asthma (56), colitis (57) and 
cardiovascular disease (58). The challenge for these studies is to identify whether there is a 
causal association in the microbial variation.  
Through the use of metagenomics, and metaproteomics the human Microbiome Project 
(HMP) is aiming to more fully understand the links between the microbial community and 
human health and disease (59).   
 
1.5 Challenges of the respiratory tract  
The respiratory system, shown in Figure 1.1, is designed for the efficient transportation of 
oxygen from the environment to the blood stream and the removal of carbon dioxide (60). In 
detail, air enters the body through the mouth or nose and travels down through the pharynx, 
into the trachea. The trachea then splits into the two bronchi, which subsequently branch into 
the bronchioles and terminate with alveoli. The alveoli are the site of gas exchange; oxygen 
is transported across the epithelial layer into the bloodstream to be transported to cells for 
respiration, while carbon dioxide is removed and travels back out the lungs to be expelled 
from the body (60). As such the lungs are the only interior organ constantly exposed to the 
exterior environment and are therefore vulnerable to any particles or organisms present in 
the air.  
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Figure 1.1 Schematic diagram of the respiratory system.   
A) The respiratory system within the human body, B) an enlarged view of the alveoli and 
surrounding capillaries, C) schematic indication the movement of gas between the alveoli 
and the blood stream.   
Reprinted in unmodified form from: http://www.nhlbi.nih.gov/health/health-
topics/topics/hlw/system.html, United States National Institute of Health: National Heart, 
Lung and Blood Institute, under Creative Commons Attribution (CC BY) licence. This work is 
in the public domain and available for public use.   
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It is estimated that the air in the Earth’s atmosphere contains around 1000 million tonnes of 
suspended particles (61). These particles range in size from 0.1-1000µm and include pollen, 
smoke, soot, dust and importantly microorganisms (62, 63). In 2007, Brodie et al used 
molecular techniques, described in detail later, to analyse the bacteria present in aerosols 
from urban areas of San Antonio and Austin (USA) over a 17 week period (64). In this study 
over 1,800 bacterial taxa were identified, including potentially pathogenic species such as, 
Burkholderia mallei (Glanders disease), Burkholderia pseudomallei (melioidosis) and 
Clostridium botulinum (botulism) (64).  
Whilst there will be some variation due to location and environmental factors (65), inside a 
building it is estimated there are between 400 and 900 individual microorganisms per cubic 
metre of air (62). Assuming an adult inhales around six litres of air per minute, this would 
mean that c. 10,000 microorganisms would be inhaled per day (61). Although the vast 
majority of these organisms are likely to be non-pathogenic, the risk of encountering 
pathogenic organisms is significantly increased in clinical environments (48). This is 
particularly true in dental surgeries where high-speed vibrating instruments have been found 
to aerosolise oral bacteria such as Staphylococci and members of the viridans streptococci 
group, the causative agents in many mouth or gingival infections as well as tooth decay (66). 
The risk of infection by the inhalation of airborne organisms is reduced further by the ability 
of the healthy airways to efficiently remove inhaled particles (61). As the air passes though 
the nasal cavity particles are filtered out, with between 70-80% of the particles that are 3-5 
µm in diameter and 60% of those around 2µm, being trapped in the hair present in the 
nostrils (60). 
With the exception of the terminal bronchioles and the alveoli, the rest of the respiratory tract 
is lined with ciliated cells, mucus secreting goblet cells and subepithelial mucus-secreting 
glands (60). The ciliated epithelium is also covered by a two-layer film known as the airway 
surface liquid (ASL), made up of a lower layer known as the periciliary fluid and an upper 
mucus gel layer (67). Particles or microorganisms breathed into the lungs become trapped in 
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the mucosal secretions and are transported by the beating cilia out of the lungs to the back 
of the throat where they can be swallowed or expectorated, this system has been described 
as a mucociliary escalator (60). It is estimated that this escalator system can move 
entrapped particles or organisms from the airways at a rate of 1 cm/minute (61).  
If particles or microorganisms make it past the mucociliary surfaces of the nasal cavity and 
the lung, the alveoli are lined with antimicrobial peptides and host defence cells, such as 
macrophages. While macrophages have the ability to phagocytose any particle or organism 
that make it past the mucociliary escalator (61), antimicrobial peptides work as natural 
antibiotics, protecting the lungs from invading microbes. Antimicrobial peptides, such as β-
defensins and lactoferrins, are produced by epithelial cells, macrophages, neutrophils and 
natural killer cells and act as natural antimicrobials against any organisms entering the 
respiratory tract (68, 69). As a result it is very difficult for microorganisms to establish 
infections in healthy individuals (70).  
It is well established that the upper airways (nasal cavity, pharynx and larynx) are colonised 
with a wide range of microorganisms which make up the “normal” microbiota (71). However, 
until recently it was thought that the lungs were a sterile environment, with no airborne 
microorganisms surviving the innate immune defences (72, 73). Work by Charlson et al 
2011, using 454 16S rRNA pyrosequencing to analyse the bacterial community from six 
healthy patients, established that the lungs of healthy individuals contains similar sequences 
to those observed in the upper respiratory tract however, in lower abundance (72). Although 
results published differ, the most commonly identified genus include; Pseudomonas, 
Streptococcus, Prevotella, Fusobacteria, and Veillonella (74-76). Differences observed may 
be the result of the different methodologies employed by these studies or the geographic 
locations at which they were carried out.  
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1.6 Lower respiratory tract infections 
The WHO lists LRTIs 3rd on the top 10 causes of death factsheet (1), with around 6% of the 
world’s total mortality being a result of these infections. This translates to 3.8% of deaths in 
high income countries and as much as 11.3% of deaths in countries with lower income.  
Importantly these figures do not include tuberculosis, which itself is ranked as the 8th biggest 
cause of death worldwide (1).  
As explained previously there are many forms of LRTI (77), as a result of this variety and 
high incidence of these infections, they represent a huge burden to national healthcare 
systems. For example, around 4% of the total National Health Service (NHS) budget is spent 
on problems associated with the respiratory system, amounting to around £4.43 billion (2). It 
is therefore both clinically and economically important to investigate better methods to 
prevent and treat LRTIs (78, 79).  
To achieve this however, we have to understand the underlying causes of disease. In recent 
years advances in culture independent technologies has led to advances in our 
understanding of human associated microbial communities in general.  
 
1.7 Cystic fibrosis 
Wehe dem Kind, das beim Kuß auf die Stirn salzig schmekt, er ist 
verhext und muss bald sterbe 
 “Woe to the child who tastes salty from a kiss on the brow, for he 
is cursed and soon must die” 18th century German literature (80).  
 
CF is the most common recessively inherited genetic disorder primarily affecting the 
Caucasian population, although it is seen in low frequencies in other populations; a study 
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carried out in 2011 revealed that 1 in 59 Hispanic, 1 in 84 African American and 1 in 242 
Asians were carriers of CF mutations (81).  
There are approximately 70,000 people suffering from CF worldwide, with around 30,000 
individuals living in the USA (82) and over 9,300 in the UK (83). Around 1 in 25 people in the 
UK carry CF causing mutations however, these numbers vary across the world (84).  
CF is a multi-systemic disorder, which has major effects on a number of body systems 
notably the gastrointestinal tract, the reproductive tract and the focus of this investigation, the 
respiratory tract. Despite medical advances, between 80 and 95% of CF patients die as a 
result of chronic lung infections and concomitant inflammation (85). Once infection has 
established, eradication of infecting species can be extremely difficult (86, 87). As a result of 
these infections and the inflammatory immune response they initiate, there is an irreversible 
loss of lung function over time, which leads to the majority of CF patients dying from 
respiratory failure (88).  
 
1.8 Cystic fibrosis history  
Although CF has been observed for centuries, it was not until 1938 that Dr Dorothy 
Andersen, a pathologist at the New York Babies Hospital, described the condition fully (89). 
Prior to this study of malnourished infants, CF was misdiagnosed as coeliac disease and 
resulted in the death of many children before they reached 6 months old. Andersen’s 
autopsy study of infants who died of this condition revealed it to be a distinct disease, termed 
“cystic fibrosis of the pancreas”.  
The disease was characterised by mucus plugging of the glandular ducts, a decreased 
ability to absorb fat and proteins, steatorrhoea (the presence of excess fat in faeces), failure 
to thrive and pulmonary infection (89). Rather than an intolerance to gluten, nutritional failure 
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was thought to be due to damage to the pancreas and lack of pancreatic enzymes, leading 
to a vulnerability to lung infections, often noted as the cause of death (89). 
In 1946, CF was recognised as an autosomal recessively inherited genetic disease (90). At 
this time, CF research focused on mucus abnormalities as the cause of CF. It was a further 
two years before Paul di Sant’Agnese observed that the levels of sodium and chloride ions in 
the sweat of patients diagnosed with CF were five times higher than that of healthy 
individuals thereby implying the mucus glands were not, as previously thought, the site of the 
basic defect (91, 92). The discovery of the ion abnormalities in the sweat of CF individuals 
lead to Gibson and Cooke developing the “sweat test” (93). This test was found to be highly 
successful due to its discriminating power, allowing easy identification of patients, even 
those with milder symptoms. 
It was not until the 1980’s that major advances in the understanding of CF came about. In 
1983 it was identified that abnormalities in ion transport, resulting in low absorption of 
chloride ions and an increased reabsorption of sodium ions, were responsible for CF (94). 
The mutated gene responsible for CF was discovered in 1989 (95-97). The gene was found 
to code for a cyclic-AMP-regulated chloride transport channel, named the cystic fibrosis 
transmembrane conductance regulator (CFTR), normally expressed in epithelial cells (95-
97).  
 
1.9 The CF mutation 
The CFTR gene, located on the long arm of chromosome seven (95), codes for a membrane 
bound ATP binding cassette (ABC) transporter protein. This protein is found in the apical 
membrane of epithelial cells (84) and maintains the osmotic balance across epithelial cells 
by controlling the transport of chloride ions (98). Mutations in both copies of the CFTR gene 
result in CF disease symptoms. These mutations translate to a wide range of physical 
manifestations including; infertility due to obstructive azoospermia, which effects 98% of CF 
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males (99); pancreatic insufficiency, leading to fat malabsorption (100); liver cirrhosis, as a 
result of ductular obstruction and abnormal bile flow (101); diabetes, as a result of 
diminished insulin production (102); and chronic inflammatory lung disease (84). However, 
there are also cases where mutations are not associated with any CF symptoms (103).   
Currently more than 1800 different mutations of the CFTR gene associated with CF have 
been identified (103). These mutations have a range of effects on the functioning of the 
CFTR and can be categorised into five different classes, resulting in a range of disease 
severities, illustrated in Figure 1.2 (104). “Classic” (class I or II) CF is characterised by a loss 
of function in both alleles resulting in no functioning CFTR. This is associated with pancreatic 
insufficiency and progressive lung disease (105). In some cases the mutation in one allele 
can result in a partially functioning CFTR associated with an improved prognosis (106). Even 
so, although some information on disease severity can be gained from information on the 
gene mutation, not all patients with the same mutation experience the same disease 
outcome (103, 106). 
The most prevalent mutation resulting in CF is the result of a deletion of phenylalanine at 
position 508 of the gene (ΔF508). It is estimated that approximately 70% of all CFTR 
mutations are due to the ΔF508 mutation (92) however, this number varies with geographic 
location as shown in Figure 1.3 (107). ΔF508 is a class II mutation resulting in misfolding of 
the CFTR protein which is then degraded in the endoplasmic reticulum and golgi body, as a 
result no functional CFTR protein is present in epithelial cells (108).  
The identification of the basic genetic defect resulting in CF has lead to the hope that gene 
therapy, inserting a functional copy of the CFTR gene into appropriate cells, could be the 
“key” to curing CF (92). Currently the UK Cystic Fibrosis Gene Therapy Consortium is 
carrying out five clinical trials using cationic lipids to carry genes into the respiratory tract of 
CF individuals. However, at this time only partial correction of the CFTR defect has been 
achieved and results still require improvement (http://www.cfgenetherapy.org.uk/).  
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Figure 1.2 CFTR mutations associated with CF have been classified into five broad 
classes based on their effect on the CFTR transporter protein. 
Adapted from the original by Zielenski and Tsui, 1995 (104), illustrations reprinted from the 
image, Ratjen, F, 2007, New pulmonary therapies for cystic fibrosis, Current Opinion in 
Pulmonary Medicine, 13:541-546 (109), under copyright licence from Lippincott Williams & 
Wilkins, Inc, License Number: 3471420161666.  
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Figure 1.3 Geographical representation of the prevalence of the CFTR mutation ΔF508 
as a percentage of all CFTR mutations and recognised by country. 
The prevalence of ΔF508 is related to the incidence of CF, countries with higher CF rates 
have greater number of CF cases. Prevalence was found to be greater in more northerly 
countries, while prevalence is generally low in Mediterranean countries.  
The figure is re-used in unmodified form from, Southern, 2007, Cystic Fibrosis and Formes 
Frustes of CFTR-Related Disease, Respiration 74:241-251(107), by permission of Karger 
Publishers, licence number 3471430204165.  
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1.10 The CF lung 
1.10.1 Mucus 
Despite the multisystemic nature of CF, the maintenance of airway function is particularly 
important as between 80 and 95% of CF suffers ultimately die as a result of chronic infection 
and associated airway inflammation (85).  Improper functioning of the CFTR protein within 
the lung leads to an inability to clear microorganisms and results typically in chronic lung 
infections. Two main theories have been suggested as to how this happens; the first is 
known as the ‘high salt’ hypothesis. This theory suggests that while the healthy lung is 
protected against infection by antimicrobial peptides, in the CF lung the absence of a 
functional CFTR protein leads to a build up in the concentration of NaCl on the airway 
surface, which degrades these antimicrobial peptides (110).  
In contrast, the second hypothesis, known as the ‘low volume’ hypothesis, explains the 
chronic infections in CF by suggesting that there is too little salt on airway surfaces leading 
to airway surface dehydration. This in turn, leads to thickened mucosal secretions, 
breakdown of the mucociliary escalator and an inability to clear invading organisms from the 
lung (111).  
The ‘low volume’ hypothesis is the more widely accepted explanation for the development of 
lung disease. In more detail, the defective Cl- ion secretion, as a result of CFTR mutations, 
leads to epithelial Na+ ion channel hyperactivity, resulting in the osmotic movement of water 
out of the ASL (112). As the ASL becomes dehydrated, the cilia are compressed, unable to 
beat and move the viscous mucus from the lower respiratory tract. When the periciliary fluid 
becomes critically dehydrated mucins within the mucus layer bind to those anchored to the 
epithelial cells. As mucociliary clearance has broken down at this stage the airways become 
vulnerable to infection (111).  The failure to clear mucus from the airways, alongside the 
continual production of mucins by goblet cells and glands results in airway surface plaques 
and intraluminal plugs which ultimately lead to airway obstruction and provide the main site 
of infection (67).   
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1.10.2 Inflammation  
As well as being characterised by airway obstruction and persistent infection, a vigorous 
inflammatory response plays a key role in the progression of CF lung disease. Epithelial cells 
orchestrate the inflammatory response by producing an abundance of IL-8 (Interleukin	  8)	  and 
other proinflammatory cytokines which induce a neutrophil response (113). Unfortunately, 
the over stimulation of neutrophil activity is combined with the deficiencies in 
immunoregulatory factors, IL-10 and nitric oxide, resulting in an excessive and prolonged 
inflammatory response (113). This in turn leads to lung tissue damage, which over time 
contributes to loss of lung function (114).  	  
Inflammation is a means by which the body is able to contain and/or control infection. 
However, within the CF lung this mechanism breaks down, becoming a pathological force. 
As stated above, it is unclear if inflammation in early infection is triggered by invading 
organisms, although it has been well established that the magnitude of the inflammatory 
response is correlated with bacterial burden (115).   
Evidence suggests that with the exception of some of the sub mucosal gland ducts, infants 
with CF are born with normally developed lungs. Never the less, shortly after birth pulmonary 
symptoms start to establish, with infection and inflammation being observed soon after 
diagnosis by newborn screening. Even so, it is still unclear if the inflammatory response is 
triggered by infection or is already a factor of the CF lung (116). What is clear however is 
that airway inflammation in early life is associated with reduced lung function and structural 
lung damage (117).  
 
1.11 CF lung infections 
In childhood years, infection tends to be transient with chronic infections establishing over 
time, leading to progressive and irreversible lung damage (85). Traditionally, CF lung 
 Chapter 1: Introduction   34 
infections have been considered to be the result of either a single or small number of species 
(118). With further investigation however, it is becoming clear that this is not representative 
of the true number of organisms present within the CF lung, which may be considered a 
complicated and diverse ecosystem (119). 
Over time the CF lung is under constant pressure from a range of factors, including, viruses, 
bacteria, fungi, allergens and irritants, creating a dynamic perturbed system (120). 
Perturbations within the lung ecosystem can lead to acute respiratory symptoms, defined as 
CF pulmonary exacerbations (CFPE) (121). Despite the importance of CFPE in CF disease 
progression no formal definition or standardised criteria exist to define them. Instead clinical 
symptoms such as; increased cough, loss of appetite, weight loss and decline in lung 
function, are used by clinicians to define the start and end of CFPE periods (121).  
In order to help maintain lung function antibiotics treatments are continually administered 
and manipulated by clinicians. During periods of CFPE clinicians intervene, generally with 
administration of intravenous antibiotic therapies (121). Understanding how the microbial 
community changes leading into, during and after exacerbation may give insight into how the 
treatment can be used to maintain lung function and slow disease progression.    
1.11.1 Sampling 
Antimicrobial therapies are an important factor in preserving lung function. It is therefore vital 
to investigate the microbial community within the CF lung.  A number of sampling methods 
are recognised for the analysis of the microbiology associated with CF lung infections. These 
include; cough swab, cough plate, oropharyngeal culture, laryngeal or nasopharyngeal 
aspirate, expectorated sputum, induced sputum, bronchoalveolar lavage (BAL) and 
bronchoscopy brush specimens (122). While all these methods are used, the most 
commonly used sampling methods are, expectorated sputum, induced sputum and BAL.  
All sampling methods introduce the risk of sampling error or bias. Sampling error occurs due 
to observing only a subset of the population rather than the whole population. It was 
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therefore important to consider the pros and cons of all sampling methods available before 
the sampling method was chosen.  
BAL is considered the gold standard for assessing the microbial community within the CF 
lung, particularly for young children who do not produce sputum, as it has been shown that 
non-BAL samples do not adequately reflect the bacterial community present in the lower 
airways in these individuals (123, 124). However, it is an invasive procedure that involves 
using a bronchoscope to infuse sterile saline into the lungs. The saline is then suctioned out 
of the lungs into a collection trap, this fluid can then be analysed to assess the microbiology 
of the lung (104). While this method has been found to be effective, its highly invasive nature 
requires patients to be anesthetised (124, 125).  
As a result the CF Trust standard laboratory procedures recommend the use of sputum for 
routine sampling. Sputum is used as an important sampling tool for the investigation of 
chronic lung disease, as it allows the investigation of protein, cellular and importantly, 
microbiological components which effect disease progression and severity (126). There are 
two methods for obtaining sputum samples, spontaneous expectoration and induction.  
Spontaneously expectorated sputum is the most widely used sampling method for CF adults 
and has been found to provide comparable microbiology results to other sampling methods, 
including induced sputum and BAL, using both culture based and molecular comparisons 
(127-129). However, not all patients are able to spontaneously produce sputum, particularly 
those with mild disease symptoms. In these cases sputum induction may be used. Sputum 
can be induced by nebulising isotonic or hypertonic saline, and has been shown to be a 
simple, non-invasive and cost effective sampling procedure (128, 130). A study by Henig et 
al (2001) revealed that induced sputum tended to show higher identification of recognised 
pathogens than BAL, while being preferred by patients, making it an important alternative to 
BAL for older children and non-sputum producing adults (130).  
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This project focused on the bacterial community present in the lung of CF adults. 
Consequently, throughout this study spontaneously expectorated sputum was used as the 
sampling method. Spontaneously expectorated sputum was chosen as the least invasive 
procedure which has also been shown to provide a comparable sample of the bacterial 
community compared with other sampling techniques.  
1.11.2 Traditional microbiology 
Routine diagnostic analysis of CF respiratory samples has traditionally involved selective 
culture, using a variety of selective media and growth temperatures, in aerobic conditions, to 
quantify and identify a number of known organisms, (131). This is generally confined to a 
small targeted group of microbes that are considered clinically important, including 
Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Burkholderia cepacia complex 
(BCC) (3), as well as species of the filamentous fungi Aspergillus (most frequently A. 
fumigatus) and yeast (commonly Candida albicans) (132, 133). Although all these organisms 
are considered to play a role in disease progression, P. aeruginosa has been regarded by 
many to be the most significant pathogen in CF due to its prevalence and persistence within 
the lung (134).   
Diagnostic microbiology has been useful in revealing key pathogens involved in the 
establishment of chronic infections and the subsequent loss of lung function. Supporting the 
understanding that over time there is a sequential acquisition of bacterial pathogens, Figure 
1.4 (135). This model suggests that early infection is dominated by S. aureus, with other 
pathogens present in a much lower percentage of the population. However, in later years an 
increased colonisation by P. aeruginosa is observed. This soon becomes the most dominant 
pathogen, colonising the lungs of around 75% of CF sufferers (135).  
Although it is well understood that these “recognised pathogens” play a role in the 
progression of CF lung disease, more evidence is being gathered suggesting that our 
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understanding of the microbial community is incomplete. For example, the use of non-
selective culture media has indicated the presence of a diverse community of organisms not 
traditionally considered CF pathogens (infectious microorganisms considered to be the 
cause of respiratory symptoms in individuals with CF) (118). Furthermore, the discovery of a 
sharp oxygen gradient in CF lung mucus and subsequent anaerobic in vitro culturing of 
sputa has lead to the detection of still more bacterial species (132). Despite much effort, 
culture based methods have been shown to be limited (43). There are many reasons for this, 
perhaps most important is the likely under representation of microbial diversity due to the 
unknown laboratory growth requirements of bacterial and fungal species that may be present 
within the lung ecosystem (136). These requirements include; chemicals (Carbon, 
NitrogenSulphur, Phosphorus, Calcium), pH, Oxygen (aerobes, facultative aerobes, obligate 
anaerobes, Aerotolerant anaerobes, Microaerophiles), intracellular requirements and 
synergistic relationships with other organisms.   
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Figure 1.4 Age dependent bacterial colonisation of the CF lung. 
Reprinted from the 2012 Cystic Fibrosis Foundation annual data report (135). Data was 
sourced from Cystic fibrosis patients under care at CF Foundation-accredited care centers in 
the United States, who consented to have their data entered in 2012. 
Figure is reprinted with permission of the ©2013 Cystic Fibrosis Foundation.  
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1.11.3 Culture independent technologies 
Molecular techniques are revolutionising the way diagnostic tests and research is being 
carried out in relation to CF lung infections (43). In order to effectively investigate the 
microbial community using molecular methodologies, a representative sample of the nucleic 
acid from the entire microbial community is required. DNA extraction methods are an 
important route for the introduction of bias when carrying out DNA based analysis. It is 
therefore vital to select a method that minimises these effects, equally recovering DNA from 
gram positive, gram negative and fungal cells, providing a complete picture of the community 
(137). The methods employed throughout this project was modified by Rogers, et al, 2003, 
from a method described in 1989 by Pitcher et al (43, 138). This method employs physical 
disruption, in the form of bead beating, in conjunction with chemical guanidium thiocyanate-
EDTA-sarkosyl (GES) lysis. Both physical and chemical disruption were included to disrupt 
the maximum number of cells and cell types and gain an accurate representation of the 
microbial community, for full methods see Chapter 2.3.  
Techniques such as, PCR, T-RFLP and 16S rRNA gene sequencing (Sanger sequencing) 
have provided fresh insight in the analysis of both bacterial (43) and fungal (139) 
communities within the CF lung. Rogers et al, 2003, showed it was possible to rapidly 
characterise the bacterial community composition and diversity using 16S rRNA gene T-
RFLP. In 2010, Nagano et al, used a mixture of non-selective and selective fungal culture to 
provide a comparison to results obtained from direct DNA extraction and sequencing, 
demonstrating a diverse fungal community that is potentially underestimated by mycological 
culture alone. They also demonstrated that potentially important pathogenic fungi may be 
missed by culture alone (139).  
As technologies have moved on, more in depth analytical techniques for sequencing DNA; 
454 high throughput pyrosequencing (140), Illumina sequencing (141), have allowed 
increased insight into the microbial communities within the CF lung by providing large 
quantities of data on the community within a sample. Roche 454 technology works using 
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emulsion PCR and pyrosequencing. Sequences are amplified onto beads in an emulsion 
PCR before being washed onto a PicoTiterPlate, where sequences attached to a single bead 
are added to each well. Bases are washed over the PicoTiterPlate in order, as a base binds 
a phosphopyruvate molecule is released, which is used to change adenosine 5´ 
phosphosulfate (APS) to Adenosine triphosphate (ATP) in the presence of sulphurylase. This 
releases ATP, then used to change luciferin to oxyluciferin in the presence of luciferase, 
releasing light.  On the other hand Illumina Miseq is based on Solexa sequencing by 
synthesis chemistry, it uses a reversible chain termination method where a flouraphor bound 
to each nucleotide acts as a chain terminator. All bases can be added simultaneously, once 
bound lasers with filters are used to take an image for each base, before the flouraphor is 
cleaved and the new bases can be added.  
By comparing the use of 454 and Illumina sequencing technologies Maughan et al (2012) 
revealed that Illumina sequencing provided better taxonomic resolution than 454 (121). In 
comparisions of benchtop sequencers, Loman et al (2012) and Junemann et al (2013) found 
that 454 provided the longest read lengths, however, Miseq provided the highest throughput 
with the lowest error rates (142, 143).   
The use of culture independent methods for identifying and quantifying microbial species is 
increasing due to the speed and reliability of these methods for identifying unusual and 
difficult to culture organisms, as well as those in low abundance (144). However, these DNA-
based methods have their own drawbacks and areas of potential bias, which are particularly 
pertinent to the study of CF microbial community diversity. These have to be addressed in 
order to be confident in the results.  
Unlike culture based methods, DNA based analyses are unable to differentiate between 
DNA from living organisms and extracellular DNA or DNA from dead or damaged cells (145). 
This has massive implications, both for drawing ecological conclusions about the microbial 
community within an environment (146), and when considering clinical infections (147). In 
order to address this, samples can be treated with propidium monoazide (PMA), a 
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membrane impermeable dye. PMA covalently binds upon exposure to light to extracellular 
DNA or DNA within cells that have damaged cell membranes (146). Once the PMA binds to 
free DNA, the DNA is rendered insoluble and as a result it is removed during the extraction 
procedure, allowing analysis of only the viable community (145).  
1.11.4 Propidium monoazide 
Discrimination between live and dead cells is important in order to analyse microbial 
communities and understand how perturbations can effect or change the community 
dynamics within the CF lung. Membrane integrity as inferred by DNA binding dyes is 
considered the most practical method for this and is widely used in microscopy and flow 
cytometry (145).  
In some early applications ethidium monoazide (EMA) was used in live-dead cell assays as it 
intercalates with DNA, covalently bonding to the DNA when exposed to visible light (148). 
EMA can penetrate cells with compromised cell walls or membranes, allowing binding to 
DNA within compromised or non-viable cells (145). Nogva et al (2003) utilised the 
photoactivated DNA binding properties of EMA to inhibit DNA from dead bacteria from 
amplification by PCR (148). This method was found to be promising however, it had a major 
disadvantage as EMA was found to readily penetrate the membrane of some viable cells, for 
example Escherichia coli (149).    
The lack of selectivity observed with the use of EMA lead Nocker et al (2006) to test PMA as 
an alternative (145). PMA was derived from propidium iodide (PI), with the addition of an 
azide group to allow DNA cross-linking when exposed to light (145). The two positive 
charges on PMA, compared to the single charge on EMA, are thought to contribute to the 
reduction in permeability of PMA across live cell membranes resulting in significantly higher 
selectivity (145).   
PMA cross-linking, shown schematically in Figure 1.5, is carried out by exposing microbial 
cells of interest to PMA in dark conditions for a period of 5-15 min Evidence suggests that 
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incubation time does not affect DNA yield, however it was noted by Nocker et al (2006) that 
after 15min there was a loss in E. coli DNA when PMA was in high concentration (145). This 
study recommended 5 minutes incubation in the dark prior to light exposure, allowing PMA to 
covalently bind to DNA. It also showed that 120 seconds of light exposure ensured efficient 
binding of PMA. Any unbound PMA after the incubation period was also found to be 
inactivated during this time (145). 





Figure 1.5 Representation of the selective detection of live cells using propidium 
monoazide. 
 PMA is added to the sample of interest and incubated in the dark. After incubation samples 
are exposed to light, resulting in PMA covalently binding to extracellular DNA and DNA from 
dead or damaged cells.  
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To investigate the effectiveness of PMA treatment Nocker et al, carried out a range of 
studies on microbial communities from various environmental systems including wastewater 
and marine sediment (146) and canal and seawater (150). These studies established the 
effectiveness of PMA treatment for suppressing the DNA signals from extracellular DNA and 
DNA from dead or damaged cells.  
Since the publication of Nocker’s work on PMA, this approach has been used in wide range 
of studies to investigate viable; bacterial (151), fungal (152) or viral (153) communities. Of 
particular importance is that, PMA has been widely investigated by Rogers et al, for use in 
the investigation of the microbial community in CF sputum. Rogers et al (2008) 
demonstrated that PMA effectively prevented unwanted DNA from being utilized as a 
template during PCR (144). Investigation into the effects of PMA treatment on community 
composition revealed that PMA treatment resulted in an increase in community evenness, by 
increasing community diversity (154). This study also suggested that failure to remove 
extracellular DNA and DNA from dead and damaged cells could lead to skewed results and 
misinterpretation of the microbial community composition (154).  
 
1.12 Microbial ecology and CF lung infections 
As described above, chronic respiratory infections have been the focus of CF lung disease 
research for many years. Previous studies using both culture and molecular methodologies 
have established that a complex and dynamic ecosystem exists within the lung (132, 154, 
155). Early investigations into the whole bacterial community within the CF lung were 
dominated by Rogers et al. They initially used T-RFLP and 16S rRNA gene sequencing to 
identify the composition and diversity of the bacterial community in 2003 (43). Papers 
published by the same group, in 2004 (156) and 2005 (131) confirm these results. The 
identification of species not previously identified as part of the CF lung community lead to the 
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investigation of areas of potential contamination and in 2006, Rogers et al, revealed 
evidence that members of the oral microbiota isolated from sputum were not a result of 
contamination but were in fact members of the lower respiratory community (157).  
Studies by Rogers et al, provided a foundation for a large number of other studies, further 
improving our understanding of the community of organisms associated with CF lung 
disease. Even so, there is still work to be done in order to translate the results of these 
studies into improved patient outcomes. Investigations into community structure, using 
recognised ecological measurements (described in detail in Chapter 2.8), are being carried 
out in order to allow us to predict how the community will react to perturbations within the 
system. For example, work carried out by van der Gast et al (2011) showed a significant 
relationship between species richness and lung function, suggesting that patients with more 
diverse bacterial communities have better disease outcomes (4). This finding was supported 
by results from Zhao et al (2012) in a longitudinal study of CF patients over the course of a 
year (140).  
Although it is clear that a diverse microbial community is present within the CF lung, we are 
yet to understand the full complexity of even the bacterial community alone. Using a 
combination of ecological measures, designed to assess species diversity and community 
composition, and mixed effects modelling, this study aimed to concentrate sequencing 
efforts on the bacterial community in an attempt to bridge some of these knowledge gaps.   
As molecular methodologies become more widely available, achieving an accurate a picture 
as possible of this bacterial community is vitally important. Understanding the optimal 
methodologies for sample handling and laboratory procedures allows us to confidently 
explore bacterial community dynamics and how these relate to disease state. Studies by 
Rogers et al (2013) have investigated the use of PMA to remove the effect of extracellular 
DNA and that from dead or damaged cells (154) however, no studies have previously 
investigated the importance of sample handling for the accurate analysis of CF sputum 
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bacterial communities. By first understanding where areas of potential bias can be 
encountered we are able to confidently explore the bacterial community from CF sputum.    
Bacterial community dynamics over time, during periods of both stability and exacerbation 
are vital in order to explore disease progression. Previous studies have looked at limited 
samples from these different disease states, however, no studies have incorporated multiple 
samples from all clinical stages. By incorporating multiple samples this study was able 
establish patterns in the data while accounting for variation both between and within patients.  
Finally, to date no large scale studies have been carried out to determine if there are any 
wider patterns in the bacterial community that may result in disease progression. A large 
scale, spatial study incorporating sputum samples from clinic across the UK and the USA 
allows us to stratify the data and identify markers that may indicate improved or worsening 
disease outcomes.    
  
1.12 Aims 
As explained in detail above, current literature has revealed the CF lung to be populated by a 
complex and diverse bacterial community. The overall aim of this study was to investigate, 
through the use of high throughput sequencing, the bacterial community diversity and 
composition within the CF lung and its relationship with patient outcomes. By investigating 
the complex relationship between the bacterial community and the host related factor this 
thesis aimed to provide insights that may ultimately influence the treatment of CF lung 
infections.  
In recent years there has been a drive towards the use of culture independent technologies 
for the investigation of bacterial community within the CF lung disease however, few studies 
have fully assess the impacts of sampling practices on detection of bacterial species. As 
such, the initial research chapters (Chapter 3, Chapter 4 and Chapter 5) will focus on 
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methodologies designed to limit bias in the investigation of the bacterial community within 
the lung. Chapter 3 aims to assess the impact of extracellular DNA and DNA from dead or 
damaged cell in the analysis of CF bacterial communities, while Chapter 4 focuses on the 
impact of the initial treatment and storage of sputum samples prior to high throughput 
sequencing. Chapter 5 aims to address the impact of multiple freeze thaw cycles on the 
bacterial community in order to minimise bias in the study of samples biobanked for use in 
multiple projects. These studies aimed to provide guidelines on sample handling allowing the 
most accurate representation possible of the bacterial community within the CF lung to be 
obtained.  
By first establishing a framework of methodologies designed to provide an accurate depiction 
of the bacterial community within the lung, these methods were then taken forward to the 
final chapters. These chapters aim was to uncover the relationship between the bacterial 
community and clinical factors related to patient disease state. Chapter 6 aims to investigate 
overall relationships between clinical factors related to CF and the bacterial community 
within the lung, using a large cohort sample set from 11 sites across Europe and North 
America. By investigating a large and diverse sample cohort this study aimed to uncover 
significant relationships between clinical factors and the bacterial community.  
While investigation of spatial samples allows insight into important clinical factors longitudinal 
sampling allows investigation into how CF lung disease progresses and ultimately leads to 
respiratory failure. Chapter 7 aims to understand the changes in bacterial community 
dynamics over the course of a CF pulmonary exacerbation, allowing novel insight into the full 
course of exacerbation as well as allowing identification of novel biomarkers of disease.  
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Materials and methods 
 
 
“Truth has nothing to do with the conclusion, and everything to do 
with the methodology.”  
Stefan Molyneux 
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2.1 Bacterial strains  
Bacterial type strains and clinical isolates were used in this study as controls; details of 
individual bacterial strains used are shown in Table 2.1. Bacterial strains used were chosen 
due to their clinical relevance in CF and other respiratory infections.  
Strains were grown by adding one bead from a frozen stock of the strain to 5ml of Luria 
Broth (LB) (Oxoid, Hampshire, UK) for 24 hours at 37°C with shaking at 100rpm. To confirm 
strain purity 100ul of LB (Oxoid, Hampshire, UK) was streaked onto LB agar (Oxoid, 
Hampshire, UK) and grown for 24 hours at 37°C. A single pure colony was then selected and 
grown in LB (Oxoid, Hampshire, UK) for 24 hours at 37°C with shaking at 100rpm. DNA 
extractions were performed as described below.  
Mock communities were made for use as sequencing controls in order to account for 
sequencing bias. PCRs were performed, as indicated in Chapter 2.4.2, on DNA from pure 
strains of Pseudomonas aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas 
maltophilia, Staphylococcus aureus and Burkholderia cenocepacia. Known concentrations 
(100 ng/µl, calculated using the NanoDrop 8000 (Thermo Fisher Scientific, Loughborough, 
UK)) of amplified DNA was then combined in sterile microcentrifuge tubes and cleaned-up as 
indicated in Chapter 2.5. Pure culture bacterial and mock communities controls were 
included in sequencing runs. 
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Table 2.1 List of bacterial control strains and sources.  
Relevant bacterial controls, isolated from CF sputum were used in all experiments to confirm 
expected results.  
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2.2 Clinical samples  
All sputum samples were collected under full ethical approval, details of ethics associated 
with each chapter will be indicated in the condensed methods present in each chapter. An 
over view of ethics details are presented in Table 2.2. Numbers of samples and collection 
location varied between chapters, patient details of the exclusion criteria are included in the 
methods of individual chapters.  Patient consent was gained before the collection of all 
samples.  
Spontaneous expectorated sputum from patients with cystic fibrosis was used as the 
sampling method for all studies. Sputum samples were collected in sterile containers and 
stored at -80°C prior to further processing. In all chapters, with the exception of Chapter 7, 
sputum was collected during routine clinical visits to local CF centres. If required, the patient 
provided separate sputum samples for routine microbiology. Samples collected in Chapter 7 
were collected by patients in their home and collected by motorcycle courier and returned to 
Southampton general hospital for storage at -80°C.  
Health professionals within the hospital collected associated patient metadata at the time of 
sample collection. All data and samples were anonymised in accordance with ethical 
requirements.  
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Table 2.2 List of ethics reference numbers.  
Ethics was obtained for the collection of sputum samples from CF patients for the study of 
the microbial community within the lung.  
 
 
Hospital  Ethics Review board Reference number 
Southampton General 
Hospital 
Southampton and South West Hampshire 
Research Ethics Committee  06/Q1704/26 
Belfast City Hospital Office for Research Ethics Northern Ireland  06/NIR01/11 
Belfast City Hospital; 
Vectura, samples from 
the UK, Eire and Poland 
1. Multi-Centre Research Ethics 
Committee for Wales (UK) gave approval 
on 18th March 2008  
  VR496/005 
2. Irish Ethics Committee (St Vincent's 
Healthcare Group Ltd Ethics) approved 
the study on 11th November 2008  
3. Polish Ethics Committee (Bioethics 
Committee of the Medical University, 
Lodz) final approval gained on the 14th 
July 2009 (previously stated as the 21st 
April 2009)  
 
Geisel School of 
Medicine at Dartmouth 
Geisel School of Medicine and Dartmouth 
College Institutional Review Board CPHS # 23809 
Maine Medical Centre Maine Medical Center Institutional Review Board IRB # 4170  
Seattle Children’s 
Hospital 
Seattle Children’s Hospital Institutional 
Review Board  IRB #12811 
Vermont Medical centre University of Vermont Institutional Review Board  M13-160 
Massachusetts General 
Hospital 
Massachusetts General Hospital 
institutional review board  2011P000620 
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2.3 Sputum sample processing 
2.3.1 Sputum wash  
Based on Rogers et al (2003) (1), a sterile scalpel was used to transfer approximately 500 
µg of frozen sputum into a sterile 15 ml centrifuge tube.  Sputum samples were washed 
three times with sterile 0.8% w/v phosphate-buffered saline (PBS) (Oxoid, Hampshire, UK) to 
remove saliva. Washing was carried by vigorously shaking samples by hand, with 5 ml of 
PBS then centrifuging at 4109 x g for 5 min. The supernatant was removed and the process 
was repeated twice more with 500µl PBS. Washed sputum was re-suspended in 500 µl of 
PBS. 
2.3.2 Propidium Monoazide treatment 
PMA treatment was performed as previously described by Nocker et al (2007) and Rogers et 
al (2008) in order to exclude free DNA and DNA from non-viable cells from further analysis 
(2, 3).  
PMA (Biotium, Hayward, CA) was diluted with 20% dimethyl sulphoxide (DMSO) (Sigma-
Aldrich, Dorset, UK) to create a 20 mM PMA stock solution, which was stored in the dark at -
20°C. Sputum suspended in 500 µl of PBS was added to black 1.5 ml micro-centrifuge tubes 
(TreffLab, Degersheim, Switzerland). In a darkened room, 1.25 µl PMA stock solution was 
added to 500 µl of sample (in black micro-centrifuge tubes) to give a final concentration of 50 
µM.  Samples were vigorously mixed (10-15 sec) prior to incubation at room temperature in 
the dark for 15 min, vortexing every 2-3 mins to ensure even mixing.  After incubation, 
contents were transferred to clear micro-centrifuge tubes and placed in an LED light box 
(see Figure 2.1) for 15 min vortexing every 2-3 mins, in order ensure all PMA molecules 
were covalently bound to free DNA molecules.  
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Figure 2.1 Photograph of LED light box.  
The light box was constructed by engineering staff at the Centre for Ecology and Hydrology, 
Wallingford. A 45-LED security floodlight (product number; BB-HL119) was attached to a 
PVC base. An electoral junction box, lined with reflective tape, was modified to fit over the 
floodlight. A clear PVC plastic sheet was fitted in the top of the box and holes were drilled to 
accommodate 24, 1.5 ml microcentrifuge tubes.   
 Chapter 2 
   
66 
2.3.3 DNA extraction 
The DNA extraction method used was based on Rogers et al (2008) (3). All sputum samples 
were treated with PMA prior to DNA extraction with the exception of those described in the 
methods of Chapter 3. Samples were transferred to individual 1.5 ml screw cap microtubes 
(Sarstedt, Leicester, UK) containing: a single 3 mm diameter tungsten carbide bead (Qiagen, 
Manchester, UK), 0.2 g of 0.18 mm diameter glass beads (Sigma-Aldrich, Dorset, UK) and 
300 µl of guanidinium thiocyanate (5 mol/l), ethylenediaminetetraacetic acid 
(EDTA)(100mmol/l) -Sarkosyl (0.5% v/v) (GES) (4). Samples were homogenised at 30 Hz in 
a Mix Mill 300 (Qiagen, Manchester, UK) for 2 x 30 sec, then incubated at 80˚C for 3 min, in 
order to help dissolve fats and denature proteins not disrupted by physical lysis, samples 
were then rapidly cooled by chilling at -20˚C for 5 min.  Beads and other debris were pelleted 
by spinning (12,000 X g for 5 min) and the supernatant removed and added to micro-
centrifuge tubes containing 141 µl of NaCl, to a final concentration of 0.5 mM, and 374 µl 
polyethylene glycol (PEG) (Fisher scientific, Loughborough, UK), to a final concentration of 
15%. DNA was precipitated for 1 hour at 4˚C.  Samples were then centrifuged (15,000 X g at 
4˚C for 10 min) to pellet the DNA. The supernatant was removed and the pellet was 
resuspended in 500 µl dH2O, prior to the addition of 500 µl Tris-buffered phenol (pH 8.0) 
(Invitrogen, Paisley, UK) and vigorous vortexing.  The tubes were left to stand for 1min at 
room temperature then centrifuged for 4min at 15,000 X g. The supernatant was added to 
fresh micro-centrifuge tubes with an equal volume of Tris-buffered phenol (pH 8.0)-
chloroform-isoamyl alcohol (1:1) (Sigma-Aldrich, Dorset, UK) and mixed vigorously before 
centrifugation at 15,000 X g for 4 min.  The supernatant was removed into fresh 
microcentrifuge tubes and an equal volume of isopropanol (1:1) (Fisher scientific, 
Loughborough, UK), 1:10 volume of 10 M ammonium acetate (Ambion, Paisley, UK) and 1 µl 
of linear polyacrylamide (LPA) (Sigma-Aldrich, Dorset, UK), added and mixed prior to 
incubation at -20˚C.  After 1 hour, samples were centrifuged at 15,000 X g for 10 min and the 
supernatant removed and discarded.  The pellet was washed three times with 500 µl 70% 
ethanol (Fisher scientific, Loughborough, UK). Pellets were air dried, resuspended in 50 µl of 
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sterile nuclease-free water and stored at -20˚C.  For every round of extractions, a sample 
containing nuclease-free water was extracted in parallel as a negative control. 
The presence of DNA was verified by Tris-Borate-EDTA (TBE)(Severn Biotech, Worcester, 
UK) agarose gel electrophoresis on 1% w/v TBE gels containing 1 µl of 10 mg/ml ethidium 
bromide (Sigma-Aldrich, Dorset, UK) per 100 ml (85 V, 30 min).  Gels were viewed and 
captured using ultra violet light, by a Bio-Rad image analyser with image lab software (Bio-
Rad image lab, version 2.0.1), (Bio-Rad laboratories, Hertfordshire, UK).  
 
2.4 PCR amplification for sequencing 
PCR amplification was modified for the use of 454 Titanium FLX+ and MiSeqTM Sequencing 
due to the ability of 454 sequencing to provide longer fragment lengths in comparison to 
MiSeq sequencing. The V3-V5 region of the 16S rRNA gene was used for 454 sequencing 
while the shorter V2-V3 region was chosen for MiSeq analysis. These regions were chosen 
by the Wellcome Trust Sanger centre for their ability to distinguish between taxa using the 
available sequencing length. The move from 454 to MiSeq sequencing was carried out by 
the Wellcome Sanger centre due to the increased accuracy, superior number of returned 
reads and the reduction in costs, compared with 454 sequencing, in 2014, mid way through 
the project. 
 
2.4.1 PCR amplification for Roche 454 Titanium FLX+™ sequencing 
Barcoded primers targeting the V3 to V5 regions of the 16S rRNA gene were used to 
generate 16S rRNA gene amplicons for Lib-L454 Titanium sequencing from extracted DNA.  
The primer 338F (5’-ACTCCTACGGGAGGCAGCAG) (MWG Eurofins, Ebersberg, Germany) 
and 926R (5’-CCGTCAATTCMTTTRAGT) (MWG Eurofins, Ebersberg, Germany) amplified 
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an approximately 550 base pair (bp) region of the 16S rRNA gene (5). 338F was modified at 
the 5’ end with 454 adaptor B (5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG), while 
926R was modified with 454 adaptor A (5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG) 
followed by a unique 12 base barcode.   
PCRs were performed in quadricate, with approximately 100 ng of template DNA used in 
each 20 µl reaction containing; 2 µl 10X AccuPrime™ PCR Buffer II  (Invitrogen, Paisley, 
UK), which contained dNTPs, 0.08 µl AccuPrime™ Taq High Fidelity (Invitrogen, Paisley, 
UK), 0.2 µl of each 10 µM Primer to a final concentration of 0.1 µM. The thermocycling 
conditions were optimised to; initial denaturation 94°C for 3 min; 25 cycles of denaturation 
(94°C for 30 sec) annealing (55°C for 30 sec) extension (72°C for 2 min). PCR machine 
used throughout was the G-storm thermocycler (GRI, Braintree, Essex).The presence of 
DNA was verified by Tris-Borate-EDTA (TBE)(Severn Biotech, Worcester, UK) agarose gel 
electrophoresis on 1% w/v TBE gels containing 1 µl of 10 mg/ml ethidium bromide (Sigma-
Aldrich, Dorset, UK) per 100 ml (85 V, 30 min).  Gels were viewed and captured using ultra 
violet light, by a Bio-Rad image analyser with image lab software (Bio-Rad image lab, 
version 2.0.1), (Bio-Rad laboratories, Hertfordshire, UK).  
2.4.2 PCR amplification for Illumina MiSeq™ sequencing 
Barcoded primers targeting the V1 and V2 regions of the 16S rRNA gene were used to 
generate 16S rRNA gene amplicons for Illumina MiSeq, from extracted DNA.  
16S rRNA gene was amplified using modified primers 27F (5’-
AGMGTTYGATYMTGGCTCAG) (MWG Eurofins, Ebersberg, Germany) and 338R (5’- 
GCTGCCTCCCGTAGGAGT) (MWG Eurofins, Ebersberg, Germany) (6). The 5’ end of the 
primer 27F was modified with a 29 base Illumina adapter, a 10 base forward primer pad and 
a 2 base linker sequence (5’-AATGATACGGCGACCACCGAGATCTACAC  TATGGTAATT  
CC).  The 5’ end of 338R was modified with the reverse complement Illumina adapter, a 12 
base Golay barcode, a 10 base reverse primer pad and a 2 base linker (5’- 
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CAAGCAGAAGACGGCATACGAGAT TCCCTTGTCTCC AGTCAGTCAG AA) (Underlined 
sequence represents an example Golay barcode). Primer pads are included to stop the 
formation of hairpins within the primers while primer linker regions are included to separate 
the 16S rRNA gene priming site from the unique barcode. Linker regions are required due to 
the variable barcode sequences which could potentially bind to the 16S rRNA gene 
sequence adjacent to the priming target, creating longer priming sites for some species. It is 
therefore important that the linker bases do not match the upstream 16S rRNA gene region 
for any known bacterial species. This ensures that priming occurs across the same number 
of bases for all species.  
PCRs were performed in quadricate, with approximately 50 ng of template DNA used in each 
25 µl reaction containing; 5 µl 5 X Q5 Buffer  (New England Biolabs, Ipswich, UK), 1 µl Q5 
High-fidelity polymerase (New England Biolabs, Ipswich, UK), 1.25 µl of each 10 µM Primer 
was added to a concentration of 0.5 µM, 0.5 µl 10 mM dNTPs. The thermocycling conditions 
were optimised by the Wellcomme Trust Sanger institute to; initial denaturation 98°C for 2 
min; 25 cycles of denaturation (98°C for 30 sec) annealing (50°C for 30 sec) extension (72°C 
for 1 min 30 sec), final extension 72°C for 5 min. 
The presence of product was confirmed by TBE agarose gel electrophoresis, as above 
(Chapter 2.4.1).  
 
2.5 PCR clean-up 
The four repeat PCRs carried out for sequencing were pooled and cleaned up using ethanol 
precipitation to remove salts from the extracted DNA. 0.3 volumes of 1M NaCl (Sigma-
Aldrich, Dorset, UK) was added to the pooled PCR volume, two volumes (relative to the new 
combined sample including NaCl volume) of cold 100% ethanol were then added. The 
samples were then mixed by inversion and stored at -20oC overnight. After incubation the 
samples were centrifuged at 4oC at 15,000 X g for 20 min. The supernatant was removed 
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and 600 µl of cold 70% ethanol was added. The samples were then centrifuged at 4oC at 
15,000 X g for a further 15 min. The supernatant was removed and samples were left to air 
dry. Once dry samples were re-suspended in 30 µl of Tris-EDTA (TE) (Sigma-Aldrich, 
Dorset, UK) buffer and stored overnight at 4oC. 
 
2.6 Sequencing  
All barcoded PCR products were quantified individually using a Qubit 2.0 fluorometer 
(Invitrogen, Paisley, UK) and combined into an equimolar mastermix prior to sequencing at 
the Wellcome Trust Sanger Institute (Cambridge, UK). Both 454 and MiSeq sequencing 
were performed at the Wellcome Trust Sanger Institute (Cambridge, UK). 
 
2.7 Sequencing analysis 
The Mothur sequencing analysis software platform was used to analyse the resulting data 
(7). Failed sequence reads, low quality sequence ends, tags and primers, were initially 
removed, followed by sequences shorter than 350bp (for 454 sequencing analysis) and 
270bp (for Illumina sequencing analysis) and any sequences which included ambiguous 
base calls and homopolymeric stretches longer than 8 bases. Any non-bacterial ribosome 
sequences or chimeras were removed using Chimera Perseus software (8) or Chimera 
uchime (9) as implemented in Mothur. Sequences were assembled into operational 
taxonomic units (OTUs) (clustered at 97% identity), to give an approximation of species (10), 
and identified using the Ribosomal database project (RDP) training set (for version used see 
individual chapters) reference database (11). Representative sequences were used to give 
an appropriate species level identification for the OTU using NCBI megablast and any 
suspect OTUs, those that appeared in control samples as well as single sequences identified 
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as being unlikely to be found in humans (e.g. hyperthermophiles, methanotrophs and 
rhizosome associated bacteria) were removed.   
 
2.8 Data and statistical analysis 
Statistical analysis was performed in R, unless otherwise stated (12). Details of Chapter-
specific statistical tests can be found in the corresponding methods sections. Details of 
statistical tests used throughout the study are detailed below.  
2.8.1 Diversity measures  
In order to assess the richness and evenness (equality of species distribution in an 
environment) of the bacterial community within each sample three complementary 
measurements of diversity were used. The indices chosen were species richness (S*), 
Shannon-Wiener diversity index (H’) and Simpson’s index of diversity (1-D), as described 
previously (13).   
As explained by Magurran (2004) there are no perfectly unified diversity indices as different 
indices emphasize species richness and evenness to varying degrees (14). By using three 
metrics we are able to gain an indication of bacterial diversity while acknowledging that each 
measure has inherent bias. S* indicates the total number of species but does not account for 
species abundance. H’ reflects the diversity and evenness of species. H’ is sensitive to 
changes in the frequency of common and less common species, however not rare species. 
1-D is a measure of the probability that two species randomly selected from a sample will 
differ, however it is heavily weighted towards the most abundant species. 
In order to account for sampling bias due to differing sampling depths (i.e. differing numbers 
of reads between sample, sample A may return 5,000 sequences while sample B returns 
10,000) a randomised resampling method was used to examine differences in bacterial 
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diversity between samples, based on Solow (1993) (15). OTUs derived from a single sample 
were sub sampled, with replacement, to a uniform sampling depth, this allowed comparisons 
to be made between samples with different numbers of sequences. Diversity indices were 
calculated for each sample and a mean, median, standard error and 95% confidence 
intervals were calculated after 1000 iterations.  
2.8.2 Similarity measures  
Community compositions of samples were compared using two similarity measures 
Sørensen (number of shared species) and Bray-Curtis (accounts for the number and 
abundance of shared species). Both measures are considered to be highly effective (14).  
Sørensen is considered to be one of the most effective presence absence measures (16), 
while Bray-Curtis was found to be one of the few measures which could satisfy the following 
6 criteria set out by Clarke and Warwick (2001): i) the value is one when two samples are the 
same; ii) the value is zero when samples have no common species; iii) a change of 
measurement does not affect the value of the index; iv) the value is unchanged by the 
inclusion of a species that do not occur in either sample; v) the inclusion of a third sample 
does not affect the similarity of the initial samples; vi) the index reflects differences in total 
abundance (17).   
To overcome biases created by differences in sample size the randomised resampling 
method was adapted from that used for assessing diversity, in order to compare the 
similarity of equal subsamples from two original samples. Sørensen and Bray-Curtis 
similarity measures were calculated for each subsample in 1000 iterations and the mean, 
median, standard error and 95% confidence intervals were calculated. 
2.8.3 Meta-analysis 
Meta-analysis is a statistical method for comparing the results from different studies in order 
to identify patterns and relationships that may be missed in a single study. This technique is 
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widely used in clinical trials for the investigation of healthcare interventions (18), as well as 
being used by ecologists to compare different experimental studies (19). Overall patterns 
between studies are calculated by weighting means, therefore accounting for factors such as 
study size within the analysis. In this project, meta-analysis was used to assess the variation 
between samples by using the replication within the same sample as a single study. To 
calculate the variation with a sample the randomised resampling explained above (Chapter 
2.8.1) was employed to give a mean and standard deviation. These values could then be 
used to provided a powerful tool to study between sample effects while accounting for the 
high variability between CF patients.  
Meta-analysis was carried out in R, using the metafor package (20). The per-sample effect 
size was calculated using the standardized mean difference (SMD), widely used for the 
comparing two groups (treatment and control). This method uses the difference between 
sample means (m1i-m2i) divided by the pooled standard deviation (sd1i and sd2i).  
Expressed as: 
 
Subsequently, the overall average effect size was calculated using a random-effects model 
using Hedges estimator (Hedges’ g). Weighted estimation (with inverse-variance weights) 
was used to eliminate scale differences while incorporating the effect of between patient 
variations. Out puts were plotted in R, using ggplot2 (21). 
2.8.4 Distribution abundance relationships (DAR) 
It has been established that at the metacommunity level, a dichotomy exists within species, 
in order to investigate this species within the metacommunity it can be partitioned into those 
that are common, persistent and abundant, and rare, transient and less abundant. A direct, 
positive, relationship between species persistence and abundance has been observed in the 
study of taxa at a range of spatial scales, importantly this relationship has been observed 
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when within the CF airways (22, 23). As with animal species this distinction in the community 
composition has been found to be related to species permanence within the ecosystem, in 
this case the CF lung (24).   
In this study we chose to use a partitioning method previously used in a study by Magurran 
and Henderson (2003) for the partitioning of fish species, from an estuarine environment 
(24). Persistence was described as the number of number of samples that contain the 
species of interest, while abundance was described as the total number of sequences from 
all samples. The log abundance was plotted against persistence to reveal a significant 
positive relationship. The most persistent and abundant organisms appearing in the upper 
quartile of the plot, i.e. in more that 75% of the total samples, these species were described 
as common, while all others were considered rare.  
2.8.5 Analysis of variance (ANOVA) 
Analysis of variance (ANOVA) is a statistical test of whether several means are equal, 
therefore providing a method of performing t-tests on more than two groups, without 
increasing the risk of type I error. After performing ANOVA tests, post-hoc Tukey honest 
significant difference (HSD) tests were then used to identify which groups in the sample were 
significantly different, P<0.05. This test allowed the comparison of OTU diversity with 
patients grouped by specific clinical factors.   
2.8.6 Analysis of similarity (ANOSIM) 
Analysis of similarity (ANOSIM) is a non-parametric test, used to test for significant 
differences between two or more groups (25). Results can be based on any distance 
measure, throughout this thesis comparisons were based on Sorensen and Bray-Curtis 
measure of similarity. This test allowed comparisons of community composition by clinical 
factors.     
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Similar to ANOVA, the ANOSIM is based on comparing distances within group to those 
between groups calculated; 
 
Where rb= the mean rank of distances between groups and rw= the mean rank of all 
distances. Significance is calculated using 10,000 permutations and pairwise ANOSIM tables 
are produced for R and P-values. Large positive R values signify dissimilarity between 
groups, while small values indicate groups are similar.  
2.8.7 Similarity percentage (SIMPER) 
Similarity percentage (SIMPER) analysis is used to assess the percentage contribution of 
taxa responsible for any observed differences between groups of samples (25). The overall 
significance of the difference in Bray-Curtis is assessed by ANOSIM.  
2.8.8 Mantel and partial Mantel tests 
Mantel tests are used to compare distance or similarity matrices. Using 9999 permutations 
the Pearson’s correlation between two matrices are calculated resulting in an r value, 
between -1 and +1 and the corresponding significance. Partial Mantel tests are calculated in 
the same way however, the correlation is calculated while controlling for the effects of a third 
matrix; 
 
where r(AB) is the correlation coefficient between A and B 
Depending on the hypothesis, Mantel tests can be calculated as, lower tailed, two way or 
upper tailed. For the purposes of this project Mantel tests are calculated using a lower tailed 
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test. This hypothesised that more similar samples, in terms of community composition, would 
be closer in distance or similarity of clinical factors.  
2.8.9 Mixed effects modeling  
Mixed effects modelling is a statistical modelling technique that contains both fixed and 
random effects. These models are used in a wide variety of disciplines and are particularly 
useful for the analysis of longitudinal studies and studies which may have missing values. 
Mixed effects models can be represented as;  
 
 is a known vector of observations, with mean ; is a unknown vector of fixed 
effects;  is an unknown vector of random effects, with mean  and variance-
covariance matrix ;  is the unknown vector of random errors and with mean  
 and the variance .  
Throughout this project mixed effects models were fitted in R, using the packages lmer (26), 
nlme (27), and GLMMADMB. Values of r2 were calculated using the R package MuMIn. 
Details of all mixed effects models used are fully explained in the materials and methods 
sections of each chapter. 
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Assessing the use of propidium 
monoazide and its impact on the bacterial 
community within the CF lung 
 
“Everything must be taken into account. If the fact will not fit the 
theory---let the theory go.”  
 Agatha Christie, The Mysterious Affair at Styles 
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3.1  Introduction 
In order to gain ecological insight into microbial communities it is important first to define the 
bacterial taxa present. By achieving this it becomes possible to assess community 
characteristics and predict the impact of perturbations on a system, through the use of a 
range of ecological measures, described in Chapter 2.8. This approach has been used 
widely to investigate microbial communities present in natural environments (1), with a move 
to adopting these techniques to investigate clinical systems in recent years. As technologies 
improve to allow this type of investigation, it becomes more important than ever to obtain the 
most accurate representation possible of the microbial community within a system.  
Polymicrobial infections, caused by various combinations of bacteria, fungi, viruses and 
parasites, are commonplace in human disease (2). To effectively treat these infections it is 
important to increase our understanding of the roles bacteria play in disease prognosis. This 
is crucial when considering lower respiratory tract infections, particularly those associated 
with cystic fibrosis (CF). In CF, the lung damage sustained as a result of respiratory 
infections is a major driver of worsening lung function and respiratory failure in many 
individuals (3). As a consequence an improved understanding of the microbial community 
within the lungs may influence therapy and improve prognosis, by allowing targeted 
indiviualied therapies to be administered. However, in order for this to be achieved it is 
important to establish an accurate/unbiased picture of the CF lung community.   
The use of culture independent methodologies for the identification and quantification of 
microbial species is increasing for a variety of reasons. These include their speed, reliability 
and ability to identify unusual and difficult to culture organisms as well as those in low 
abundance (4). Whilst these techniques avoid the selective biases associated with culture 
based microbiology they have their own limitations. For example; the ability to lyse cells, 
primer efficiency, contaminating DNA, as well as the intrinsic error rate involved in the use of 
sequencing technologies (5, 6). Another limitation that this study aims to address is the issue 
that standard PCR based analyses are unable to differentiate between live (or viable) 
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organisms, DNA associated with dead or damaged cells (including extracellular DNA). As 
such, this DNA may be amplified leading to overestimation of the abundance of living 
organisms. This can have implications for the analysis of microbial communities, as free 
DNA is known to persist for days or even weeks, depending on the environment, after cell 
death (7). Studies carried out on environmental samples found that DNA from dead or 
damaged cells is estimated to make up 70-74% of the total bacterial counts from marine 
sediment (8), while 76% of the total bacterial cells stained from a eutrophic river was not 
considered to be viable or active (9). Further, studies of clinical samples have revealed that if 
the issue of extracellular DNA or DNA from dead of damaged cells is not addressed, PCR 
based methodologies can result in false positives. For example, Panousis et al (2005) 
revealed a positive predictive value of 34%, when PCR was used for the diagnosis of 
infections in newly fitted prosthetic joints (10). This could lead to unnessecary treatments.    
In the context of the CF lung, the exclusion of extracellular DNA and DNA from dead or 
damaged cells is immensely important as failure to identify effective treatments and therefore 
prolonged unnecessary treatment. The reduced ability to clear the airways (11), alongside 
the pressures from the host immune response (12) and antibiotic therapy (13) results in a 
highly perturbed system, where the bacterial community is under constant stress. In 
combination, these factors result in a build up of DNA not associated with viable cells within 
the lung (4, 14, 15). 
The inclusion of extracellular DNA and DNA from dead and damaged cells in molecular 
analysis can have marked effects on community characterisation. This can lead to 
overestimation of bacterial density, a distortion of the actual relative abundance of species 
and the masking of rare, low abundant species by those in higher abundance. These 
importantly include the recognised pathogens, Achromobacter xylosoxidans, Haemophilus 
influenzae, and members of the Burkholderia cepacia complex (16). It may also mask any 
changes in community dynamics as a result of treatment or exacerbation, and it is therefore 
vital to exclude non-viable DNA from analysis. Consequently, this study uses propidium 
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monoazide (PMA) treatment to investigate the impact of extracellular DNA and DNA from 
dead or damaged cells on the bacterial community composition of CF sputum samples.  
PMA is a membrane impermeable dye that covalently binds to DNA in the presence of light 
effectively reducing the amount of extra cellular DNA and DNA from dead or damaged cells 
in a sample (7). PMA treatment has been shown to be effective, in a range of contexts, for 
assessing viable microbes using molecular techniques. For example, Nocker et al (2007) 
used end-point PCR and denaturing gradient gel electrophoresis (DGGE) to assess the 
efficacy of PMA treatment on the bacterial species detected in environmental samples. PMA 
treated samples which had been previously spiked with known quantities of heat killed 
Escherichia coli O157:H7 showed PMA could successfully suppress DNA signals (17). While 
Bae et al (2009) found that PMA treatment could be effectively used to quantify viable 
Bacteroidales cells from human faeces and wastewater influent and effluent (18). Further 
Kralik et al (2010) used similar strategies to ascertain that PMA treatment, at a concentration 
of 25 µM for 5 min, followed by 2 min of light exposure, prior to qPCR could help accurately 
quantify viable Mycobacterium avium subsp. paratuberculosis as an alternative to culture 
(19).  
Importantly for this investigation, the use of PMA has been assessed in the context of CF 
airway infections. In 2008, Rogers et al, used T-RFLP in investigate the effect of PMA 
treatment on the bacterial community within CF sputum. This study highlighted the significant 
contribution of non-viable bacteria in the CF lung to the signal obtained by T-RFLP analysis 
and the importance of avoiding this bias in community analysis (4). Further work, was also 
published by Rogers et al, in 2010, and revealed that failure to remove the influence of non-
viable organisms could result in the inability to identify statistically significant changes in 
bacterial load, particularly that of Pseudomonas aeruginosa (15). In 2013, PMA was used to 
assess community changes using qPCR and 454 high-throughput pyrosequencing, revealing 
that although there were no significant changes in the overall diversity and community 
membership, when samples were partitioned into common and rare, PMA treatment 
highlighted rare community diversity which was found to be obscured by the most common 
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and abundant species (16). Importantly for clinicians and patients, this work showed that the 
detection of recognised pathogens, particularly Achromobacter xylosoxidans (undetected to 
satellite), Haemophilus influenzae (undetected to satellite), members of the Burkholderia 
cepacia complex (undetected to core) and Mycobacterium sp. (undetected to satellite), was 
significantly influenced by PMA treatment (16). Failure to identify these species may have 
considerable influence on treatment decisions and therefore patient outcomes.        
In this study 16S rRNA gene pyrosequencing was used to assess how the bacterial 
community is affected by pre-treatment of samples with PMA. This research was undertaken 
to critically evaluate the use of PMA for the exclusion of free DNA and DNA from dead or 
damaged cells from the analysis of the bacterial community from CF lung infections, while 
allowing modelling techniques for the analysis of bacterial community changes to be 
evaluated. Finally, this study allowed the results from previous studies into the effect of PMA 
treatment to be investigated and confirmed. By assessing the use of PMA and its impact on 
the bacterial community, this study can be used to underpin the results obtained throughout 




3.2.1 Sample collection 
Sputum samples were collected from 42 adult CF patients attending the regional Cystic 
Fibrosis Centre in Southampton General Hospital, under full ethical approval from 
Southampton and South West Hampshire Research Ethics Committee (06/Q1704/26). 
Samples were collected and stored at -80°C until processing.   
3.2.2 DNA extraction and Pyrosequencing 
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Sterile scalpels were used to divide frozen samples into two equal portions, prior to a sputum 
wash being performed as described in Chapter 2.3.1. The first portion was treated with PMA 
to exclude free DNA and DNA from non-viable cells from analysis via the method described 
in Chapter 2.3.2. The second half of the sample was left untreated prior to DNA extraction. 
DNA extraction was then performed on all samples as previously stated in Chapter 2.3.3. 
Following the method outlined in Chapter 2.4.1, bacterial Golay barcode encoded 454 FLX 
Titanium amplicon pyrosequencing was performed using the primer 338F (5’- 
ACTCCTACGGGAGGCAGCAG) and 926R (5’- CCGTCAATTCMTTTRAGT). 454 
pyrosequencing using the Lib-L kit was performed at the Wellcome Trust Sanger Institute, 
Hinxton, UK. Resulting data was analysed using the Mothur sequencing analysis platform as 
previously described in Chapter 2.7 (20). The sequence data reported in this paper have 
been deposited in the European Nucleotide Archive under Study Accession Number; 
ERP007059, and Sample Accession Number; ERS551400. The relevant barcode 
information for each sample is shown in Table A3.1.  
3.2.3 Statistical analysis 
To determine whether sample size was large enough to effectively assess the bacterial 
diversity within each sample, Mothur was used to create intra-sample rarefaction curves 
without replacement (20). All further statistical analysis was performed in R version 
3.1.1(2012-07-10) (21).  
Changes in bacterial diversity were assessed using three complementary measures; species 
richness (S*), Shannon-Wiener (H’), and Simpson’s (1-D) indices of diversity as described 
previously, Chapter 2.8.1. To avoid potential bias all measures were calculated using a 
uniform, randomised resampling, see Chapter 2.8.1 (16). Diversity measures were re-
sampled to the lowest number of sequence reads (n=202).  
Meta-analyses were used to summarise the effect of PMA treatment on measures of 
bacterial diversity and composition using Hedges estimator of effect size, as explained in 
Chapter 2.8.3. The R package Metafor, was used to compare treated to untreated samples 
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by summarising the overall effect of the 36 paired samples, each patient was treated as a 
separate independent study (22). The overall effect of treatment was calculated using the 
standardised mean difference for each sample was calculated using hedges g. 
Species were partitioned using a variety of criteria, explained below, to allow investigation of 
the effect of PMA treatment on different aspects of the bacterial community. Firstly, species 
were partitioned into common, the most persistent and abundant, and rare, transient and 
less abundant, using a distribution abundance relationship, described by Magurran and 
Henderson (2003) (23). Common species were described as those present in more that 75% 
of the total samples, while all others were considered to be rare. Bacterial species were then 
partitioned according to oxygen tolerance; the aerobic species group consisted of all aerobic 
species, facultative anaerobes and microaerophiles. The anaerobic species group contained 
only strict anaerobes. Finally members of the oral microbiota were identified using the 
human oral microbiome database (HOMD, http://www.homd.org).  
The similarity of treated samples were compared to untreated in order to assess the changes 
community composition as a result of PMA treatment using Bray-Curtis measure of similarity 
(accounting for both presence/absence and abundance of species), as described in Chapter 
2.8.2. To avoid potential bias Bray-Curtis measure of similarity was calculated using a 
modified version of the uniform resampling method previously used (n=202), see Chapter 
2.8.2 for full details (16).  
Mixed effects models, using the R package lme4 were used throughout the analysis of this 
data to allow comparisons between treated and untreated samples using a variety of 
diversity and composition measures as well as using different partitioning criteria to gain an 
overall understanding of the effect of PMA treatment in the bacterial community (24). All 
models used patient as a random effect in order to account for between patient variability. r2 
values were calculated using the MuMIn package in R (21).  
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3.3 Results 
A total of 260087 bacterial sequences (mean = 2653.9 ± SD 2196.7, n=96), were generated 
with 152818 sequences from non-PMA samples (mean = 3118.7 ± SD 2322, n=49) and 
107269 sequences from PMA samples (mean = 2189.1 ± SD 1979.6, n=49).  
The diversity and composition of bacterial communities within each of the paired samples 
(non-PMA n=42, PMA n=42) was assessed by 16S rRNA gene 454 pyrosequencing. 
Rarefaction curves were used to test whether the number of sequences per sample was 
sufficiently large to capture a robust cross-section of the bacterial diversity (Figure 3.1.1, 
Figure 3.1.2). To this end, 6 paired samples, from patient 5, 26, 28, 32, 40 and 55, were 
removed due to insufficient sampling depth, indicated by rarefaction curves not reaching an 
asymptote. This resulted in, no PMA treatment n=36 and PMA treatment n=36, (Total 
samples n=72), samples being included in the study for further analysis. Following removal 
of these samples, a total of 215649 bacterial sequence reads (mean = 2995.11 ± SD 
2012.41, n=72) identifying 41 genera and 98 bacterial species remained, a complete list is 
shown in Table A3.2. No difference was observed between the PMA and non-PMA samples 
after the removal of samples that did not have the required sampling depth.  
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3.3.1 Diversity 
As a result of varying levels of sampling depths obtained, a feature of high throughput 
sequencing, a randomised resampling method (with a uniform sub-sample size of n=202 
sequences, equating to the smallest number of sequences recovered), as described in 
Chapter 2.8.1, was applied to the samples to reduce potential bias in the comparison of 
community diversity. Three recognised metrics of community diversity were applied to the 
data, species richness (S*), Shannon-Wiener index (H’), and Inverse Simpson’s index (1-D).  
All diversity measures were found to be highly variable between individual samples, 
regardless of treatment. As shown in Figure 3.2, meta-analysis revealed both significantly 
positive and significantly negative effects of PMA treatment for each individual sample. 
However, the overall effect of each diversity measure, calculated using Hedges g, revealed 
no overall significant changes, indicated by the confidence intervals crossing 0, in any of the 
3 diversity measures, shown in detail in Figure 3.3. Mixed effect models confirmed the 
findings of the meta-analysis, S*, P=0.542, r2=0.0004, H’, P=0.070, r2=0.008, 1-D, P=0.051, 
r2=0.012. Changes in overall species richness were observed between the treated and non-
treated samples, with 81 species observed in the non-treated samples compared with 91 in 
the treated however, this was not significant when between patient variability was accounted 
for.   
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Figure 3.2 The effect of PMA treatment on the bacterial community diversity using 
weighted mean differences.   
A) species richness (S*), B) Shannon-Wiener index (H’) and C) Inverse Simpson’s (1-D). 
The overall effect of PMA treatment on each diversity measure was calculated using 
Hedges’ g effect size measure, error bars represent 95% confidence intervals of the effect 
size (n=36). Negative values indicate lower diversity in PMA treated samples. Error bars 
crossing zero indicate no significant effect of PMA treatment.  
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Figure 3.3 The overall effect of PMA treatment on the diversity measure. 
Species richness (S*), Shannon-Wiener index (H’) and Inverse Simpson’s (1-D) using 
Hedges’ g effect size measure, error bars represent 95% confidence intervals of the effect 
size (n=36). Error bars crossing zero indicate no significant effect of PMA treatment.  
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A distribution abundance relationship (DAR), was employed to partition the species in those 
considered to be common (both persistent and abundant) and those considered to be rare 
(transient with low abundance). The log species abundance was plotted against the sample 
persistence (the number of samples in which a particular species appears) showing a 
significant positive relationship for both the untreated (n=36, F(1,83)=310.6, P<0.001), and 
treated (n=36, F(1,89)=243.6, P<0.001) samples. This direct relationship between species 
persistence and abundance indicates a coherent metacommunity. Species present in more 
than 75% of the samples were denoted as common, all others were deemed rare.  As shown 
in Figure 3.4, the DAR revealed 5 species present in more than 75% of both the treated and 
untreated samples, Prevotella melaninogenica, Veillonella dispar, Streptococcus 
pneumoniae, S. parasanguinis and Pseudomonas aeruginosa.  Gemella morbillorum was 
categorised as common in the untreated samples and rare in those exposed to PMA 
treatment.  
Mixed effect models were used to investigate the effect of PMA treatment on the species 
identified as common. These changes were found to be variable by species, a significant 
positive effect of PMA treatment was observed in the relative abundance of the OTUs, S. 
pneumoniae (P<0.001, r2=0.07) and S. parasanguinis (P<0.001, r2=0.05). While PMA 
treatment was found to have a significant negative effect on the abundance of; P. aeruginosa 
(P=0.004, r2=0.03).  No significant change in relative abundance was observed for P. 
melaninogenica (P=0.024, r2=0.02) or V. dispar (P=0.03, r2=0.04). G. morbillorum was the 
only species to be classified as both common and rare, being common in the untreated 
samples but rare in the treated, despite this no significant difference in abundance was 
observed (P=0.058, r2=0.01). Of the rare species present in more than 50% of the samples 
(but <75%), PMA was found to result in significant increase in the abundance of; Bacteroides 
acidifaciens (P=0.01, r2=0.03), Shuttleworthia satelles (P=0.04, r2=0.01), Granulicatella 
adiacens (P<0.001, r2=0.05), and Porphyromonas catoniae (P=0.006, r2=0.06).   
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Figure 3.4 Persistence abundance curves.   
A) Untreated samples (n=36, F(1,83)=310.6, P<0.001), B) PMA treated samples (n=36, 
F(1,89)=243.6, P<0.001).  Common species were defined as those that fell in the upper 
quartile (right of the vertical line), all species that fell below the line were considered to be 
rare, These OTUs are shown in Table S2.  
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3.3.2 Aerobic and anaerobic species 
Recent studies have revealed a steep oxygen gradient within the mucus of the CF lung and 
as a result anaerobic species have been repeatedly isolated from the lung of CF patients 
through both culture and culture independent methodologies (25-27). To investigate the 
contribution of anaerobes to the bacterial community within the CF lung all species were 
partitioned into either aerobic or anaerobic species. All species able to grow in aerobic 
conditions, including facultative anaerobes and microaerophiles, were considered aerobic. 
Only strict anaerobes were partitioned into the anaerobic group. Species identified as 
anaerobes are indicated in Table A3.2.   
No significant change in the relative abundance of aerobes (n=44, P=0.813, r2<0.001) and 
anaerobes (n= 54, P=0.655, r2<0.001) was found when samples were treated with PMA.  
However, when diversity measures were applied there was a significant increase in 
Simpson’s diversity index for the aerobic group (P=0.036, r2=0.021) when samples were 
treated with PMA. This was not observed for S* (P=0.121, r2=0.007) or H’ (P=0.087, 
r2=0.013). Furthermore this change was not observed in the anaerobic species; S*, P=0.108, 
r2=0.005, H’, P=0.763, r2<0.001, 1-D, P=0.606, r2=0.002. This shows that more rare aerobic 
OTUs are identified with the use of PMA, suggesting that when free DNA is removed from 
the sample a more complete picture of rare OTUs can be observed.  
3.3.3 The oral microbiota 
Using the strict criteria above, both aerobic and anaerobic species are found to make up the 
oral microbiota. Several studies have investigated the presence of members of the human 
oral microbiota in the CF lung, establishing that their presence is unlikely to be due to 
contamination, but true members of the bacterial community (25, 28). Therefore, oral species 
present within the CF lung represent potential pathogens that may be clinically important. In 
this study 75 of the bacterial species identified were known to be commonly present in the 
oral cavity, Table 3.1 (29). All species partitioned as common were identified as members of 
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the oral microbiota. Treating samples with PMA resulted in a significant decrease in the 
abundance of the total oral species detected (P<0.001, r2=0.02) and S* (P=0.026, r2=0.09), 
however, no changes in the community diversity were observed; S*, P=0.185, r2=0.003, H’, 
P=0.755, r2<0.001, 1-D, P=0.614, r2<0.001.  
3.3.4 Community composition 
In order to compare changes in community composition between treated and untreated 
samples, the Bray-Curtis measure of similarity (SBC, which accounts for the number and 
abundance of species present in each community and those that are shared) was used. To 
minimise possible bias due to sampling depth, SBC was calculated using randomised 
resampling to assess the similarity of treated to untreated samples. High variability was 
observed between samples with a range of similarities between 0.99 and 0.11, as shown in 
Figure 3.5.   
To investigate possible explanations for the variation in similarity observed, the results of SBC 
were compared to values of dominance. The Berger-Parker measure of dominance, the 
proportional abundance of the most abundant species present in the community (30), was 
calculated showing a significant decrease in dominance when samples were treated with 
PMA (P=0.028, r2=0.02). To investigate any relationship between dominance and changes in 
similarity, Berger-Parker was plotted against SBC. A significant positive relationship was 
found between change in similarity and dominance (P<0.001, r2=0.34). Samples more highly 
dominated by a single species were found to show less change in similarity with PMA 
treatment than those with a more diverse community, Figure 3.6. Dominance was also found 
to have a significant relationship with species richness (P<0.001, r2=0.48), where less 
diverse communities were found to be more highly dominated by one or a small number of 
species.  
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Figure 3.5 The effect of PMA treatment on community composition using the Bray-
Curtis measure of similarity.  
Points represent the Bray-Curtis similarity between non-treated and PMA treated samples for 
each individual patient. The closer the given value is to 1 the more similar the community is 
to the original untreated sample community. This suggests some patients show very few 
changes in community composition with PMA treatment while other show considerable 
changes in both the OTUs identified and their abundance, leading to values closer to 0.   
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Figure 3.6 The relationship between community similarity (Bray-Curtis) and 
dominance (Berger-Parker). 
The difference in similarity, between non-treated and PMA treated samples using Bray-Curtis 
similarity, plotted against the dominance measured by Berger-Parker dominance measure.  
A linear model has been fitted to the data (P<0.001, r2=0.34) in order to highlight the 
significant relationship between similarity and dominance. An arc-sine transformation was 
applied to the Bray-Curtis measure in order to make the data normal in order to correctly fit 
the model without violating assumptions.  
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3.4 Discussion 
As highlighted in the introduction (Chapter 1.5), the lower respiratory tract can be a 
challenging environment for bacterial species to colonise and persist in. Despite the lack of 
an effective mucociliary escalator in patients with CF, bacteria colonising the CF lung, 
continue to be subjected to host immune responses as well as a wide variety of antimicrobial 
therapies (16). Whilst some cells may be capable of growth in this context, the host immune 
response and use of antimicrobials mean that only a certain percentage of cells entering the 
lower respiratory tract will be viable. By conventional molecular analysis, DNA from dead 
cells, lysed cells and otherwise non-viable cells still have the potential to contribute signal to 
culture-independent studies. As such, the persistence of extracellular DNA and that from 
dead or damaged microbial cells under this perturbed system makes it challenging to define 
the bacterial community using culture independent technologies. This study aimed to 
establish the effect of pre-treating sputum samples, from patients suffering from CF, with 
PMA.  
Several previous studies have observed high variability in the bacterial communities between 
CF patients (14, 31, 32). In order to account for this high degree of inter-individual variation 
several methods are available. In this study, meta-analysis, which allows an overall effect 
size to be calculated from weighted mean differences, is compared to mixed effect 
modelling, which can be used to model any changes between the groups while accounting 
for between patient differences. Both methods showed no significant overall change in 
diversity with the use of PMA. However, the use of the meta-analysis approach supported 
the findings of Rogers et al (2013) suggesting that without the use of PMA the diversity of the 
local bacterial community in individual samples can be under or over estimated.  
Previous studies have established that there is a divide in the metacommunity, between the 
common and locally abundant species and those that are rare or transient, within the CF 
lung (32, 33). As a result failure to make the distinction between groups can result in 
important aspects of the species abundance distributions being neglected. In such studies, 
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the core-satellite group approach was established using a Poisson distribution to partition 
species into groups. This method allowed samples to be partitioned into those that were 
randomly (satellite) and non-randomly (core) distributed. However, due to a quirk in this 
analysis some species with low persistence across the dataset could be assigned as a core 
species due to their high abundance in a small number of samples. To overcome this, a 
distribution abundance relationship was employed to partition and allow only the species 
appearing in more than 75% of the samples to be considered common. This distribution 
showed a direct relationship between persistence and abundance, indicating a coherent 
metacommunity. By partitioning identified species into common and rare groups it was 
observed that the use of PMA treatment had a significant effect on the abundance of S. 
pneumoniae, S. parasanguinis and importantly the recognised pathogen P. aeruginosa. 
Significant changes in the abundance of these species could have marked consequences for 
downstream analysis of sequencing, as important community changes as a result of 
treatment or other perturbations may be masked. This could also have implications for 
treatment decisions that may be informed by misrepresentative data.  
Rogers et al (2013) observed changes in species distribution between the treated and non-
treated samples, importantly the movement of recognised pathogens were observed 
between the core and satellite groups (16). However, in this study only Gemella morbillorum 
moved between the common and rare groups with PMA treatment. No movement of 
recognised CF pathogens was observed, which may be due to the more stringent 
partitioning applied to the community, or alternatively, a result of the highly P. aeruginosa 
dominated communities observed in this study. 
It has been well established that anaerobic species make up an important part of the 
bacterial community within the CF lung (25-27). As such, all identified species were 
partitioned into anaerobes (strictly anaerobic species) and aerobes (aerobic, facultative 
anaerobes or microaerophiles) in order to establish the effect of PMA on the relative 
abundance and community diversity of each species group. While it was observed that 
treatment with PMA had no overall effect on the anaerobic community diversity, a significant 
 Chapter 3   100 
increase (P<0.05) in Simpson’s index of diversity was shown in the aerobic community. 
Furthermore, the fact that there was no change in the other diversity measures used 
suggests that the community shift observed was not simply to do with a change in richness 
or abundance, but rather a combination of the two factors leading to an increase in 
community diversity. One explanation may be that the antibiotic treatments used targeted the 
most abundant aerobic species, thereby allowing more of the rare community to be 
identified. 
Questions about whether the detection of members of the oral microbiota is due to sampling 
contamination rather than their presence within the lung community have been raised in 
previous studies (26, 28, 32, 34). Despite the use of PBS washes to remove saliva, and 
therefore possible oral contamination, the majority (n=75) of the species identified within our 
sample set are known to be present in the human oral cavity. This strongly suggests these 
species are true (and important) members of the lower respiratory bacterial community, 
perhaps colonising as a result of microaspiration of microbes from the oral cavity into the 
lower respiratory tract. While no change in diversity was observed, there was a significant 
decrease in the relative abundance of the members of the oral community, implying that 
PMA treatment changes the community composition allowing less abundant aerobic 
members of the community to be identified.   
Bray-Curtis measure of similarity was used to investigate changes in community 
composition. PMA treated samples were compared to the untreated sample in all cases, 
revealing a high level of variation between samples. By comparing these results to those 
generated using the Berger-Parker sample dominance measure, samples revealed to be 
more highly dominated by a single species showed less change in community composition 
with PMA treatment. Patients dominated by a single species were found to have less diverse 
bacterial communities in terms of species richness. This would explain the conserved nature 
of dominated communities, where the dominant species out competes less abundant taxa for 
space and resources. As such, similar patterns have been observed when the diversity and 
community composition of grasslands was investigated (35). Therefore, the effect of PMA 
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treatment on the diversity and community composition of highly dominated samples is 
expected to be significantly less than those with more diverse communities.  
The CF lung contains a wide range of species, making up highly variable communities under 
constant pressure from a wide range of immune and therapeutic factors (36, 37). These 
perturbations within the lung create a dynamic community that is constantly evolving. To 
investigate how the community is affected by perturbations, it is important to be able to 
differentiate between viable organisms and DNA from dead or damaged cells. This is 
particularly important when considering the effect of antibiotic treatment regimes, which may 
be masked by the presence of DNA from dead or damaged cells, resulting in skewed results 
and ultimately failure to assess the effectiveness of treatment.  
In this study it the inclusion of DNA from dead or damaged cells prevents accurate 
characterisation of the bacterial community by leading to an over or under estimation of 
diversity and significant changes in the relative abundance of the most common species, as 
well as those characterised as members of the oral microbiota. Analysis of the viable 
community can allow the identification of rare bacterial species that would otherwise be 
masked by DNA from non-viable sources. This study also highlighted the huge variation 
observed in bacterial community composition between patient samples. By using mixed 
effect models, which allow this variation between patients to be investigated, the effect of 
PMA treatment could efficiently be calculated for a range of ecological measures.  
From a clinical perspective, the use of PMA treatment for the exclusion of DNA from dead 
and damaged cells appears increasingly vital to provide accurate information on treatment 
progression and effectiveness. Therefore PMA treatment will be incorporated into the 
methodologies used to prepare samples for culture independent sequencing techniques 
throughout this dissertation.    
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3.6 Appendix 
Table A3.1 The raw sequence data reported in this Chapter have been deposited in the 
European Nucleotide Archive short read database  
Study Accession Number: ERP007059, Sample Accession Number: RS551400. A list of 








ACAGTGCTTCAT	   10	   No	  
ACATCACTTAGC	   10	   Yes	  
ACATGATCGTTC	   11	   No	  
ACATTCAGCGCA	   11	   Yes	  
ACATGTCACGTG	   12	   No	  
ACCACATACATC	   12	   Yes	  
ACCAGCGACTAG	   14	   No	  
ACCTCGATCAGA	   14	   Yes	  
ACCTGTCTCTCT	   15	   No	  
ACGAGTGCTATC	   15	   Yes	  
ACGACGTCTTAG	   16	   No	  
ACGATGCGACCA	   16	   Yes	  
ACGCGATACTGG	   18	   No	  
ACGCTATCTGGA	   18	   Yes	  
ACGCTCATGGAT	   19	   No	  
ACGGTGAGTGTC	   19	   Yes	  
ACGGATCGTCAG	   20	   No	  
ACGTACTCAGTG	   20	   Yes	  
ACGTCTGTAGCA	   21	   No	  
ACGTGCCGTAGA	   21	   Yes	  
ACGTGAGAGAAT	   22	   No	  
ACGTTAGCACAC	   22	   Yes	  
ACTACAGCCTAT	   23	   No	  
ACTAGCTCCATA	   23	   Yes	  
ACTACGTGTGGT	   24	   No	  
ACTATTGTCACG	   24	   Yes	  
ACTCACGGTATG	   25	   No	  
ACTCGATTCGAT	   25	   Yes	  
ACTCAGATACTC	   26	   No	  
ACTCGCACAGGA	   26	   Yes	  
ACTGACAGCCAT	   28	   No	  
ACTGTACGCGTA	   28	   Yes	  








ACTTGTAGCAGC	   29	   Yes	  
AAGCTGCAGTCG	   3	   No	  
AATCGTGACTCG	   3	   Yes	  
ACTGTGACTTCA	   30	   No	  
AGAACACGTCTC	   30	   Yes	  
AGACCGTCAGAC	   31	   No	  
AGACTGCGTACT	   31	   Yes	  
AGACGTGCACTG	   32	   No	  
AGAGAGCAAGTG	   32	   Yes	  
AGAGCAAGAGCA	   33	   No	  
AGAGTCCTGAGC	   33	   Yes	  
AGATCGGCTCGA	   35	   No	  
AGATGTTCTGCT	   35	   Yes	  
AGATCTCTGCAT	   36	   No	  
AGCACACCTACA	   36	   Yes	  
AGCACGAGCCTA	   37	   No	  
AGCAGTCGCGAT	   37	   Yes	  
AGCAGCACTTGT	   38	   No	  
AGCATATGAGAG	   38	   Yes	  
AATCAGTCTCGT	   4	   No	  
ACACACTATGGC	   4	   Yes	  
AGCGACTGTGCA	   40	   No	  
AGCGCTGATGTG	   40	   Yes	  
AGCGTAGGTCGT	   41	   No	  
AGCTCCATACAG	   41	   Yes	  
AGCTATCCACGA	   42	   No	  
AGCTCTCAGAGG	   42	   Yes	  
AGCTGACTAGTC	   43	   No	  
AGGACGCACTGT	   43	   Yes	  
AGGTGTGATCGC	   45	   No	  
AGTACTGCAGGC	   45	   Yes	  
AGTACGCTCGAG	   46	   No	  








AGTCACATCACT	   47	   No	  
AGTCTACTCTGA	   47	   Yes	  
AGTCCATAGCTG	   48	   No	  
AGTCTCGCATAT	   48	   Yes	  
ACACATGTCTAC	   5	   No	  
ACACGGTGTCTA	   5	   Yes	  
AGTGCGATGCGT	   50	   No	  
AGTGTCACGGTG	   50	   Yes	  
AGTTAGTGCGTC	   52	   No	  
AGTTCTACGTCA	   52	   Yes	  
ATACACGTGGCG	   54	   No	  
ATACGTCTTCGA	   54	   Yes	  
ATACTATTGCGC	   55	   No	  
ATAGCTCCATAC	   55	   Yes	  
ATACTCACTCAG	   56	   No	  
ATAGGCGATCTC	   56	   Yes	  
ATATGCCAGTGC	   58	   No	  
ATCACTAGTCAC	   58	   Yes	  
ACACGAGCCACA	   6	   No	  
ACACTAGATCCG	   6	   Yes	  
ATGCACTGGCGA	   67	   No	  
ATGCCTGAGCAG	   67	   Yes	  
ATGGATACGCTC	   69	   No	  
ATGGCGTGCACA	   69	   Yes	  
ACACTGTTCATG	   7	   No	  
ACAGAGTCGGCT	   7	   Yes	  
ATTATCGTGCAC	   73	   No	  
CAACACGCACGA	   73	   Yes	  
GTCGTGTGTCAA	   77	   No	  
GTCTATCGGAGT	   77	   Yes	  
GTCTACACACAT	   78	   No	  
GTCTCATGTAGG	   78	   Yes	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Table A3.2 Species-level identities of detected bacterial taxa identified from 36 sputum 
samples collected from CF patients. 
Given the length of the ribosomal sequences analysed (approx 350bp), these identities 
should be considered putative. Ae denotes aerobe and An, Anaerobe. Only strict anaerobes 
were classified as anaerobes, whereas aerobes, facultative anaerobes, and microaerophiles 
were classified as aerobes. O indicates members of the oral microbiota according to the 
Human Oral Microbiome database (38). Organisms  considered to be common are 
highlighted in bold.  
Class Family Species Anaerobes Oral 
Actinobacteria Actinomycetaceae Actinobaculum massiliense Ae 
 
  
Actinomyces massiliensis Ae O 
  
Actinomyces odontolyticus Ae O 
  
Actinomyces oris Ae O 
 







Microbacteriaceae Microbacterium oxydans Ae 
 
 
Micrococcaceae Rothia dentocariosa Ae 
 
 
Nocardiaceae Nocardia cyriacigeorgica Ae 
 
 
Propionibacteriaceae Propionibacterium acnes Ae O 
  
Propionibacterium 
propionicum Ae O 
 
Bifidobacteriaceae Scardovia wiggsiae An 
 
 
Coriobacteriaceae Atopobium parvulum An O 
  
Cryptobacterium curtum An O 
  
Olsenella uli An O 
  
Slackia exigua An O 
Bacteroidia Bacteroideceae Bacteroides acidifaciens An 
 
 
Porphyromonadaceae Barnesiella intestinihominis An 
 
  
Paludibacter propionicigenes An 
 
  
Porphyromonas catoniae An 
 
  
Porphyromonas endodontalis An O 
  
Tannerella forsythia An O 
 
Prevotellaceae Alloprevotella rava An 
 
  
Prevotella bivia An O 
  
Prevotella denticola  An O 
  
Prevotella loescheii An O 
  
Prevotella maculosa An O 
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Table A3.2 Continued 
Class Family Species Anaerobes Oral 
  Prevotella melaninogenica An O 
  
Prevotella nanceiensis An 
 
  
Prevotella nigrescens An O 
  
Prevotella oris An O 
  
Prevotella pallens An O 
  
Prevotella pleuritidis An O 
  Prevotella shahii An O 
  
Prevotella tannerae An O 
  
Prevotella timonensis An 
 
Flavobacteria Flavobacteriaceae Capnocytophaga gingivalis Ae O 
  
Capnocytophaga haemolytica Ae O 
  
Capnocytophaga ochracea Ae O 
  
Capnocytophaga sputigena Ae O 
Bacilli 
Bacillales Incertae Sedis 
XI Gemella morbillorum Ae O 
 
Staphylococcaceae staphylococcus aureus Ae O 
 
Aerococcaceae Abiotrophia defectiva Ae O 
 
Carnobacteriaceae Granulicatella adiacens Ae O 
 
Lactobacillaceae Lactobacillus fermentum  Ae O 
  
Lactobacillus johnsonii Ae O 
  
Lactobacillus salivarius Ae O 
 
Streptococcaceae Streptococcus parasanguinis Ae O 
  
Streptococcus pneumoniae Ae O 
  
Streptococcus sanguinis Ae O 




Sedis XI Parvimonas micra An O 
  
Peptoniphilus lacrimalis An O 
  
Mogibacterium diversum An O 
 
Eubacteriaceae Eubacterium brachy An O 
  
Eubacterium infirmum An O 
 
Lachnospiraceae Butyrivibrio hungatei An O 
  
Catonella morbi An O 
  
Howardella ureilytica An 
 
  
Oribacterium sinus An O 
  
Shuttleworthia satelles An O 
  
Stomatobaculum longum An 
 
  
Lachnoanaerobaculum orale  An O 
 
Peptococcaceae Peptococcus niger An 
 
 
Peptostreptococcaceae Peptostreptococcus stomatis An O 
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Table A3.2 Continued 
Class Family Species Anaerobes Oral 
 
Veillonellaceae Anaeroglobus geminatus An O 
  
Dialister invisus An O 
  
Dialister micraerophilus An O 
  
Dialister pneumosintes An O 
  
Megasphaera micronuciformis An O 
  
schwartzia succinivorans An O 
  
Selenomonas noxia An O 
  
Selenomonas sputigena An O 
  
Veillonella dispar An O 
  
Veillonella ratti An O 
Fusobacteria Fusobacteriaceae Fusobacterium nucleatum An O 
 
Leptotrichiaceae Leptotrichia buccalis An O 
  
Leptotrichia wadei An O 
  
Sneathia sanguinegens An O 
Alphaproteobacteria Sphingomonadaceae Sphingomonas leidyi Ae 
 
Betaproteobacteria Alcaligenaceae Achromobacter xylosoxidans Ae O 
 
Burkholderiaceae Lautropia mirabilis Ae O 
  
Ralstonia pickettii Ae 
 
 
Comamonadaceae Comamonas testosteroni Ae 
 
 
Neisseriaceae Kingella oralis Ae O 
  
Neisseria bacilliformis Ae O 
  
Neisseria flavescens Ae O 
  
Neisseria oralis Ae O 
Epsilonproteobacteria Campylobacteraceae Campylobacter concisus Ae O 
Gammaproteobacteria Cardiobacteriaceae Cardiobacterium valvarum Ae 
 
 
Enterobacteriaceae Escherichia coli Ae O 
 
Pasteurellaceae Haemophilus haemolyticus Ae 
 
  
Haemophilus parainfluenzae Ae O 
 
Moraxellaceae Moraxella osloensis Ae O 
 
Pseudomonadaceae Pseudomonas putida Ae 
 
  
Pseudomonas aeruginosa Ae O 
 
Xanthomonadaceae Stenotrophomonas maltophilia Ae O 
Mollicutes Mycoplasmataceae Mycoplasma salivarium Ae O 
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Chapter 4: Collection to storage time affects 
respiratory samples 
 
Time between sputum sample collection 
and storage significantly influences 
bacterial sequence composition from 
Cystic Fibrosis respiratory infections 
 
Cuthbertson L, Rogers G.B., Walker A.W., Oliver A., Hafiz T., Hoffman L.R., Carroll M.P., 
Parkhill J., Bruce K.D., van der Gast C.J. (2014) Bacterial respiratory infection 
composition changes with increasing time between sputum sample collection and 
storage. Journal of Clinical Microbiology, 52(8):3011-3016 
 
As outlined in the previous chapter, accurate investigation of the microbial community within 
CF sputum is hugely important to inform treatment choices. The use of PMA allows only the 
viable community to be analysed preventing free DNA and DNA from dead or damaged cells 
from being included in analysis, therefore giving a true picture of the community within the 
lung. As a continuation of this, Chapter 4 investigates how sample handling can affect the 
bacterial community within sputum. This Chapter has been published in the Journal of 
Clinical Microbiology. 
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4.1 Abstract 
Spontaneously expectorated sputum is traditionally used as the sampling method for the 
investigation of lower airway infections. Whilst guidelines exist for the handling of these 
samples for culture-based diagnostic microbiology, there is no comparable consensus on 
their handling prior to culture-independent analysis. The increasing incorporation of culture-
independent approaches in diagnostic microbiology means it is of critical importance to 
assess potential biases. The aim of this study was to assess the impact of delayed freezing 
on culture-independent microbiological analyses, and to identify acceptable parameters for 
sample handling. Sputum samples from eight adult cystic fibrosis (CF) patients were 
collected and aliquoted into sterile Bijou bottles. Aliquots were stored at room temperature 
before freezing at -80°C for increasing intervals up to 72 hour period. Samples were treated 
with propidium monoazide, to distinguish live from dead cells, prior to DNA extraction, and 
16S rRNA gene pyrosequencing was used to characterise the bacterial composition. 
Substantial variation was observed in samples with high diversity bacterial communities over 
time, whereas low diversity communities dominated by recognised CF pathogens varied little 
regardless of time to freezing. Partitioning into common and rare species demonstrated that 
the rare species drove changes in similarity. The percentage abundance of anaerobes over 
the study significantly decreased after 12 hours at room temperature (P=0.008). Failure to 
stabilise samples at -80°C within 12 hours of collection results in significant changes in the 
detected community composition. 
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4.2 Introduction  
Next generation sequencing techniques are increasingly being used to characterise 
respiratory microbiota in many lung diseases, including cystic fibrosis (CF) lower airway 
microbiota (eg.1-4). These analyses have revealed microbial communities within the CF lung 
to be more complex and diverse than previously considered. Importantly, they have also 
detected many bacterial species that would not be reported by standard diagnostic 
microbiology (eg. 5,6), as well as identifying relationships between microbiota characteristics 
and host age, lung function, and disease progression (7-9).  
In the majority of cases, these investigations relied on spontaneously expectorated sputum 
as a means to sample the bacterial communities in the lower airways. Sputum is favoured 
due to ease of collection, and the fact that culture-based microbiological studies, of adult 
patients have traditionally used sputum samples as a basis for microbiological analysis. 
Whilst guidelines exist for the handling of respiratory samples for culture-based diagnostic 
microbiology (10), there is no consensus on how such samples should be handled to ensure 
that resulting culture-independent analyses yield results reflecting the microbes therein. With 
the increasing move towards the incorporation of culture-independent methods into 
diagnostic microbiology (11) it is increasingly important to identify and minimise areas of 
potential bias  
Post-collection sample transportation and storage represents a period during which changes 
can occur in bacterial community of clinical samples, resulting in analytical bias due to, for 
example, bacterial proliferation, cell death or degradation of nucleic acids. In order to 
minimise these biases sputum samples collected for culture-independent analyses are 
typically stored at -80°C. However, many clinical sites, including those that treat CF patients, 
lack ready access to ultra-low temperature freezers; the standard recognised method for 
maintenance of sample integrity and biobanking. As a result, sputum samples may remain at 
room temperature for extended periods, impacting both traditional and culture-independent 
analyses.  
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A prior study used 16S rRNA gene pyrosequencing of a single sample to assess the effect of 
extended periods of incubation at room temperature on bacterial community profiles, but did 
not find significant divergence in community composition over the study period (12). 
Conversely, in an earlier study, using ribosomal transcripts to examine the V3 region of the 
16S rRNA gene by quantitative PCR and denaturing gradient gel electrophoresis (DGGE), 
significant divergence in bacterial quantitation and community profiling was observed (13). 
RNA-based approaches have the advantage of limiting analysis to active cells. However, a 
related exclusion of non-viable cells and extracellular DNA can be achieved in DNA-based 
analysis through the treatment of samples with propidium monoazide (PMA), as we have 
demonstrated in previous analyses of CF sputum (14-16). 
We hypothesised that the period of time between sample collection and stabilisation by 
freezing is significantly related to the resultant bacterial community composition, as 
determined by 16S rRNA gene pyrosequencing in combination with PMA treatment. From 
this our overarching aim was to determine an appropriate window of time from sample 
collection to storage at -80°C that would allow reliable culture-independent microbiological 
analysis of sputum samples. 
 
4.3 Methods 
4.3.1 Sample collection 
Sputum samples were collected, under full ethical approval from the Southampton and South 
West Hampshire Research Ethics Committee (06/Q1704/26), from eight adult patients 
attending the regional Cystic Fibrosis Centre in Southampton General Hospital for treatment 
for clinical exacerbation. Patients were chosen for their abilities to provide sputum samples 
of 3 ml or more.  
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Samples were collected during physiotherapy and immediately aliquoted into sterile 5 ml 
Bijou bottles and stored at room temperature until freezing to -80°C at specified intervals. 
Samples at t=0 were stored at -80°C immediately. The remaining samples were held at room 
temperature before storage at -80°C, for 1, 3, 6, 9, 12, 18, 24, 36, 48, 60 and 72 hours. The 
72 hour storage period was chosen to allow investigation of changes in the bacterial 
community beyond the maximum 48 hour storage recommended by Health Protection 
England for culture-based diagnostic microbiology (10). 
4.3.2 DNA extraction and Pyrosequencing 
Sputum samples were washed three times with 1x phosphate buffered saline. Free DNA and 
DNA from non-viable cells were excluded from analysis via crosslinking with PMA (14, 15) 
prior to DNA extraction, as previously described (16). Bacterial Golay Barcode encoded FLX 
amplicon pyrosequencing was performed using the primer 338F (5'- 
ACTCCTACGGGAGGCAGCAG) and 926R (5'- CCGTCAATTCMTTTRAGT). Initial 
generation 16S rRNA gene amplicons involved a one step PCR of 25 cycles using 
AccuPrimeTM Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA). 454 
pyrosequencing using the Lib-L kit was performed at the Wellcome Trust Sanger Institute, 
Hinxton, UK. 
4.3.3 Sequence analysis 
The mothur sequencing analysis platform was used to analyse the resulting data (17). Failed 
sequence reads, low quality sequence ends, tags and primers, were initially removed, 
followed by sequences below 400bp and any sequences that included ambiguous base calls 
and homopolymers longer than 8 bases.  Chimeras were removed in mother using the 
Perseus software program (18). Sequences were assembled into operational taxonomic 
units (OTUs) clusters at 97% identity, to give an approximation of species (19), and identified 
using the RDP reference database. Representative sequences were used to give an 
appropriate species level identification for OTUs using NCBI BlastN.  The raw sequence data 
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generated within the current study have been submitted to the NCBI Short Read Archive 
database under the study accession number SRP036061, Table S2. 
4.3.4 Statistical analysis 
All statistical analysis was performed in R (20). Three complementary measures of diversity 
were used as previously described (9) to identify changes in bacterial diversity in the same 
sample kept at room temperature for different durations; species richness (S*), Shannon-
Wiener (H’), and Simpson’s (1-D) indices of diversity (21). The Bray-Curtis similarity index 
(21) was calculated using randomised re-sampling to compare changes in community 
composition over time at room temperature. To avoid potential biases due to sampling depth, 
randomised re-sampling with a uniform resample size (n=200 to match smallest sample size) 
was carried out (22), as described previously (9, 23). 1000 iterations of each resampling 
were performed to obtain the mean diversity and similarity coefficients and standard 
deviation of the mean. The Berger-Parker (d) measure of dominance was calculated using 
the BiodiversityR package (24). 
Bacterial species at t=0 for each patient were partitioned into common and rare species 
using the inflection point method from rank abundance curves as previously described (25). 
A one-way ANOVA was calculated with two independent categorical variables, time and 
partition (common or rare), to compare the difference in similarity between common and rare 
species (20). The post-hoc Tukey honest significant difference (HSD) test was used in 
conjunction with the ANOVA to compare treatment means in order to find significant 
differences (20).  
Change in anaerobe abundance over time was investigated using nlme (26) to fit mixed 
effect models, r2 values were calculated using the MuMIn package (27). 
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4.4 Results  
Sputum samples were collected from eight patients and then aliquoted into 12 equal portions 
and stored at room temperature (mean ± standard error of mean (SE), 20.1°C±0.1) for 
specified intervals over a 72hour study period. Of the 96 sample aliquots sequenced, 12 
were excluded from further analysis due to insufficient number of sequences (i.e. fewer than 
200 sequences). A total of 182,989 bacterial sequences (n=84, 2178±250SE/sample) were 
generated from 84 samples, identifying 51 genera and 78 distinct OTUs classified to species 
level (Table S1). 
4.4.1 Bacterial diversity  
Changes in bacterial diversity were assessed over the study period using the recognised 
measures of diversity, species richness (S*, the total number of species), Shannon-Wiener 
index (H’, a metric accounting for both number and relative abundance of species) and 
Simpson’s diversity index (1-D, a measure of the probability that two species randomly 
selected from a sample will differ).  S*, H’ and 1-D were calculated for each sample from 
each patient over the 72 hour study period, using randomised re-sampling as previously 
described (23), as pairwise comparisons are affected by large differences in sample size (n) 
(28). 
High levels of variation were observed when examining diversity measures, both between 
and within patients. In order to investigate this variation, sample diversity at t=0 was plotted 
for S*, H’ and 1-D (Fig. 1). 
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Fig 4.1 Comparison of diversity and dominance of bacterial communities across patients at 
t=0.  Values  of (a) species richness (S*), (b) Shannon-Wiener index of diversity (H’), and (c) 
Simpson’s index of diversity (1-D) as shown.  The three diversity indices were calculated 
with a uniform re-sample size following 1000 iterations in each instance. Error bars represent 
the standard deviation of the mean (n = 1000). In each instance, the overall mean (solid line) 
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and the standard deviation of the mean (dashed lines) across patients are shown. Also given 
is (d) Berger-Parker index of dominance (d).   
Typically, low diversity communities are dominated by a few highly abundant species 
whereas high diversity communities are characterised by species that are more evenly 
distributed in their abundances (29). In order to explain the observed variation in diversity in 
the current study, the Berger Parker index of dominance (d, the proportional abundance of 
the most abundant organism) was calculated for all t=0 samples (Fig. 1) and for samples at 
all time points (Fig. S1). Here, we also observed that low diversity (as defined by S*, H’ and 
1-D) was related to high dominance (d) in sample communities: for example, the t=0 
community of patient 6 was dominated by Pseudomonas aeruginosa (S*= 4, d= 0.96), and 
the t=0 communities of Patients 2 and 7 were dominated by Achromobacter xylosoxidans 
(Patient 2; S*= 3, d= 0.88, Patient 7; S*= 4, d= 0.80), while Patient 1 showed a much more 
diverse t=0 community (S*= 14, d= 0.51), Figs. 1 and S1.  Given the high level of variation in 
diversity between patients, linked to species dominance, these measures were unsuitable as 
metrics to indicate changes over time, suggesting that comparisons of community similarity 
over time would be more appropriate. 
4.4.2 Bacterial community membership 
The Bray-Curtis measure of similarity (SBC, which accounts for the number and abundance of 
species present in each community and those that are shared) was used to compare 
changes in community composition between samples, resulting in a value between 0 and 1 
(higher values indicating greater similarity).  As with the diversity measures, community 
composition were compared between the sample at t=0 and each subsequent sample. Using 
randomised re-sampling, total change in SBC similarity was assessed (22). 
For both PCR and sequencing, sampling bias can result in variation between repeat samples 
of the same community (12).  In order to evaluate whether changes in similarity across the 
sampling period were due to true community changes or within sample variation, a cut off 
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value for similarity was calculated using eight samples each sequenced in triplicate. The 
overall mean SBC similarity between sample replicates was 0.782±0.1(SE) (n=24), therefore 
similarity values, below 0.682 (0.782-0.10SE), between t=0 and subsequent samples were 
judged to be different from the original sample.  
The mean change in similarity over the study period was not judged to be significant, when 
accounting for within sample variation (Fig. 2(A)). When diversity measures were examined 
for individual patients, high levels of variation were observed (Fig. 3).  These results were 
compared to the value of dominance calculated previously using d (Fig. 1). The greater the 
relative abundance of the dominant species, the lower the variation in community similarity 
over the study period (P=0.03, r2=0.05). This finding indicated that samples more highly 
dominated by a single species, and hence having low overall diversity, were less likely to 
show a significant change in community similarity with longer time at room temperature prior 
to freezing.  
To further examine how dominant species affect community similarity, rank abundance 
curves were used to partition sample communities at t=0 into common and rare species 
groups (Fig. S2)(25). Change in SBC similarity was calculated, from t=0, for the partitioned 
groups revealing much greater variation in species characterised as rare Fig 2. Using 
ANOVA a significant difference in similarity was observed between the common and rare 
species (F(1,148)=77.93, P<0.001). Post-hoc Tukey HSD testing revealed that the difference in 
similarity between t=0 and the rare species were on average 30.93% lower than the 
differences observed in the common species.  
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Fig. 4.2 Mean changes in bacterial community composition, from t=0 across patients over 
time using the Bray-Curtis index of similarity for (a) whole communities, (b) common and (c) 
rare species groups. Error bars represent the standard deviation of the mean (n = 8). 
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0, for each patient over time 
Fig. 4.3 Changes in community composition from t=0, for each patient over time, using the 
Bray-Curtis index of similarity.  Solid lines represent the overall mean similarity from within 
sample replicates and dashed lines represent the standard error of the mean (n = 24). 
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4.4.3 Differential impact on aerobic and anaerobic species 
Over the study period, samples were aliquoted and stored in sterile sample containers, it 
was expected that this would result in a decrease in anaerobic species due to prolonged 
exposure to atmospheric oxygen resulting in preferential conditions for aerobic populations. 
To that end, bacteria were partitioned into aerobic/facultative anaerobes and strict anaerobic 
species. A mixed effects model was used to investigate the change in percentage 
abundance of anaerobic species present in each sample over the study period. The best-fit 
distribution was a second order polynomial relationship (r2=0.08, P=0.004) (Fig. 4). This 
distribution indicated a consistent decline in the relative abundance of anaerobic species 
over the first 48 hours, followed by an increase during the following 24 hours. Using mixed 
effect models, the decline in anaerobes was found to represent a significant divergence from 
the original sample after 18 hours (P=0.008). This decline continued until after 48 hours of 
storage at room temperature, at which point the percentage abundance of anaerobes started 
to increase. This finding suggests that changes in anaerobe abundance was due to sputum 
storage in sealed containers allowing anaerobic organisms to proliferate after available 
oxygen had been depleted, resulting in community divergence.  
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Fig. 4.4 Changes in anaerobic species abundance for all patients over time. Solid circles 
represent percentage abundance of anaerobic species for each patient at a given time point. 
A second order polynomial model has been fitted to the data (r2 = 0.08, P = 0.004). 
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4.5 Discussion 
The handling and storage of respiratory samples can substantially bias the results of 
microbiological analyses. The aim of the current study was to determine an acceptable 
period of time between sputum sample collection and storage prior to using next generation 
sequencing to characterise CF lower airway microbiota. Previous studies based on 
diagnostic bacterial culture suggest that 48 hours can elapse from specimen collection to 
either freezing or processing and still provide comparable results (10). However, with the 
increasing incorporation of culture-independent approaches to diagnostic microbiology (11) it 
is vital to identify and mitigate all potential biases relevant for these more sensitive, culture-
independent techniques. 
Changes in bacterial diversity, as a result of storage at room temperature for different 
intervals prior to freezing, were assessed within samples from each patient.  We found that 
diversity was highly variable across patients at t=0 (Fig. 1) and within patients over storage 
time, post collection (Fig. S1).  This variability could be attributed to differences in dominance 
within sample communities.  Freshly collected (t=0) samples with low species diversity were 
found to be highly dominated by recognised CF pathogens; conversely, those samples with 
a more diverse communities were not dominated by a particular bacterial species. 
Furthermore, communities dominated by fewer species changed less with increasing time at 
room temperature compared to those with higher diversities.  Given the differences in 
diversity between and within patient samples, commonly used measures of diversity, e.g. 
species richness, Shannon-Wiener diversity index and Simpson’s diversity index, were 
unsuitable as a metric of change in the bacterial communities during storage.  
Using the Bray-Curtis index of similarity, we assessed how community composition changed 
from the original (t=0) sample. As previous studies have indicated that bacterial communities 
within the CF lungs are not homogenously distributed (30), this may result in a variation 
within different portions of a single sample (12). In order to account for within sample 
variance, eight CF sputum samples were sequenced in triplicate, using different sample 
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aliquots for each replicate, and the similarity between replicates was calculated. Then, we 
analysed all samples for all subjects, finding that the shortest period of sample storage within 
which a change in similarity was observed, beyond that expected for within-sample variation, 
was 1 hour after sputum collection (Fig. 2). In addition where a community was dominated by 
few or one species, the variation in community similarity was found to be significantly lower 
than in more diverse communities. However, since it is difficult to guess the microbial 
diversity in a sputum sample a priori, our results suggest that sputum samples should be 
frozen within 1 hour of collection in order to obtain the best possible representation of the 
true community using culture independent analyses.   
Previous studies have demonstrated the value of partitioning bacterial communities in 
respiratory infections into common and rare species groups (9).  Categorization of 
component species provides useful insights into communities that would be neglected 
without such a distinction (3, 9). When samples were partitioned into common and rare 
species in the current study, a greater level of community stability with difference in storage, 
was associated with species defined as common compared to rare species, suggesting that 
characterisation of the latter group will be most affected by a delay in sample freezing. This 
effect accounted for the greater change in similarity observed in more diverse communities 
that have a wider range of rare species present within the community (Fig. 2). 
We hypothesised that prolonged exposure to atmospheric levels of oxygen would result in a 
decrease in the relative abundance of viable, strictly anaerobic species within the sputum 
samples. Despite high variability in anaerobe relative abundance between samples, a 
statistically significant 2nd order polynomial relationship was found between storage duration 
at room temperature and anaerobe abundance, with the latter decreasing for up to 48 hours, 
followed by an increase after that time (Fig. 4).  A potential explanation for this relationship is 
the reduction in oxygen tension as a result of growth of aerobic and aerotolerant species in 
the sealed Bijou containers.  Furthermore, the decline in anaerobe abundance, which 
represents a major shift in the community, was found to be significantly different from t=0 
after 12 hours (Fig. 4). This effect could potentially lead to under- or over-estimation of the 
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importance of anaerobic species in disease progression depending on the period elapsed 
between storage and freezing.  
Sputum samples are one of the most widely used ways of sampling lower respiratory tract 
infections. With the moves toward incorporating culture independent techniques to analyse 
the microbial determinant of these conditions and make informed treatment choices.  In the 
current study, we found that the optimal window for sample storage at room temperature 
before freezing at -80°C is within 1 hour of collection.  In practical terms it may not be 
possible to store a sample within 1 hour of collection. In this event, our results indicate an 
acceptable window of up to 12 hours without significant divergence in community 
composition. Whilst this work has focused on CF airway infections, these findings are 
important for the analysis of microbiota from other respiratory conditions.  
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Fig. S2. Rank abundance curves for each patient bacterial community at t=0. Abundances 
are expressed as percentage of total abundance within each community. The arrows 
indicate the inflection point of each curve. Species to the left of the arrow were classified as 
common, and those at the right side were classified as rare. 
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Table S2. The raw sequence data reported in this paper have been deposited in the NCBI 
Short Read Archive database (Accession number. SRP036061). A list of barcodes used and 
their associated sample are listed below.  









AGATGTTCTGCT 1 0 
AGCTATCCACGA 1 1 
AGTGCGATGCGT 1 3 
ATCTGAGCTGGT 1 6 
AGTTAGTGCGTC 1 9 
ATACAGAGCTCC 1 12 
AGAACACGTCTC 1 18 
ATCCGATCACAG 1 24 
ATCTACTACACG 1 36 
AGCTCCATACAG 1 48 
ATCACGTAGCGG 1 60 
ATCTGGTGCTAT 1 72 
ATATGCCAGTGC 2 0 
ATCCTCAGTAGT 2 3 
ATACACGTGGCG 2 6 
ATCTCTGGCATA 2 9 
ATCGTACAACTC 2 12 
ATCAGGCGTGTG 2 24 
ATGGATACGCTC 2 36 
ATGGCAGCTCTA 2 48 
ATGCACTGGCGA 2 60 
ATGCAGCTCAGT 2 72 
ACCACATACATC 3 0 
ACATGTCACGTG 3 1 
ACCTGTCTCTCT 3 3 
ACTGATCCTAGT 3 6 
ACGAGTGCTATC 3 18 









AGACCGTCAGAC 3 36 
ACAGTTGCGCGA 3 48 
ACACTGTTCATG 3 60 
ACAGCTAGCTTG 3 72 
ACTACGTGTGGT 4 0 
AGTCTCGCATAT 4 1 
AGACGTGCACTG 4 3 
ATAATCTCGTCG 4 6 
ACGCAACTGCTA 4 9 
AGCTTGACAGCT 4 12 
AGGTGTGATCGC 4 18 
AGAGAGCAAGTG 4 24 
AGCGCTGATGTG 4 36 
AGAGCAAGAGCA 4 48 
ACGTGAGAGAAT 4 60 
AGTGTTCGATCG 4 72 
AGTACGCTCGAG 6 0 
ATGAGACTCCAC 6 3 
AGTGTCACGGTG 6 6 
AGTGAGAGAAGC 6 12 
ATATCGCTACTG 6 18 
ATCGCGGACGAT 6 24 
ATAGGCGATCTC 6 36 
ATGCCTGAGCAG 6 60 
ATGACTCATTCG 6 72 
ACGGATCGTCAG 7 0 
ACGCTATCTGGA 7 1 









AGATCGGCTCGA 7 6 
AGCACACCTACA 7 9 
ACGTCTGTAGCA 7 12 
AGCGAGCTATCT 7 18 
ACTCACGGTATG 7 24 
AGCAGCACTTGT 7 36 
AGTCTACTCTGA 7 48 
ACTGTGACTTCA 7 60 
ACTCAGATACTC 7 72 
ACGTACTCAGTG 9 0 
AGCACGAGCCTA 9 3 
AGCCATACTGAC 9 6 
ACTAGCTCCATA 9 18 
ACGCGCAGATAC 9 36 
ACTTGTAGCAGC 9 48 
ATCGATCTGTGG 9 60 
ACGTTAGCACAC 9 72 
ACACTAGATCCG 11 0 
ACAGAGTCGGCT 11 1 
ACGCGATACTGG 11 3 
ACTGACAGCCAT 11 6 
ACCGCAGAGTCA 11 9 
ACAGCAGTGGTC 11 12 
ACCAGACGATGC 11 18 
ACCTCGATCAGA 11 24 
ACGGTGAGTGTC 11 36 
ACCAGCGACTAG 11 48 
ACAGACCACTCA 11 72 
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Implications of multiple freeze-thawing on 
respiratory samples for culture 
independent analysis 
Cuthbertson L., Rogers G.B., Walker A.W., Oliver A., Carroll M.P., Parkhill J., Bruce K.D., 
van der Gast C.J. (2014) The effects of freeze thaw cycles on the microbial community 




The use of biobanking for long term storage of respiratory samples for the use in multiple 
studies is increasing. It was established in the previous chapter that sample handling and 
storage has marked effects on bacterial community composition. As a result of these findings 
this chapter aimed to assess the effect of freeze-thaw cycles on the bacterial community 
within CF sputum.  This chapter has been published in the Journal of Cystic Fibrosis.   
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Best practice when performing culture-independent microbiological analysis of sputum 
samples involves their rapid freezing and storage at -80°C. However, accessing biobanked 
collections can mean material has been passed through repeated freeze-thaw cycles. The 
aim of this study was to determine the impact of these cycles on microbial community 
profiles.  
Methods  
Sputum was collected from eight adults with cystic fibrosis, and each sample was subjected 
to six freeze-thaw cycles. Following each cycle, an aliquot was removed and treated with 
propidium monoazide (PMA) prior to DNA extraction and 16S rRNA gene pyrosequencing. 
Results  
The impact of freeze-thaw cycles was greatest on rare members of the microbiota, with 
variation beyond that detected with within-sample repeat analysis observed after three 
cycles.  
Conclusion 





5.2 Introduction  
The application of next-generation sequencing technologies for the investigation of lower 
respiratory tract infections in patients with cystic fibrosis has revealed complex and highly 
diverse microbial communities [1, 2]. As technologies have improved and the associated 
costs have fallen, it is becoming possible to use these platforms, not only for research but 
also for diagnostic microbiology [3], making it more important than ever to identify and 
minimize the introduction of bias. 
Spontaneously expectorated sputum is one of the most common specimen types used to 
investigate the microbial community responsible for lower respiratory infections in adults with 
CF. In order to perform culture-independent analysis on a representative airway sample, the 
methods used to collect and store specimens are hugely important. Current best practice 
involves the rapid stabilisation of sputum samples by freezing at -80°C within 12 hours of 
collection [4]. To allow profiling of the viable microbial community, samples can be treated 
with propidium monoazide (PMA) to remove the impact of extracellular DNA or DNA from 
dead and damaged cells, prior to DNA extraction and DNA sequencing [5]. Received wisdom 
suggests that once defrosted, respiratory samples may not be refrozen and sub-sampled 
again at a later date without incurring significant changes in the microbial community. 
There is an increasing awareness of the importance of in-depth analysis for the investigation 
of the microbial communities responsible for infection. This has lead to many clinics 
collecting large detailed sample biobanks in ultralow temperature freezers, which can be 
accessed in order to address a wide range of clinical questions. However, biobanked 
samples may be accessed multiple times for culture independent analysis, thus passing 
though several freeze thaw cycles, a process that could result in changes to the microbial 
community. To date, no studies have used next-generation sequencing technologies to 
define how multiple freeze-thaw cycles affect the microbial community within collected 
sputum. We hypothesized that microbial community profiles would be significantly altered 
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5.3.1 Sample collection 
Sputum samples were collected, under full ethical approval from the Southampton and South 
West Hampshire Research Ethics Committee (06/Q1704/26), from eight patients attending 
the regional Cystic Fibrosis Centre in Southampton General Hospital. All patients were 
chronically colonised with Pseudomonas aeruginosa.  Patients were selected based on their 
ability to typically produce more than 2 mls of sputum. Sputum samples were collected and 
frozen at -80°C within 1 hour. Each sputum sample was subjected to six freeze-thaw cycles. 
Samples were removed from the -80°C freezer, a 250 µl aliquot removed for DNA extraction, 
and the remaining sample allowed to completely thaw at room temperature for 30 min before 
being returned to -80°C for 24 hours.  
5.3.2 DNA extraction and Pyrosequencing 
Sputum samples were washed three times with 1x phosphate buffered saline to remove 
saliva, as previously described [1]. Extracellular DNA and DNA from non-viable cells were 
excluded from analysis via crosslinking with PMA [6, 7] prior to DNA extraction, as described 
previously [8]. Bacterial Golay barcode-encoded FLX amplicon pyrosequencing was 
performed using the primer 338F (3’- ACTCCTACGGGAGGCAGCAG) and 926R (3’- 
CCGTCAATTCMTTTRAGT). Initial generation of 16S rRNA gene amplicons involved a one 
step PCR of 25 cycles using AccuPrimeTM Taq DNA Polymerase High Fidelity (Invitrogen, 
Carlsbad, CA). 454 pyrosequencing using the Lib-L kit was performed at the Wellcome Trust 
Sanger Institute, Hinxton, UK. 
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Resulting data were analysed using the Mothur sequencing analysis platform [9] as 
described previously [4]. The raw sequence data generated within the current study have 
been submitted to the NCBI Short Read Archive database under the study accession 
number SRP040968. The barcodes associated with each sample are shown in Table S1. 
Two aliquots were excluded due to insufficient number of sequence reads generated. 
5.3.3 Statistical analysis 
Statistical analysis was performed in R [10]. Changes in bacterial diversity were assessed 
using three complementary measures: species richness (S*,the total number of species), 
Shannon-Wiener (H’, a metric accounting for both number and relative abundance of 
species), and Simpson’s (1-D, a measure of the probability that two species randomly 
selected from a sample will differ) indices of diversity as described previously [4, 11]. The 
Bray-Curtis (SBC, which accounts for the number and abundance of species present in each 
community and those that are shared), resulting in a value between 0 and 1 (higher values 
indicating greater similarity) measure of similarity was used to assess changes in community 
composition with each freeze-thaw cycle.  
To avoid potential bias, all measures were calculated using randomised resampling to a 
uniform number of sequence reads per sample [5]. Mean diversity measures were calculated 
from the re-sampling of the reads from each specimen to the lowest number of sequence 
reads among all specimens (n=261) for 1000 iterations. SBC was calculated by re-sampling 
to the minimum number of sequence reads per specimen within each patient and comparing 
community composition to the original sample for 1000 iterations. Bacterial species detected 
at the first point for each patient were partitioned into common and rare species using rank 
abundance curves [12]. The R package nlme [13] was used to fit mixed effect models to 
investigate the relationships between measures of diversity, similarity, and number of freeze 




5.4 Results  
To test the study hypothesis, sputum samples from eight CF patients were subjected to six 
freeze-thaw cycles. Aliquots of sputum were removed for DNA extraction and 16S rRNA 
gene pyrosequencing to assess the bacterial community after each cycle, and the remaining 
sample was allowed to defrost completely before being returned to -80°C. All samples were 
treated with PMA prior to DNA extraction to focus the analysis on the viable bacterial 
community. A total of 106,065 sequences (mean ± standard error (SE) per sample 2306 
±239) were generated from 46 samples, identifying 49 genera and 76 distinct operational 
taxonomic units (OTUs) classified to species level (Table S2). 
5.4.1 Bacterial diversity 
Species richness, S*, was found to be highly variable between patients (max= 49, min=4), no 
pattern in raw richness values was observed over the freeze-thaw cycles either within 
patients (P=0.6, r2=0.0004) or when using randomised resampling to calculate mean S* (P 
=0.7, r2= 0.0001). High levels of variability in bacterial diversity were also observed between 
patients as measured by H’ and 1-D. However, as with S*, no pattern in either of these 
diversity measures was observed over the 6 freeze-thaw cycles (H’ (P=0.4, r2=0.001), 1-D 
(P=0.1, r2=0.003) (Fig 1).    
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Fig 1. Boxplots from each patient showing variation in diversity over the 6 freeze-thaw 
cycles. Values  of (A) species richness (S*), (B) Shannon-Wiener index of diversity (H’), and 
(C) Simpson’s index of diversity (1-D) were calculated with a uniform re-sample size 
following 1000 iterations in each instance. Lines in boxplot represent mean and standard 





5.4.2 Bacterial community membership 
Changes in community composition were compared using the SBC measure of similarity.  A 
significant decrease in similarity was observed over the 6 cycles (P < 0.0001, r2= 0.40) (Fig 
2). Variation in intra-sample composition could contribute to the effect associated with 
freeze-thaw cycles [4, 15]. Therefore, to account for within-sample variation, a cut off value 
for similarity was calculated by comparing the within-sample similarities of triplicate 
sequence datasets of eight samples that were published previously [4]. Based on this data, 
Bray-Curtis similarity values below 0.682 were judged to differ significantly from the original 
sample.  
To minimise bias, changes in similarity were measured using randomised resampling to a 
uniform subsample size. Analysis showed that, despite a significant trend of decreasing 
similarity between aliquots within each sample over the six freeze-thaw cycles, none of these 
changes in within-sample similarity fell below the cut-off value of 0.682 for significant within-
sample variation.  
To investigate the drivers of this trend in community composition, we partitioned the 
community into common and rare species using rank abundance curves, indicating the 
breakpoint between the common and rare using the inflection point (Fig. S1) [12]. Once 
partitioned, the Bray-Curtis similarity was calculated for the common and rare species. The 
common and abundant species were most important in determining the overall trend in 
community similarity, while the rare species were shown to be more variable (Fig 2). Over 
the six cycles, the common species were not found to fall below the cut-off value for within-
sample variation. In contrast, however, substantial variation was observed in the detection of 
rare species, for which the mean change in similarity among aliquots from each sample 





Fig 2. Mean changes in bacterial community composition over six freeze-thaw cycles, using 
Bray-Curtis index of similarity for (A) whole communities, (B) common and (C) rare species 
groups. Error bars represent the standard error of the mean (n = 6). Whole community 
similarity was calculated with a uniform re-sample size following 1000 iterations. Solid lines 
represent the overall mean similarity for within sample replicates and dashed lines represent 




The handling of respiratory samples for culture-independent analysis is vital if an unbiased 
picture of the microbial community is to be obtained. Storage of samples at -80°C is the 
standard recognised method for maintenance of sample integrity during biobanking. 
However, whether repeated sub-sampling of these specimens, which will require repeated 
thawing and freezing, leads to sample degradation and changes in community composition 
detected has not been reported.  
In searching for changes in bacterial diversity due to freeze-thaw cycles, no significant 
overall trend was observed. A significant negative trend in community similarity was 
observed using the Bray-Curtis measure of similarity. Despite this observation, over the 6 
cycles the change in similarity never fell below the expected level for within-sample variation, 
indicating that repeat freeze-thaw cycles will not affect the overall bacterial community 
composition. However, the rare community fell below the level of within sample variation 
from 4 freeze-thaw cycles.   
Our results challenge the long-held view that the microbial community within respiratory 
samples will significantly change once samples have been defrosted during subsampling. 
More than three freeze-thaw cycles will result in significant divergence of the rare community 
from the original sample. If the sample is subjected to four or more cycles community 
analysis may be carried out on the common community but the rare should be interpreted 
with care. In practical terms, these findings support the aliquoting of samples to avoid 
unnecessary freeze-thaw cycles. 
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5.3 Supplementary information 
Fig S1. Rank abundance curves for each patient’s bacterial community after a single freeze 
thaw cycle. Abundances are expressed as percentage of total abundance within each 
community. The arrows indicate the inflection point of each curve.  Species to the left of the 
arrow were classified as common, and those at the right side were classified as rare. 
 




Table S1. The raw sequence data reported in this paper have been deposited in the NCBI 
Short Read Archive database (Accession number PRJNA243349 ). A list of barcodes used 
and their associated sample are listed below. 




ATGGCGTGCACA 1 1 
CAACACGCACGA 1 2 
GTCTATCGGAGT 1 3 
GTGAGGTCGCTA 1 4 
GTGTGTGTCAGG 1 5 
TAAGCGCAGCAC 1 6 
ATGGTCTACTAC 2 1 
CAACTATCAGCT 2 2 
GTCTCATGTAGG 2 3 
GTGATAGTGCCG 2 4 
GTGTTGCAGCAT 2 5 
TACACACATGGC 2 6 
ATGTACGGCGAC 3 1 
CAACTCATCGTA 3 2 
GTCTCTCTACGC 3 3 
GTGCAATCGACG 3 4 
GTTAGAGCACTC 3 5 
TACACGATCTAC 3 6 
ATGTCACCGTGA 4 1 
CAAGATCGACTC 4 2 
GTCTGACAGTTG 4 3 
GTGCACATTATC 4 4 
GTTCGCGTATAG 4 5 






ATGTGCACGACT 5 1 
GTCGCTGTCTTC 5 2 
GTCTGGATAGCG 5 3 
GTGGCGATACAC 5 4 
GTTGACGACAGC 5 5 
TACAGTCTCATG 5 6 
ATGTGTCGACTT 6 1 
GTCGTAGCCAGA 6 2 
GTCTTCGTCGCT 6 3 
GTGTACCTATCA 6 4 
GTTGTATACTCG 6 5 
ATTATCGTGCAC 7 1 
GTCGTGTGTCAA 7 2 
GTGACCTGATGT 7 3 
GTGTCTACATTG 7 4 
TAACAGTCGCTG 7 5 
ATTCTGTGAGCG 8 1 
GTCTACACACAT 8 2 
GTGACTGCGGAT 8 3 
GTGTGCTATCAG 8 4 
TAACTCTGATGC 8 5 
TACGATGACCAC 8 6 
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Table S2. Bacterial taxa samples across eight sputum samples from adult CF patients. 
Species-level identities of detected taxa are reported here. However, given the sequence 
read length of the ribosomal sequences analysed, these identities should be considered 
putative 
Table A5.2 Bacterial taxa samples across eight sputum samples from adult CF patients 
Class Family Taxon name 








Micrococcaceae Rothia mucilaginosa 
 
Propionibacteriaceae Propionibacterium propionicum 
Bacillales Bacillales  Gemella morbillorum 
 
Staphylococcaceae Staphylococcus aureus 






































Rikenellaceae Alistipes finegoldii 
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Table S2 Continued 
Class Family Taxon name 
Burkholderiales Alcaligenaceae Achromobacter xylosoxidans 
 
Burkholderiaceae Lautropia mirabilis 
 
Sutterellaceae Sutterella wadsworthensis 
Campylobacterales Campylobacteraceae Campylobacter concisus 
Clostridiales Clostridiaceae Clostridium sp.  
 
Clostridiales  Parvimonas micra 
 
















Peptostreptococcaceae Peptostreptococcus stomatis 
Coriobacteriales Coriobacteriaceae Atopobium parvulum 
  
Olsenella uli 
Enterobacteriales Enterobacteriaceae Escherichia coli 













Lactobacillales Aerococcaceae Abiotrophia defectiva 
 
Carnobacteriaceae Granulicatella adiacens 
 









Mycoplasmatales Mycoplasmataceae Mycoplasma salivarium 
Neisseriales Neisseriaceae Kingella denitrificans 
Pasteurellales Pasteurellaceae Haemophilus parainfluenzae  
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Table S2 Continued 
Class Family Taxon name 
 
Pseudomonadaceae Pseudomonas aeruginosa 
  
Pseudomonas putida 
Rhizobiales Hyphomicrobiaceae Hyphomicrobium sp. 
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Chapter 6: The complex relationships between 
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6.1 Introduction 
In recent years, through a range of culture independent techniques, the complex and diverse 
nature of the bacterial community associated with cystic fibrosis (CF) lung infections has 
been recognised (1-6). However despite this insight, chronic infection and concomitant 
inflammation are still the major cause of morbidity and mortality in individuals with CF (7). 
Therefore, in order to improve patient management it is important to increase our 
understanding of the bacterial community within the CF lung in relation to clinical factors for 
example; gender, age, body mass index (BMI), lung function, liver disease, diabetes, 
pancreatic insufficiency and genotype.  
Over the last few years, the importance of relating clinical outcomes to changes in the 
bacterial community has been recognised. In 2010, Klepac-Ceraj et al examined the 
influence of clinical factors on the bacterial community present in 45 CF children using 
PhyloChip hybridization (8). This study examined the relationship between the community 
composition and clinical factors including age, CFTR genotype, and antibiotic therapy; as 
well as examining the effect of Pseudomonas aeruginosa colonisation (8). While this study 
found no relationship between bacterial diversity and lung function, bacterial diversity was 
found to decrease with age (8). Further, a study by Cox et al (2010) used an age stratified 
patient cohort to reveal a significant negative relationship between age and lung function of 
patients from 0 -72 years old. They identified that older patients tended to have a more 
conserved bacterial community than younger individuals (3). 
The lack of association of the bacterial community with lung function, observed by Klepac-
Ceraj et al (2010), was considered to be a result of CF children having lung function scores 
comparable with healthy individuals. Therefore, it was unsurprising that in a study of 14 adult 
CF patients, van der Gast et al (2011) using full length 16S rRNA gene sequencing to 
investigate the metacommunity within the CF lung, revealed a significant positive relationship 
between bacterial diversity and lung function (9). This result was also observed in a study by 
Delhaes et al (2012) who found that bacterial diversity was correlated with lung function and 
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poor clinical status (6). Despite the significant relationship observed, the variance associated 
with this relationship was shown to be high in both these studies (6, 9).  As a result, to 
establish if this relationship could be used in order to predict clinical outcomes a much larger 
sample set would be required (6).  
While the effect of relationship between the bacterial community and lung function is clearly 
important, it cannot account for all the variance observed between patients, so other clinical 
factors must be considered. It has been established that different cystic fibrosis 
transmembrane regulator (CFTR) genotypes result in different clinical outcomes for CF 
patients (10). By grouping patients into high and low risk CFTR mutation categories, McKone 
et al (2006) found significantly different survival rates as a result of mutation type (11). 
ΔF508 is the most common CFTR mutation associated with CF and is classified as one of 
the severe mutations associated with disease. In order to investigate if differences in CFTR 
genotype influence the bacterial community within the CF lung, Klepac-Ceraj et al (2010) 
partitioned their samples into 3 distinct groups, ΔF508 homozygote’s, ΔF508 heterozygote’s 
and other non-ΔF508 mutations (8). Their results suggested that the ΔF508 mutation may 
have a marked effect on the environment within the CF lung, resulting in a distinct bacterial 
composition (8). However, they do accept that a larger cohort study would be required to 
investigate this relationship further (8).  
Several large prospective studies have demonstrated that there is a gender gap in CF, 
resulting in significantly poorer prognosis for female CF patients compared to males (11, 12).  
Early studies showed that between the ages of 1 and 20 years, females were 60% more like 
to die than males (12). With improvements in treatment regimes and increase in patient 
survival rates, Verma et al (2006) investigated if differences in disease prognosis were still 
an issue despite advances in patient care (13). This study concluded that with modern 
treatments, no significant difference was observed between the lung function of male and 
female patients however, females tended to show poorer growth rates than males. This 
study did not investigate changes in the bacterial community between the two sexes and 
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therefore was unable to uncover if the differences in growth rate observed were related to 
patient gender.  
The course of disease progression may also be affected by the centre attended by an 
individual patient. This could be explained by differences in treatment regimens or simply by 
the environmental microbiota present in different geographical regions. In 1998, Johansen et 
al undertook a study to investigate differences in clinical status between two CF centres, one 
in Toronto, Canada and the other in Copenhagen, Denmark (14). This study found that 
despite differing treatment regimes between centres, pulmonary and nutritional statuses 
between the two cohorts was not significantly different (14). A similar study was carried out 
by Stressmann et al (2011), using T-RFLP to investigate differences in bacterial community 
composition between samples collected from Southampton, United Kingdom and those 
originating from Chapel Hill, United States (15). This study revealed geographical differences 
between the presence and relative abundance of species identified (15). The most common 
organisms identified were found to be common to both sites (15) however, while this study 
showed that the community present in the US samples were less diverse than those in the 
UK, changes in the metacommunity between centres was not investigated.  
As indicated above, although some evidence has been obtained linking the bacterial 
community to clinical factors the studies have been limited by participation. Typically, these 
studies have been carried out using samples from a small number of patients (ca. less than 
50 patients) attending a single CF centre. In this study over 300 sputum samples were 
collected from 11 different sites across Europe and North America, making this the largest 
study of its kind, and resulting in statistical power unrivalled by the currently published work. 
This dataset therefore results in a unique opportunity to test the relationships previously 
observed in much smaller datasets and whether previously unobserved associations can be 
revealed.  
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6.2 Materials and methods 
6.2.1 Sample collection 
Sputum samples were collected from CF patients attending CF clinics across Europe and 
the United States of America. For full details of clinics and associated ethics see Table 2.2. 
Single samples were collected from each patient alongside associated clinical metadata. 
Once collected, samples were stored at -80°C prior to transport on dry ice to the Centre for 
Ecology and Hydrology in Wallingford. Clinical metadata associated with each sample was 
collected at the time of sampling, a summary is shown in Table 6.1.  
A total of 379 individual samples were sequenced. After processing in Mothur a total of 44 
technical control samples, including reference strains (shown in Table 2.1), were used to 
remove contaminating OTUs. All controls used are shown in Table 6.2. Due to a lack of 
sequences, or as a consequence of contamination, 24 samples were removed from the final 
analysis. As a result, a total of 292 CF sputum samples were included in the analysis of this 
dataset. Additionally, 19 non-CF healthy controls, sampled by sputum induction using 
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Table 6.1 Patient data and samples. 
Variable  n 
Non-CF healthy controls 9 male 10 female 
Patients 292 
Sex 170 male 122 female 
BMI, n [min-max] 183 [14.4-43.8] 
FEV1, n [min-max] 276 [0.43-4.93] 
Age, n [min-max] 254 [14-71] 
CFTR genotype, n (%) 252 
ΔF508/ΔF508 135 (54) 
ΔF508/other 98 (39) 
other/other 19 (8) 
Clinical Status, n (%)* 216 
Stable 162 (75) 
Exacerbation 54 (25) 
Pancreatic sufficient, n (%) 225 
Sufficient 86 (38) 
Insufficient 139 (62) 
Liver disease, n (%) 225 
Yes 37 (16) 
No 188 (84) 
Diabetes, n (%) 287 
Yes 98 (34) 
No 189 (66) 
Location, n (%) 292 
Belfast, UK 60 (21) 
Southampton, UK 35 (12) 
London, UK 14 (5) 
Dublin, Eire 6 (2) 
Warsaw, Poland 17 (6) 
Dartmouth, Bedford, NH 17 (6) 
Dartmouth, Lebanon, NH 4 (1) 
Portland, ME 22 (8) 
Boston, MA 15 (5) 
Seattle, WA 75 (26) 
Vermont, ME 27 (9) 
 Bold text indicate the total number of samples with available metadata relating to particular 
clinical variables, square brackets indicate the sample range, round brackets indicate the % 
of the total number of samples with data for the specified variable. * Patients diagnosed and 
in current treatment for a CF pulmonary exacerbation (CFPE) were defined as having a 
clinical status of “Exacerbation”. 
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Table 6.2 Technical control samples included in sequencing analysis. 
Mock communites contained equal quanties of Achromobacter xylosoxidans, Burkholderia 
cenocepacia, Burkholderia multivorans, Pseudomonas aeruginosa, Staphylococcus aureus 
and Stenotrophomonas maltophilia. Extraction controls were carried out using sterile water 
during every extraction protocol and sequenced to identify extraction contaminants. A mock 
community was included in each run, the PCR controls were carried on sterile water.  
Controls  n 
Achromobacter xylosoxidans 3 
Burkholderia cenocepacia 3 
Burkholderia multivorans 3 
Pseudomonas aeruginosa 3 
Staphylococcus aureus 3 
Stenotrophomonas maltophilia 3 
Mock communities 9 
Extraction controls 14 
PCR controls 3 
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6.2.2 DNA extraction and pyrosequencing 
All samples were stored at -80°C until processing. A sterile scalpel was used to transfer 
approximately 250µl of frozen sputum into a 15ml centrifuge tube, as described in Chapter 
2.3.1, to allow a sputum wash to be performed. Using the method described in Chapter 
2.3.2, washed sputum was then treated with propidium monoazide (PMA) prior to DNA 
extraction; Chapter 2.3.3.  
Extracted DNA was amplified using modified primers 27F (5’-
AGMGTTYGATYMTGGCTCAG) (MWG Eurofins, Ebersberg, Germany) and 338R (5’- 
GCTGCCTCCCGTAGGAGT) (MWG Eurofins, Ebersberg, Germany) for 16S rRNA gene 
sequencing using Illumina MiSeq, and as described in Chapter 2.4.2. 16S rRNA gene 
amplicons were initially generated using a one step PCR of 25 cycles using Q5® High-
Fidelity DNA Polymerase (New England Biolabs, Ipswitch, UK). Illumina MiSeq sequencing 
was performed at the Wellcome Trust Sanger Institute, Hinxton, UK. 
6.2.3 Sample processing and sequence analysis 
Resulting data was analysed using the Mothur sequencing analysis platform using a 
modified version of the method described in Chapter 2.7. Before analysis the two sets of 
output reads for each sample were combined to create contigs. Sequences shorter than 270 
bases and longer than 400 bases were removed, along with any sequences that included 
ambiguous base calls and homopolymeric stretches longer than 7 bases. Any non-bacterial 
ribosome sequences or chimeras were removed using Chimera uchime software, as 
implemented in Mothur (16). Sequences were classified using the Ribosomal database 
project (RDP) training set version 9 and any lineage identified as chloroplast, mitochondria, 
unknown, archaea or eukaryote were removed (17). Prior to creating a distance matrix and 
clustering OTUs, each barcoded sample was subsampled to 2000 sequences. Sequences 
were then assembled into operational taxonomic units (OTUs) (clustered at 97% identity), to 
give an approximation of species (18), and identified using the RDP reference database 
version 9 (2012) (17). Representative sequences were used to give an appropriate species 
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level identification for the OTU using NCBI multiblast and any suspect OTUs, those that 
appeared in control samples as well as single sequences identified as being common 
contaminants (e.g. hyperthermophiles, methanotrophs and rhizosome associated bacteria), 
were removed (19). 
6.2.4 Statistical analysis 
Statistical analysis was performed in R version 3.1.1(2012-07-10) (20), PAST (version 2.17) 
and XLSTAT (version 2014.3, Addinsoft, USA).  
Species were partitioned using a distribution abundance relationship (DAR), described by 
Magurran and Henderson (2003) (21). The most persistent and abundant species, those 
present in more that 75% of the total samples, were described as common, while all others 
were considered to be rare.  
Three recognised measures of bacterial diversity were used to assess bacterial richness and 
evenness; species richness (S*), Shannon-Wiener diversity index (H’) and Simpson’s index 
of diversity (1-D), as described in Chapter 2.81. Randomised resampling was carried out 
while assessing diversity measures in order to standardise the effect of variable read 
numbers returned by sequencing each sample. Diversity measures were calculated with the 
resulting data using the vegan package in R (22). The relationship between diversity and 
continuous metadata was assessed using linear regression in R. Alternatively analysis of 
variance (ANOVA) was used to assess differences in categorical variables and Tukey HSD 
tests were used to compare differences between categories.   
Community composition was investigated using Sørensen and Bray-Curtis measures of 
similarity, see Chapter 2.8.2 for full details. Analysis of similarity (ANOSIM) was used to 
assess the similarity between continuous variables, using PAST (version 2.7) (23). This 
method uses similarity measures to investigate similarity within variables and compares the 
allowing differences to be assessed. R values are on a scale of +1 to -1; values of +1 
indicating the most similar samples are within the same group, and -1 that the most similar 
samples are outside the group. Significant R values indicate that the community similarities 
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are more similar within the disease period and therefore can be considered significantly 
different.  
The contribution of each OTU to the observed Bray-Curtis similarity between significant 
variables was assessed using Similarity of Percentages (SIMPER) analysis. This was done 
in order to identify those OTUs that are important in creating the observed pattern of 
similarity. SIMPER analyses were performed as previously described by Clarke (1993) (24), 
using PAST (version2.7) (23). 
Mantel tests were used to relate the variability in bacterial community similarity to the clinical 
factors shown in Table 5.1 (25). Bray-Curtis similarity matrices were created in using PAST 
(version 2.7), and similarity matrices were generated by calculating absolute differences 
between variables. Similarity matrices for categorical data were created by assigning 0 to 
samples which were in the same category and 1 to those that were different, this avoided 
any weighting associated with the categories. Lower tailed Mantel and partial Mantel tests 
were conducted using XLSTAT (version 2014.3) with P-values based on 9999 permutations 
(9, 26).  
 
6.3 Results  
Sputum samples collected from CF patients across Europe and North America were 
collected with complementary clinical information. The bacterial diversity and community 
composition was assessed for each sample by 16S rRNA gene sequencing using Illumina 
MiSeq. A total of 311 sputum samples were included in this analysis. Each sample was 
subsampled to 2000 sequences in Mothur and any contaminating OTUs were removed post 
Mothur analysis. As a result a total of 577,889 bacterial sequences (mean± standard 
error/sample 1858±11, n=311), comprising of 240 genera and 444 distinct OTUs were 
classified to species level (Table A6.1).  
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6.3.1 Partitioning of species  
A DAR was used to partition species into common, most persistent and abundant, and rare, 
transient taxa found in low abundance. The log abundance of each OTU was plotted against 
persistence (the number of samples in which a particular species appeared) showing a 
significant positive relationship (F(1,433)=29.32, P<0.001), presented in Figure 6.1. Species 
present in more than 75% of the samples were considered to be common, while the 
remaining species were rare.  
A total of five OTUs representing distinct species were considered to be common when the 
whole data set was considered; Prevotella melaninogenica, Rothia mucilaginosa, 
Streptococcus mitis, Veillonella parvula, Pseudomonas aeruginosa. These OTUs were found 
to make up over 55% of the total sequences in the study (318,866 sequences), while the 
rare OTUs made up just over 44% of the total sequences (259,023 sequences).  




Figure 6.1 Persistence abundance curve of all OTUs.  
All OTUS were plotted with Persistance, the number of samples in which they appear, 
against log abundance, total number of sequences, in order to partition OTUs into those that 
are common and those that are rare. Common OTUs were defined as those that fell in the 
upper quartile (right of the vertical line), all OTUs that fell below the line were considered to 
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6.3.2 Diversity 
Three recognised measures of community diversity were applied to the data, species 
richness (S*), Shannon-Wiener index (H’), and inverse Simpson’s index (1-D). As varying 
levels of sampling depth in this study were accounted for during the sequencing analysis 
step, resampling, as performed in previous chapters, was not carried out on these data. 
Bacterial diversity was found to be highly variable between samples. In order to investigate if 
clinical factors were influencing this variation, linear relationships between bacterial diversity 
and clinical factors were investigated, these are highlighted below.  
6.3.2.1  Lung function (FEV1) 
Published data suggests that a significantly positive linear relationship exists between 
diversity and lung function. To investigate if this result was not purely an artefact of the small 
sample sets used, the relationship between bacterial diversity (as measured by S*, H’ and 1-
D) was modelled against lung function. Lung function data was available from 95% of the 
sequenced sputum samples.  As shown in Figure 6.2, a significant positive relationship was 
seen between lung function, forced expiratory volume in 1 second (FEV1), and the 3 
measures of diversity investigated. Model results are show in Table 6.3.  
6.3.2.2 Age 
It was hypothesised that this relationship would be mirrored with patient age. Patient age at 
the time of sample collection was available for 87% of the CF samples sequenced. However 
no significant relationship was found between diversity and patient age for any of the 
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Figure 6.2 The relationship between diversity and lung function (FEV1).  
A significant positive linear relationship was observed using a linear regression model, fitted 
to the data for each of the following measures of diversity; A) Species richness (P<0.001, 
r2=0.22, F(1,293)=82.8) B) Shannon-Wiener index (P<0.001, r2=0.21, F(1,293)=79.92) C) Inverse 
Simpson’s index (P<0.001, r2=0.17, F(1,293)=61.95). 
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Table 6.3 Summary of linear regression statistics between bacterial diversity and 
continuous clinical factors. 
Linear regressions were calculated to predict the relationship between bacterial diversity, 
species richness (S*), Shannon-weiner (H') and Inverse Simpson’s (1-D), and continuous 
clinical factors, forced expiratory volume in 1 second (FEV1), Age and  body mass index 
(BMI). Significant relationships (P-value <0.001) are indicated in bold. n; number of samples 
included in each analysis, df; degrees of freedom, F; F-statistic describes the explained 
variation over the unexplained varation, r2; the proportion of variation in the y-variable due to 
variation in the x-variable  
Clinical	  factor	   Diversity	   n	   df	   F	   r2	   P	  
FEV1	  
All	  
S*	   276	   1,274	   43.11	   0.136	   <0.001	  
H'	   276	   1,274	   41.8	   0.132	   <0.001	  
1-­‐D	   276	   1,274	   36.53	   0.12	   <0.001	  
Common	  
S*	   276	   1,274	   43.11	   0.133	   <0.001	  
H'	   276	   1,274	   37.11	   0.119	   <0.001	  
1-­‐D	   276	   1,274	   29.51	   0.097	   <0.001	  
Rare	  
S*	   276	   1,274	   35.03	   0.113	   <0.001	  
H'	   276	   1,274	   11.28	   0.04	   <0.001	  
1-­‐D	   276	   1,274	   9.32	   0.034	   0.002	  
Age	  
All	  
S*	   254	   1,252	   0.006	   <0.001	   0.94	  
H'	   254	   1,252	   <0.001	   <0.001	   0.998	  
1-­‐D	   254	   1,252	   0.01	   <0.001	   0.92	  
Common	  
S*	   254	   1,252	   0.006	   <0.001	   0.939	  
H'	   254	   1,252	   0.524	   0.002	   0.47	  
1-­‐D	   254	   1,252	   0.805	   0.003	   0.37	  
Rare	  
S*	   254	   1,252	   0.017	   <0.001	   0.897	  
H'	   254	   1,252	   2.959	   0.012	   0.086	  
1-­‐D	   254	   1,252	   2.458	   0.01	   0.118	  
BMI	  
All	  
S*	   183	   1,181	   7.252	   0.039	   0.008	  
H'	   183	   1,181	   4.583	   0.02	   0.03	  
1-­‐D	   183	   1,181	   3.002	   0.02	   0.08	  
Common	  
S*	   183	   1,181	   7.252	   0.039	   0.008	  
H'	   183	   1,181	   5.278	   0.028	   0.023	  
1-­‐D	   183	   1,181	   5.196	   0.028	   0.02	  
Rare	  
S*	   183	   1,181	   8.517	   0.045	   0.004	  
H'	   183	   1,181	   1.72	   0.009	   0.191	  
1-­‐D	   183	   1,181	   0.866	   0.005	   0.353	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6.3.2.3 Body mass index 
The relationship between body mass index (BMI) and bacterial community diversity was 
investigated using linear regression. BMI at the time of sample collection was recorded from 
63% of patients and was modelled against each of the three diversity measures. As shown in 
Table 6.3, using analysis of variance, a significant relationship (P-value <0.001) was seen 
between BMI and species richness and the Shannon-Wiener index however, no significant 
relationship was observed between BMI and the Inverse Simpson’s index. 
6.3.3 Analysis of variance (ANOVA) 
To investigate relationships between bacterial diversity and categorical clinical factors 
ANOVAs were employed, results are shown in Table 6.4. Bacterial diversity was not found to 
be related to patient gender, liver disease, pancreatic insufficiency, diabetes or CFTR 
genotype. Significant differences in diversity were only observed as a result of clinical status 
(stable, exacerbation or control) and location. 
Clinical status was found to be significant for the whole community as well as the partitioned 
common and rare groups. Post-hoc Tukey HSD test revealed that the bacterial diversity of 
control samples was significantly different from the diversity observed between stable and 
exacerbating patients (P<0.001) as illustrated in Figure 6.3. While the variability in diversity 
in both CF groups was found to be high, the change in diversity between stable and 
exacerbating patients was also significant (P=0.009). 
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Table 6.4 Summary statistics of ANOVA comparing bacterial diversity to categorical 
clinical data. 
Analysis of the changes in diversity, species richness (S*), Shannon-weiner (H') and Inverse 
Simpson’s (1-D) of the whole bacterial community, common and rare taxa groups associated 
with clinical factors, including; gender, diabetes and liver disease. P- values of <0.05 are 
considered significant and shown in bold.    
Clinical factor Diversity n df F r2 P 
Gender 
All 
S* 292 1,290 31.18 0.01 0.078 
H' 292 1,290 2.871 0.01 0.091 
1-D 292 1,290 43.652 0.02 0.032 
Common 
S* 292 1,290 3.118 0.01 0.079 
H' 292 1,290 1.493 0.005 0.223 
1-D 292 1,290 0.706 0.002 0.402 
Rare 
S* 292 1,290 0.372 0.001 0.542 
H' 292 1,290 0.102 <0.001 0.749 
1-D 292 1,290 0.266 <0.001 0.606 
Diabetes 
All 
S* 287 1,285 0.584 0.02 0.445 
H' 287 1,285 0.268 <0.001 0.605 
1-D 287 1,285 0.908 0.005 0.908 
Common 
S* 287 1,285 0.584 0.002 0.445 
H' 287 1,285 0.464 0.002 0.496 
1-D 287 1,285 0.173 <0.001 0.678 
 Rare 
S* 287 1,285 2.668 0.009 0.104 
H' 287 1,285 0.131 <0.001 0.717 




S* 225 1,223 0.606 0.003 0.437 
H' 225 1,223 0.226 0.001 0.635 
1-D 225 1,223 0.357 0.005 0.551 
Common 
S* 225 1,223 0.606 0.003 0.437 
H' 225 1,223 0.031 <0.001 0.861 
1-D 225 1,223 0.241 0.112 0.624 
Rare 
S* 225 1,223 0.045 <0.001 0.832 
H' 225 1,223 0.56 0.003 0.455 
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Table 6.4 Continued  




S* 225 1,223 0.467 0.002 0.495 
H' 225 1,223 0.13 <0.001 0.709 
1-D 225 1,223 0.835 0.003 0.362 
Common 
S* 225 1,223 0.467 0.002 0.495 
H' 225 1,223 1.012 0.004 0.315 
1-D 225 1,223 0.915 0.004 0.34 
Rare 
S* 225 1,223 2.233 0.01 0.137 
H' 225 1,223 0.455 0.002 0.501 
1-D 225 1,223 0.131 <0.001 0.718 
Clinical status 
All 
S* 269 1,232 31.53 0.204 <0.001 
H' 269 1,232 32.01 0.216 <0.001 
1-D 269 1,232 20.18 0.148 <0.001 
Common 
S* 269 1,232 45.69 0.164 <0.001 
H' 269 1,232 8.826 0.037 0.003 
1-D 269 1,232 5.265 0.022 0.023 
Rare 
S* 269 1,232 52.51 0.312 <0.001 
H' 269 1,232 28.72 0.199 <0.001 
1-D 269 1,232 13.44 0.104 <0.001 
Genotype 
All 
S* 254 1,249 1.045 0.008 0.353 
H' 254 1,249 1.144 0.009 0.32 
1-D 254 1,249 1.125 0.009 0.326 
Common 
S* 254 1,249 1.045 0.008 0.353 
H' 254 1,249 0.356 0.003 0.701 
1-D 254 1,249 0.493 0.004 0.59 
Rare 
S* 254 1,249 0.763 0.006 0.218 
H' 254 1,249 0.191 0.002 0.558 
1-D 254 1,249 0.012 <0.001 0.989 
Location 
All 
S* 292 1,281 4.012 0.12 <0.001 
H' 292 1,281 3.371 0.107 <0.001 
1-D 292 1,281 3.005 0.097 <0.001 
Common 
S* 292 1,281 4.012 0.125 <0.001 
H' 292 1,281 2.36 0.077 0.011 
1-D 292 1,281 2.14 0.071 0.022 
Rare 
S* 292 1,281 4.325 0.133 <0.001 
H' 292 1,281 1.685 0.057 0.084 
1-D 292 1,281 1.098 0.037 0.364 
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Figure 6.3 Changes in diversity associated with clinical status.  
Each point represents the mean value of diversity for each clinical state, lines indicate the 
standard error of the mean. Clinical status 0; Non CF healthy controls, 1; Stable, 2; Cystic 
fibrosis pulmonary exacerbation (CFPE). Results of the associated ANOVA are shown in 
Table 6.4.   
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The relationship of bacterial diversity with geographical location was investigated using 
ANOVA, considering each unique site as a different variable. This analysis therefore did not 
account for the differences in distance between sites. As shown in Table 6.4, bacterial 
diversity was found to be significantly different between sample collection sites. These 
differences in bacterial diversity between sites are visualised in Figure 6.4, and show high 
variability between sites. A post-hoc Tukey HSD test was then used to assess the statistical 
differences between each centre. This analysis revealed that while the overall difference by 
location was significant, the difference in diversity between most centres was not significant.  
Difference in species richness between, Southampton, UK and Belfast, UK (P=0.02), 
London, UK and Belfast, UK (P=0.005), Portland, ME and London, UK (P=0.04), Boston, MA 
and London, UK (P=0.02) were shown to be significant. When considering Shannon’s 
diversity index, only Southampton, UK and Belfast, UK (P=0.03) and Belfast, UK and 
Vermont, ME (P=0.02) were found to be significantly different. Further, the significant 
difference observed between and Belfast, UK and Vermont, ME (P=0.03) observed using 
Shannon’s diversity index was also observed using the inverse Simpson’s index. 
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Figure 6.4 Changes in diversity associated with Location.  
Each point represents the mean value of diversity for each location, lines indicate the 
standard error of the mean. Location 1; Belfast, UK, 2; Southampton, UK, 3; London, UK, 4; 
Dublin, Eire, 5; Warsaw, Poland, 6; Dartmouth, Bedford, NH, 7; Dartmouth, Lebanon, NH, 8; 
Portland, ME, 9; Boston, MA, 10, Seattle, WA, 11; Vermont, ME. Results of the associated 
ANOVA are shown in Table 5.4. 
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6.3.4 Mantel and partial Mantel tests 
To examine which clinical factors were related to community similarity, lower tailed Mantel 
and partial Mantel tests were employed. These tests compared the Bray-Curtis similarity of 
the whole community, as well as the common and rare groups, to distance matrices created 
for each clinical factor. It was hypothesised that patients with more similar communities 
would have more similar clinical outcomes and therefore a lower tailed Mantel test was used 
for every comparison.  All clinical factors were compared to each other using a two-tailed 
Mantel test, this analysis allowed us to account for auto-correlation in the partial Mantel tests 
(Table A6.2). Factors shown to be auto-correlated were then examined using the lower-tailed 
test, with autocorrelation accounted for in subsequent analyses.   
6.3.4.1 Mantel tests 
Continuous clinical variables were compared to the similarities of the whole, common and 
rare taxa groups. It was hypothesised that patients with more similar lung function (FEV1), 
age and BMI would have more similar bacterial communities. This relationship was 
confirmed by the Mantel test (Table 6.5) which showed a significant negative relationship 
between community similarity and all continuous clinical factors (P<0.001).  
Categorical clinical variables were also compared to community similarity using Mantel test, 
shown in Table 6.5. In order not to weight the categories, matrices were calculated so that 
samples falling into the same categories were coded as 0 and those that were different were 
coded as 1. Genotype, was found to show no significant relationship with community 
composition (whole; P=0.92,	   common;	   P=0.972,	   rare; P=0.282). Table 6.5 also shows that 
diabetes, gender and pancreatic insufficiency were found to only relate to significant 
differences in community composition when compared to the rare taxa group. Conversely 
the relationship between community composition and both liver disease and clinical status 
(whether a patient is considered clinically stable or experiencing a CF pulmonary 
exacerbation (CFPE)) were found to be significant in all groups (Table 6.5).  
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Table 6.5 Mantel test analyses for the association between bacterial community 
composition and clinical factors.  
The P-values have been calculated using the distribution of the Mantel test statistic (r) 
estimated for 9999 permutations. N= number of samples, n= number of pair wise 
comparisons between groups. Significant P-values are indicated in bold. 
Clinical	  Factor	   N	   n	   	  	   r	   P	  
Location	   292	   42486	  
All	   -­‐0.024	   <0.001	  
Common	   -­‐0.022	   <0.001	  
Rare	   -­‐0.044	   <0.001	  
FEV1	   276	   37950	  
All	   -­‐0.098	   <0.001	  
Common	   -­‐0.106	   <0.001	  
Rare	   -­‐0.035	   <0.001	  
Clinical	  status	   217	   23436	  
All	   -­‐0.031	   <0.001	  
Common	   -­‐0.04	   <0.001	  
Rare	   -­‐0.069	   <0.001	  
Age	   255	   32385	  
All	   -­‐0.022	   <0.001	  
Common	   -­‐0.021	   <0.001	  
Rare	   -­‐0.015	   <0.001	  
BMI	   182	   16471	  
All	   -­‐0.066	   <0.001	  
Common	   -­‐0.07	   <0.001	  
Rare	   0.028	   1	  
Diabetes	   287	   41041	  
All	   -­‐0.003	   0.318	  
Common	   0.001	   0.724	  
Rare	   -­‐0.032	   <0.001	  
Gender	   292	   42486	  
All	   0.001	   0.575	  
Common	   0.001	   0.579	  
Rare	   -­‐0.022	   <0.001	  
Genotype	   252	   31626	  
All	   0.006	   0.92	  
Common	   0.008	   0.972	  
Rare	   -­‐0.002	   0.282	  
Liver	  Disease	   226	   25425	  
All	   -­‐0.094	   <0.001	  
Common	   -­‐0.092	   <0.001	  
Rare	   -­‐0.041	   <0.001	  
Pancreatic	  
insufficiency	   225	   25200	  
All	   0.029	   1	  
Common	   0.03	   1	  
Rare	   -­‐0.013	   <0.001	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To examine how geographical location affected the bacterial community composition 
samples were partitioned by centre. The data was split into 11 geographical locations, shown 
in Table 6.1. Coordinates, shown in Table 6.6, from each of the clinics who provided 
samples were collected and the distances between centres were calculated. It was 
hypothesised that the bacterial community composition would be more similar in clinics 
closer in geographical distance whereas those further apart would be more distinct. Mantel 
tests were used to investigate this relationship, revealing a significant correlation between 
community similarity and geographical distance (P<0.001). This result was observed for the 
whole community and the common and rare groups, Table 6.5.  
6.3.4.2 Partial Mantel tests 
Partial Mantel test were used to further investigate the observed relationship between FEV1 
and bacterial community composition. FEV1 was compared to community composition for the 
whole community as well as the common and rare groups, controlling for each clinical factor 
in turn; shown in Table 6.7. As a result of some values being unavailable for all clinical 
factors a subset of the data was investigated using partial Mantel test. This subset consisted 
of 79% of the total samples, from 9 of the original 11 centres. Consequently, all samples 
from Belfast and Seattle were removed due to a lack of associated clinical metadata.  
This analysis revealed that for the whole community and common group, only clinical status 
(P<0.001), BMI (P<0.001) and liver disease (P<0.001) were correlated with FEV1 and 
bacterial community composition (Table 6.7). However, the rare OTU group was found to 
correlate with location (P<0.001), clinical status (P=0.008), gender (P<0.001) and pancreatic 
insufficiency (P<0.001).  
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Table 6.6 List of clinic locations and co-ordinates. 
Exact clinic locations were not available for samples collected in UK, Eire or Poland. 
Therefore co-ordinates relate to central locations in each of the county capitals. 
Reference Location Clinic Coordinates 
1 Belfast, UK Belfast city hospital 
54.5875° N, 
5.9408° W 
2 Southampton, UK Southampton general hospital 
50.9330° N, 
1.4340° W 
3 London, UK Belfast city hospital 
51.5000° N, 
0.1167° W 
4 Dublin, Eire Belfast city hospital 
53.0000° N, 
8.0000° W 
5 Warsaw, Poland Belfast city hospital 
52.2167° N, 
21.0333° E 













8 Portland, ME Maine Medical Center 
43.6530° N, 
70.2760° W 
9 Boston, MA Massachusetts General Hospital 
42.3628° N, 
71.0686° W 
10 Seattle, WA Seattle general hospital 
47.6628° N, 
122.2817° W 
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Table 6.7 Partial Mantel test analyses for the association between bacterial community 
composition and clinical factors.  
A) The correlation with the whole community, B) the correlation with the common OTU group 
and C) the correlation with the rare OTU group. The P-values have been calculated using 
the distribution of the Mantel test statistic (r) estimated for 9999 permutations. N= number of 
samples, n= number of pair wise comparisons between groups. Significant P-values are 
indicated in bold.  
A	   	  	  
	   	   	   	   	   	  Clinical	  
factor	   Control	  for	  	   r	   P	   Clinical	  factor	  
Control	  
for	  	   r	   P	  
FEV1	  
Location	   -­‐0.145	   <0.001	   Location	  
FEV1	  
0.016	   0.961	  
status	   -­‐0.145	   <0.001	   clinical	  status	   -­‐0.075	   <0.001	  
Age	   -­‐0.146	   <0.001	   Age	   0.025	   0.996	  
BMI	   -­‐0.145	   <0.001	   BMI	   -­‐0.038	   <0.001	  
Diabetes	   -­‐0.146	   <0.001	   Diabetes	   0.007	   0.771	  
Gender	   -­‐0.146	   <0.001	   Gender	   -­‐0.004	   0.33	  
Liver	  disease	   -­‐0.14	   <0.001	   Liver	  disease	   -­‐0.109	   <0.001	  
Pancreatic	  
insufficiency	   -­‐0.146	   <0.001	  
Pancreatic	  
insufficiency	   -­‐0.004	   0.315	  
	   	  
	   	  
	   	  
	   	   
B	  
	   	  
	   	  
	   	  Clinical	  
factor	   Control	  for	  	   r	   P	   Clinical	  factor	  
Control	  
for	  	   r	   P	  
FEV1	  
Location	   -­‐0.15	   <0.001	   Location	  
FEV1	  
0.019	   0.98	  
status	   -­‐0.15	   <0.001	   clinical	  status	   -­‐0.085	   <0.001	  
Age	   -­‐0.15	   <0.001	   Age	   0.015	   0.952	  
BMI	   -­‐0.149	   <0.001	   BMI	   -­‐0.05	   <0.001	  
Diabetes	   -­‐0.15	   <0.001	   Diabetes	   0.007	   0.778	  
Gender	   -­‐0.15	   <0.001	   Gender	   0.001	   0.555	  
Liver	  disease	   -­‐0.144	   <0.001	   Liver	  disease	   -­‐0.107	   <0.001	  
Pancreatic	  
insufficiency	   -­‐0.15	   <0.001	  
Pancreatic	  
insufficiency	   0.004	   0.669	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Table 6.7 Continued 
C	   	  	  
	   	  
	   	  
	   	  Clinical	  
factor	   Control	  for	  	   r	   P	   Clinical	  factor	  
Control	  
for	  	   r	   P	  
FEV1	  
Location	   -­‐0.055	   <0.001	   Location	  
FEV1	  
-­‐0.104	   <0.001	  
status	   -­‐0.053	   <0.001	   clinical	  status	   -­‐0.022	   0.008	  
Age	   -­‐0.053	   <0.001	   Age	   -­‐0.001	   0.45	  
BMI	   -­‐0.054	   <0.001	   BMI	   0.028	   0.999	  
Diabetes	   -­‐0.053	   <0.001	   Diabetes	   -­‐0.012	   0.104	  
Gender	   -­‐0.053	   <0.001	   Gender	   -­‐0.041	   <0.001	  
Liver	  disease	   -­‐0.053	   <0.001	   Liver	  disease	   -­‐0.009	   0.17	  
Pancreatic	  
insufficiency	   -­‐0.053	   <0.001	  
Pancreatic	  
insufficiency	   -­‐0.036	   <0.001	  
 
 Chapter 6  183 
6.3.5 Analysis of similarity (ANOSIM)  
Using both Sørensen and Bray-Curtis similarity, ANOSIM’s were carried out to further 
investigate the relationship between genotype and bacterial community composition. No 
significant difference was observed using Sørensen similarity index, however results 
comparing Bray Curtis similarity showed a significant difference in the whole bacterial 
community when homogeneous ΔF508 genotype was compared to heterogeneous ΔF508 
genotype (P=0.0379) (Table A6.3). 
Using Mantel tests it was revealed that when comparing genders, there was a significant 
change in the community composition of the rare OTU group. ANOSIMs, using both 
Sørensen and Bray-Curtis similarity, were used to further investigate this relationship. No 
significant difference was observed between males and females using Sørensen for the 
whole community (R=0.008, P=0.202) or the common OTU group (R=0.002, P=0.403) 
however, a significant difference was observed between genders in the rare OTU group 
(R=0.029, P=0.021). When using Bray-Curtis similarity index, a significant difference was 
observed in the whole community (R=0.026, P=0.029). From partitioning it was clear that this 
difference in community composition was driven by the rare taxa (R=0.032, P=0.01) as no 
significant difference was observed in the common OTU group (R=0.003, P=0.331).  
Mantel tests revealed that the community composition from samples collected from sites 
closer in geographic distance were more similar than those from geographically distinct 
locations. Analysis of similarity (ANOSIM) was used to back up these results and determine 
how the community composition changed between centre using both the Sørensen (Table 
6.8) and Bray-Curtis (Table 6.9) measures of similarity.  
The non CF healthy control group was included in this analysis as a distinct location. Using 
Sørensen similarity coefficient, the control group was found to be significantly different from 
all centres with the exception samples from of Southampton (R=0.049, P=0.161). However, 
when examining changes in OTU presence and abundance using Bray-Curtis similarity, the 
control samples were found to be significantly different from all centres. While Sørensen 
similarity showed the common taxa group to be similar to all centres apart from Poland 
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(R=0.075, P=0.009) and Bedford, Dartmouth (R=0.073, P=0.009), all centres were found to 
be significantly different when accounting for species abundance using Bray-Curtis similarity 
measure. When the rare group was explored, similar community composition was observed 
with both Sørensen and Bray-Curtis similarity measures, revealing similar composition in the 
control samples as those from Belfast (Sørensen; R=-0.045, P=0.711, Bray-Curtis, R=-
0.0143, P=0.992), Southampton (Sørensen; R=-0.0131, P=0.552, Bray-Curtis, R=-0.0088, 
P=0.514) and Seattle (Sørensen; R=0.059, P=0.206, Bray-Curtis, R=-0.007, P=0.517). 
ANOSIMs performed using Sørensen measure revealed the common taxa to be conserved 
between groups, with only samples from Seattle, WA (e.g. Belfast, UK; R=0.042, P=0.007) 
and Vermont, ME (eg. Portland, ME; R=0.109, P=0.004) showing significant differences from 
other clinic locations, Table 6.8B. On the other hand, significant differences in rare taxa were 
found to occur when compared to least one other CF centre, Table 6.8C. Belfast, UK, was 
the only centre to be found to be significantly different from a single other location, in this 
case Seattle, WA (R=0.134, P<0.001). Comparison of the differences in whole community 
composition and the common and rare groups indicated that the rare community was driving 
differences between centres.  
A similar pattern was observed when comparing community composition between CF 
centres using Bray-Curtis measure of similarity. However, when considering OTU 
abundance, more significant differences were observed in the common OTU group. This was 
particularly prevalent between samples from Belfast, UK, which were shown to have 
significantly different community composition from 4 other sites (Dartmouth, Bedford, NH, 
Portland, ME, Seattle, WA and Vermont, ME) and Vermont, ME, which was shown to be 
significantly different from 6 other sites (Belfast, UK, Warsaw, Poland, Dartmouth, Lebanon, 
NH, Portland, ME, Boston, MA and Seattle, WA), Table 6.9B. When the rare OTU group was 
compared more significant differences were observed, again suggesting that the rare 
community is responsible for driving the changes in community composition between CF 
centres.   
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Table 6.8 Comparison of community composition using analysis of similarity 
(ANOSIM) for each centre location. 
ANOSIMs were carried out using Sorensen measure of similarity, for the A) whole, B) 
common and C) rare communities. Matrices below show R values in the lower half and P 
values on the upper. Significant R values indicate the samples within a group are more 
similar than would be expected by random chance, therefore the two groups can be 
considered significantly different. 1) Belfast, UK, 2) Southampton, UK, 3) London, UK, 4) 
Dublin, Eire, 5) Warsaw, Poland, 6) Dartmouth, Bedford, NH, 7) Dartmouth, Lebanon, NH, 8) 
Portland, ME, 9) Boston, MA, 10) Seattle, WA, 11) Vermont, ME. 
P values less than 0.05 were considered significant. Significant P values are highlight in 
green.   
A 
  1 2 3 4 5 6 7 8 9 10 11 12  
 1 r2       P 0.22 0.8542 0.3681 0.6404 0.3345 0.444 0.0995 0.0703 0.0001 0.6653 0.0473  
 2 0.0261 r2       P 0.9242 0.4748 0.1288 0.0648 0.2457 0.0006 0.007 0.0008 0.0563 0.1605  
 3 -0.087 -0.097 r2       P 0.0001 0.0092 0.0003 0.005 0.0008 0.0003 0.1137 0.0392 0.0001  
 4 0.031 -0.002 0.535 r2       P 0.1721 0.0044 0.0049 0.0352 0.2279 0.0453 0.0382 0.0002  
 5 -0.031 0.0693 0.139 0.1057 r2       P 0.0045 0.1397 0.0003 0.0199 0.0003 0.0023 0.0001  
 6 0.0254 0.0887 0.3126 0.3603 0.1526 r2       P 0.6166 0.7063 0.0648 0.0005 0.1968 0.0001  
 7 0.0025 0.0966 0.595 0.7381 0.1727 -0.047 r2       P 0.5933 0.9171 0.0416 0.2987 0.0016  
 8 0.0814 0.1795 0.2957 0.2301 0.2075 -0.025 -0.052 r2       P 0.0734 0.0002 0.0293 0.0001  
 9 0.1238 0.1952 0.2354 0.0834 0.1083 0.0679 -0.208 0.0764 r2       P 0.0002 0.0064 0.0001  
 10 0.1338 0.164 0.0972 0.2094 0.2711 0.2824 0.2817 0.2738 0.3703 r2       P 0.0326 0.0024  
 11 -0.024 0.048 0.1286 0.2427 0.1904 0.0339 0.0695 0.0704 0.2044 0.1078 r2       P 0.0001  
 12 0.1208 0.0496 0.5099 0.8882 0.548 0.5801 0.6969 0.5013 0.6073 0.2227 0.3464 r2       P  







  1 2 3 4 5 6 7 8 9 10 11 12  
 1 r2       P 0.9215 0.887 0.8222 0.6527 0.5663 0.3859 0.0312 0.1369 0.0073 0.8519 0.9926  
 2 -0.053 r2       P 0.6037 0.677 0.2041 0.1365 0.1409 0.0009 0.017 0.2836 0.2853 0.9174  
 3 -0.108 -0.025 r2       P 0.4542 0.2532 0.336 0.0678 0.9069 0.1029 0.4902 0.654 0.0642  
 4 -0.154 -0.083 -4E-04 r2       P 0.8587 0.7934 0.2364 0.9854 0.9845 0.5141 0.596 0.4344  
 5 -0.037 0.0533 0.0095 -0.14 r2       P 0.9655 0.3601 0.7324 0.1333 0.0631 0.1787 0.0099  
 6 -0.021 0.076 0.0053 -0.142 -0.025 r2       P 0.4158 0.9269 0.18 0.0484 0.1954 0.0099  
 7 0.0343 0.1966 0.3141 0.1548 0.0628 0.0269 r2       P 0.8198 0.6739 0.0957 0.1532 0.0673  
 8 0.1421 0.1885 -0.064 -0.236 -0.025 -0.04 -0.154 r2       P 0.6523 0.0001 0.0037 0.0386  
 9 0.1024 0.192 0.0311 -0.221 0.0278 0.019 -0.099 -0.026 r2       P 0.0018 0.0241 0.0023  
 10 0.0419 0.0232 -0.006 -0.048 0.1314 0.1462 0.2639 0.3568 0.3117 r2       P 0.2731 0.9171  
 11 -0.058 0.009 -0.035 -0.081 0.0448 0.042 0.2031 0.1089 0.1536 0.031 r2       P 0.9621  
 12 -0.155 -0.063 0.0529 0.0739 0.0748 0.0729 0.373 0.0525 0.1532 -0.1 -0.046 r2       P  
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Table 6.8 Continued. 
 
C. Comparison of rare community composition using analysis of similarity (ANOSIM) for 
each centre location. 
1) Belfast, UK, 2) Southampton, UK, 3) London, UK, 4) Dublin, Eire, 5) Warsaw, Poland, 6) 
Dartmouth, Bedford, NH, 7) Dartmouth, Lebanon, NH, 8) Portland, ME, 9) Boston, MA, 10) 
Seattle, WA, 11) Vermont, ME. 
 
 1 2 3 4 5 6 7 8 9 10 11 12  
1 r2       P 0.6024 0.9939 0.6388 0.5378 0.5001 0.609 0.2607 0.0819 0.0001 0.8722 0.7112  
2 -0.014 r2       P 0.9478 0.487 0.0683 0.0516 0.2564 0.0006 0.0056 0.0082 0.0344 0.5518  
3 -0.185 -0.118 r2       P 0.0001 0.0225 0.0005 0.0041 0.0006 0.0008 0.3873 0.0839 0.0001  
4 -0.057 -0.013 0.5505 r2       P 0.2948 0.0121 0.005 0.0196 0.2963 0.1453 0.068 0.0002  
5 -0.012 0.1028 0.1016 0.0629 r2       P 0.0008 0.2337 0.0002 0.0134 0.0009 0.0017 0.0001  
6 -0.005 0.1081 0.2854 0.3212 0.1739 r2       P 0.7071 0.6067 0.046 0.0015 0.1786 0.0001  
7 -0.063 0.1101 0.6116 0.7857 0.123 -0.086 r2       P 0.4731 0.9549 0.062 0.3559 0.0016  
8 0.0349 0.1939 0.3102 0.2664 0.2642 -0.015 -0.018 r2       P 0.0186 0.001 0.0299 0.0001  
9 0.1178 0.2233 0.2102 0.0502 0.1184 0.0772 -0.235 0.1266 r2       P 0.0001 0.0029 0.0001  
10 0.1342 0.1235 0.0198 0.1395 0.2807 0.2653 0.261 0.2463 0.3729 r2       P 0.0576 0.2062  
11 -0.059 0.0539 0.0984 0.2087 0.2078 0.0398 0.0494 0.0685 0.2202 0.0945 r2       P 0.0003  
12 -0.045 -0.013 0.4979 0.9086 0.4836 0.5331 0.7048 0.4711 0.5514 0.0595 0.2746 r2       P  
	  1	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Table 6.9 Comparison of community composition using analysis of similarity 
(ANOSIM) for each centre location. 
ANOSIMs were carried out using Bray-Curtis measure of similarity, for the A) whole, B) 
common and C) rare communities. Matrices below show R values in the lower half and P 
values on the upper. Significant R values indicate the samples within a group are more 
similar than would be expected by random chance, therefore the two groups can be 
considered significantly different. 1) Belfast, UK, 2) Southampton, UK, 3) London, UK, 4) 
Dublin, Eire, 5) Warsaw, Poland, 6) Dartmouth, Bedford, NH, 7) Dartmouth, Lebanon, NH, 8) 
Portland, ME, 9) Boston, MA, 10) Seattle, WA, 11) Vermont, ME. 
P values less than 0.05 were considered significant. Significant P values are highlighted in 
green.   
A 
 
  1 2 3 4 5 6 7 8 9 10 11 12  
 1 r2       P 0.0003 0.0295 0.7071 0.977 0.0305 0.0919 0.0295 0.173 0.0002 0.0016 0.0001  
 2 0.169 r2       P 0.7363 0.8735 0.3203 0.0576 0.1413 0.0195 0.133 0.0527 0.2608 0.0122  
 3 0.1763 -0.044 r2       P 0.0649 0.001 0.3053 0.0308 0.0325 0.0267 0.0611 0.201 0.0001  
 4 -0.087 -0.135 0.1615 r2       P 0.0159 0.7382 0.0047 0.6338 0.936 0.7903 0.5422 0.0001  
 5 -0.136 0.0207 0.2943 0.365 r2       P 0.0108 0.0193 0.0721 0.024 0.6996 0.0118 0.0001  
 6 0.1574 0.0847 0.0109 -0.085 0.116 r2       P 0.3516 0.7966 0.37 0.0025 0.1156 0.0001  
 7 0.2316 0.1644 0.2386 0.5159 0.4841 0.036 r2       P 0.3307 0.3389 0.0273 0.0403 0.001  
 8 0.1319 0.0953 0.117 -0.062 0.0619 -0.032 0.0651 r2       P 0.4035 0.0105 0.0898 0.0001  
 9 0.0765 0.0725 0.1197 -0.176 0.0881 0.0028 0.0565 0.0005 r2       P 0.0276 0.0204 0.0001  
 10 0.108 0.0582 0.1021 -0.079 -0.031 0.1849 0.2605 0.1356 0.1324 r2       P 0.1123 0.0002  
 11 0.1811 0.012 0.0405 -0.02 0.1391 0.0516 0.2478 0.0443 0.1267 0.0493 r2       P 0.0008  








  1 2 3 4 5 6 7 8 9 10 11 12  
 1 r2       P 0.0012 0.0349 0.8561 0.9881 0.044 0.1651 0.0307 0.2119 0.0003 0.0021 0.0001  
 2 0.1439 r2       P 0.3899 0.8974 0.0543 0.1522 0.1286 0.0217 0.1066 0.2422 0.313 0.0073  
 3 0.1717 0.0125 r2       P 0.2129 0.0008 0.2324 0.1168 0.167 0.0526 0.0841 0.263 0.002  
 4 -0.152 -0.119 0.0656 r2       P 0.0454 0.7379 0.0377 0.8074 0.9663 0.954 0.226 0.0001  
 5 -0.154 0.0885 0.3099 0.264 r2       P 0.0088 0.0199 0.1955 0.0193 0.7474 0.0065 0.0001  
 6 0.1415 0.0433 0.022 -0.072 0.1487 r2       P 0.5728 0.73 0.2858 0.0844 0.1052 0.0001  
 7 0.1732 0.1312 0.1602 0.3333 0.4677 -0.027 r2       P 0.4662 0.3707 0.0914 0.0496 0.0007  
 8 0.1365 0.0904 0.0491 -0.122 0.0254 -0.027 -0.02 r2       P 0.569 0.0178 0.0419 0.0001  
 9 0.0662 0.0718 0.0945 -0.188 0.1015 0.0105 0.0255 -0.018 r2       P 0.0675 0.0104 0.0001  
 10 0.0806 0.0177 0.0766 -0.132 -0.036 0.0646 0.138 0.11 0.0916 r2       P 0.4138 0.0008  
 11 0.1769 0.0071 0.0249 0.0558 0.1768 0.047 0.1811 0.0642 0.1469 0.0049 r2       P 0.0085  
 12 0.4539 0.1416 0.2248 0.9312 0.8343 0.3571 0.73 0.3187 0.5677 0.1604 0.1291 r2       P  
	  1	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Table 5.9 Continued. 
 
1) Belfast, UK, 2) Southampton, UK, 3) London, UK, 4) Dublin, Eire, 5) Warsaw, Poland, 6) 
Dartmouth, Bedford, NH, 7) Dartmouth, Lebanon, NH, 8) Portland, ME, 9) Boston, MA, 10) 





  1 2 3 4 5 6 7 8 9 10 11 12  
 1 r2       P 0.4969 0.9935 0.7131 0.6179 0.36 0.2517 0.1755 0.1199 0.0001 0.6784 0.992  
 2 -0.003 r2       P 0.8774 0.2307 0.0313 0.0022 0.089 0.0003 0.0051 0.0418 0.0036 0.514  
 3 -0.176 -0.087 r2       P 0.0005 0.5108 0.0012 0.0058 0.0014 0.0056 0.2154 0.0691 0.0001  
 4 -0.079 0.0918 0.4319 r2       P 0.1258 0.0001 0.0032 0.0217 0.6996 0.031 0.1305 0.0001  
 5 -0.024 0.1201 -0.011 0.131 r2       P 0.0027 0.0789 0.0003 0.0278 0.0002 0.0004 0.0001  
 6 0.0205 0.1963 0.2332 0.4437 0.1686 r2       P 0.1543 0.9635 0.0279 0.0001 0.2081 0.0001  
 7 0.0973 0.249 0.4842 0.6746 0.1929 0.1607 r2       P 0.1903 0.6506 0.0059 0.0689 0.0002  
 8 0.0512 0.2217 0.246 0.2672 0.2013 -0.054 0.1466 r2       P 0.0217 0.0001 0.0945 0.0001  
 9 0.0916 0.2202 0.1173 -0.08 0.0899 0.0869 -0.084 0.118 r2       P 0.0001 0.0014 0.0001  
 10 0.1699 0.0774 0.06 0.2312 0.3142 0.3368 0.4424 0.2976 0.3682 r2       P 0.0028 0.517  
 11 -0.026 0.0951 0.1006 0.14 0.2325 0.0365 0.2583 0.0408 0.2223 0.1637 r2       P 0.0007  
 12 -0.143 -0.009 0.4512 0.5974 0.5051 0.5467 0.8201 0.42 0.4652 -0.007 0.1888 r2       P  
	  1	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6.3.6 Similarity percentage (SIMPER) 
Similarity percentage analysis (SIMPER) was carried out in order to examine the taxa 
responsible for the changes in community composition between genders, observed using 
ANOSIM.  Using Bray-Curtis measure of similarity SIMPER tables were created to examine 
the contribution of species from the whole community as well as the common and rare 
groups, between genders (Table 6.10). Pseudomonas aeruginosa was found to contribute 
the most to the whole community and common group similarity between genders. Of the rare 
group, Staphylococcus aureus was observed to have the biggest contribution to community 
similarity.    
The mean abundance of the recognised CF pathogens; Pseudomonas aeruginosa, 
Staphylococcus aureus, Burkholderia cepacia complex and Stenotrophomonas maltophilia, 
were all found to be higher in female patients than males.     
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Table 6.10 Similarity of percentages (SIMPER) analysis of the bacterial dissimilarity 
(Bray-Curtis) of the bacterial community between genders. 
Given is the mean % abundance of sequences for each OTU present in females and males. 
In addition, the average dissimilarity between genders is given. Percentage contribution is 
calculated from the mean contribution divided by the mean dissimilarity between genders. A) 
SIMPER analysis of the whole community, B) SIMPER analysis of the common OTU group 
C) SIMPER analysis of the rare OTU group. *Indicates organisms partitioned as common; 









%	  Female	   Male	  
Pseudomonas	  aeruginosa*	   801	   686	   22.47	   30.37	   30.37	  
Prevotella	  melaninogenica*	   101	   150	   5.169	   6.987	   37.36	  
Staphylococcus	  aureus	   120	   93.1	   4.992	   6.747	   44.11	  
Burkholderia	  cepacia	  
complex	   113	   67.7	   4.484	   6.061	   50.17	  
Prophorymonas	  catoniae	   74.4	   101	   3.935	   5.318	   55.48	  
Haemophilus	  influenzae	   53	   90.3	   3.572	   4.827	   60.31	  
Veillonella	  parvula*	   69.7	   96.3	   3.096	   4.185	   64.5	  
Stenotrophomonas	  
maltophilia	   64.8	   30.9	   2.462	   3.328	   67.82	  
Streptococcus	  mitis	  *	   60.5	   54.2	   2.28	   3.082	   70.91	  
Prevotella	   39	   44.4	   2.048	   2.768	   73.67	  
Rothia	  mucilaginosa*	   31.6	   41.4	   1.513	   2.045	   75.72	  
Prevotella	  oris	   39.8	   19.7	   1.359	   1.837	   77.55	  
Neissaria	  flavescens	   20.3	   28	   1.212	   1.639	   79.19	  
Prevotella	  denticola	   20.8	   16.7	   0.9569	   1.293	   80.49	  
Streptococcus	  parasanguinis	   14.5	   17.8	   0.7596	   1.027	   81.51	  
	  1	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%	  Female	   Male	  
Pseudomonas	  aeruginosa*	   801	   686	   40.26	   59.45	   59.45	  
Prevotella	  melaninogenica*	   101	   150	   10.99	   16.23	   75.68	  
Veillonella	  parvula*	   69.7	   96.3	   7.261	   10.72	   86.41	  
Streptococcus	  mitis*	   60.5	   54.2	   5.539	   8.179	   94.58	  
Rothia	  mucilaginosa*	   31.6	   41.4	   3.667	   5.415	   100	  











%	  Female	   Male	  
Staphylococcus	  aureus	   120	   93.7	   10.9	   12.02	   12.02	  
Prophorymonas	  catoniae	   74.4	   102	   9.14	   10.09	   22.11	  
Burkholderia	  cepacia	  
complex	   113	   68.1	   7.622	   8.41	   30.52	  
Haemophilus	  influenzae	   53	   90.8	   7.217	   7.963	   38.48	  
Stenotrophomonas	  
maltophilia	   64.8	   31	   4.562	   5.033	   43.51	  
Prevotella	   39	   44.6	   4.319	   4.765	   48.28	  
Prevotella	  oris	  	   39.8	   19.9	   3.26	   3.597	   51.88	  
Neissaria	  flavescens	   20.3	   28.1	   2.539	   2.801	   54.68	  
Granulicatella	  adiacens	   7.82	   24.9	   2.188	   2.414	   57.09	  
Prevotella	  denticola	  	   20.8	   16.8	   2.146	   2.368	   59.46	  
Streptococcus	  parasanguinis	  	   14.5	   17.9	   2.067	   2.281	   61.74	  
Fusobacterium	  nucleatum	   6.92	   18.6	   1.976	   2.18	   63.92	  
Porphyromonas	  catoniae	  	   9.75	   17.7	   1.633	   1.802	   65.72	  
Porphyromonas	  
endodontalis	   1.98	   19.4	   1.418	   1.565	   67.29	  
Leptotrichia	  wadei	   15.9	   11	   1.405	   1.55	   68.84	  
Actinomyces	  meyeri	   7.56	   13.8	   1.394	   1.538	   70.37	  
Prevotella	  pallens	   12.5	   8.22	   1.35	   1.49	   71.86	  
Megasphaera	  
micronuciformis	   9.13	   9.82	   1.214	   1.339	   73.2	  
Haemophilus	  parainfluenzae	   8.9	   10.4	   1.156	   1.275	   74.48	  
Prevotella	  nanceiensis	  	   5.25	   10.6	   0.9745	   1.075	   75.55	  
Streptococcus	  infantis	  	   10.2	   6.46	   0.9417	   1.039	   76.59	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6.4 Discussion 
Culture independent technologies have provided a wealth of previously unconsidered 
information on the bacterial community within the CF lung. However, the power of these 
studies has been limited by the number of samples investigated. To date studies have relied 
on small sample sets of less than 50 samples, typically collected from a single centre (3, 6, 
8, 9). In their paper published in 2012, Delhaes et al, acknowledge that the cohort size they 
use is small, 45 CF individuals, making it difficult to understand the underpinning 
relationships between the bacterial community and disease state (6).  
Despite the limitations of previous studies, researchers have recognised the importance of 
understanding how the bacterial community relates to clinical factors and patient well being. 
Studies by Klepac-Ceraj et al (2010), Cox et al (2010), van der Gast et al (2011) and 
Delhaes et al (2012), investigated the relationship between bacterial diversity, age and lung 
function (3, 6, 8, 9). While Klepac-Ceraj et al (2010) found that in children, although diversity 
is not correlated with lung function, they did find a strong relationship between bacterial 
diversity and age using throat swabs from children between 2 and 16 years, analysed using 
Phylochip hybridisation (8). This suggests that as children age, bacterial diversity decreases 
(8). Similar findings were seen by Cox et al (2010) using a cohort of 51, age stratified 
patients (from 1 to 72 years old) observing a decrease in lung function with age (3). Smaller 
sample sets of 14 and 4 patients, van der Gast et al (2011) and Delhaes et al (2012) failed to 
show a correlation between age and lung function, however they did identify a strong 
correlation between bacterial community diversity and lung function (6, 9).  
The relationship between age, lung function and bacterial diversity could potentially be an 
important marker of disease progression in CF patients. However, a high degree of variation 
was observed in the previously published studies. By investigating this relationship with the 
much larger cohort of patients involved in this study a more complete understanding of these 
relationships could be gained. It followed that using the three recognised measures of 
bacterial diversity; species richness, the Shannon-Wiener index and the inverse Simpson’s 
index, no significant pattern in diversity was observed with age.  
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Although, no significant trend in diversity was observed with age (mean age 29.9± SD 9.74, 
max 71, min 14.24), a significant positive relationship was found between diversity and lung 
function. The failure to identify a significant pattern between diversity and age, in this adult 
CF cohort is perhaps surprising as longitudinal studies have previously demonstrated that 
lung function decreases over the life of CF patients (4). However the rate of this decline has 
been demonstrated to be dependent on the nature of the CF symptoms experienced by an 
individual patient; with some individuals experiencing a more progressive disease phenotype 
than others (4). This interpatient variation results in age being a poor predictor of bacterial 
diversity and lung function; while older patients are in theory likely to have worse lung 
function and therefore a less diverse microbial community than younger individuals, a patient 
who survives beyond the average age of mortality (~37 years of age) is likely to have a 
milder disease phenotype than other individuals. As such, while lung function may be a 
better predictor of bacterial diversity than age, a more longitudinal approach may be required 
for individual patients in order to be confident in the results.  
Despite the failure to observe any pattern in diversity with age, the relationship between 
bacterial diversity and lung function has been observed in previous studies. However, while 
van der Gast et al (2011) reports r2 values of over 0.4 when describing this relationship (9), 
the variance observed using a significantly larger data set resulted in r2 values of 0.22, 0.21, 
0.17 (for species richness, the Shannon-Wiener index and the inverse Simpson’s index 
respectively). Despite the fact that lung function (as measure by forced expiratory volume in 
1 second (FEV1)) has been found to be the single best predictor of mortality in CF patients 
(27), the high degree of variation implies that single point measurements of lung function 
alone are unable to give a satisfactory indication of species diversity.  
To further examine the relationship between, age, lung function and the bacterial community, 
Mantel and partial Mantel test were utilized. Using the Mantel test it was found that 
community composition, as measured by Bray-Curtis measure of similarity, showed a 
significant correlation with both age and lung function for the whole community as well as for 
the common and rare groups. This result suggests that patients with similar bacterial 
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communities were more likely to be similar in age or lung function. To investigate if these two 
variables were correlated partial Mantel tests were used, revealing that while controlling for 
age, FEV1 was correlated with lung function, this was not the case when FEV1 was used to 
control for age. Importantly no autocorrelation was observed between age and lung function 
(r=0, P=0.965). This suggests that similarities in lung function are related to bacterial 
composition. The observed correlations between lung function and community composition 
adds weight to the results of the diversity data, and suggests that lung function is strongly 
associated to the bacterial community and that this is irrespective of age. 
Despite relationships observed between the bacterial community and lung function, the 
variance explained by FEV1 was still found to be low, suggesting that other clinical factors 
were involved. In order to investigate additional clinical factors influencing the correlation 
observed between FEV1 and community composition partial mantel tests were used. These 
tests revealed that FEV1 and clinical status (stable or being treated for CFPE), BMI and liver 
disease were correlated with similarity in bacterial community composition. Correlation 
between FEV1 and clinical status was not surprising as it has previously been shown that 
CFPE have negative effects on lung function (28). This relationship between the bacterial 
community and CFPE is further explored in Chapter 7.  
The relationship between the bacterial community and clinical status has been explored in 
several publications (5, 29, 30) however, it is unclear how liver disease is related to the 
bacterial community within the lung. Investigation into changes in bacterial diversity as a 
result of this showed no significant relationship, suggesting that although liver disease did 
not correlate with bacterial diversity it did with community composition. Liver disease may 
therefore be an area which requires further examination.  
Patients with similar heights and weights would be expected to have similar lung capacities. 
Further, it has also been shown in previous studies that increases in BMI are associated with 
increases in FEV1 (31). It therefore makes clinical sense for BMI and FEV1 to be correlated 
with community composition. Investigation of the relationship between bacterial diversity and 
BMI revealed that BMI had a significant positive relationship between the common group 
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bacterial diversity. This relationship however, explained very little of the variance (S*;  
r2=0.039, H’; r20.028 ,1-D; r2=0.028), suggesting that while changes in BMI are associated 
with changes in the bacterial community other factors are effecting this relationship, one of 
these is likely to be FEV1.   
The high levels of interpatient variation observed when considering the bacterial community 
in relation to age and lung function, suggests that other factors may be playing a significant 
role in patient outcomes. Previous studies have implied that CFTR genotype may have 
potentially important consequences for disease progression (10). While the majority of 
patients were found to ΔF508 homozygous, the huge variation in other mutations seen in the 
non-homozygous individuals resulted in it being impossible to look for trends due to specific 
mutations. As a result, and following the convention outlined by Klepac-Ceraj et al (2010), 
data was partitioned into 3 groups; ΔF508 homozygotes, ΔF508 heterozygotes and other 
mutations.  Whilst results of the investigation by Klepac-Ceraj et al (2010) suggested a 
significant difference in the bacterial community between patients with ΔF508 mutations and 
other mutations (8), our results show no significant change in bacterial diversity between 
genotype groups. Although ANOSIM, using Bray-Curtis similarity index revealed a significant 
difference (P=0.03) in community composition between patients with homozygous and 
heterozygous ΔF508 mutations. This was only observed when the whole community was 
investigated. Mantels tests on the other hand, revealed no difference in bacterial 
composition. While there is still a probability that genotype plays a role in disease 
progression, our results suggest that it does not have a significant effect on bacterial 
diversity, although some evidence was observed that there might be some changes in 
community composition. In order to advance our understanding of the impact genotype plays 
on the bacterial community a much larger cohort of rare genotypes would be required.    
Historically the survival rates of CF patients have shown that female patients are likely to die 
before male (11, 12). In recent years this gap has been shown to close (13) however, there 
still remains the question of what causes this disparity between genders. In order to 
investigate if the bacterial community differs between male and female patients samples 
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were partitioned by gender and bacterial diversity and composition. The comparison of 
bacterial diversity using ANOVA revealed only a significant difference in the inverse 
Simpson’s index, indicating that female patients have a lower diversity when accounting for 
species presence and abundance. Even so, this finding accounted for very little of the 
variance observed (r2=0.02).  
To further investigate any relationship between the bacterial community and gender, analysis 
of similarity was employed. ANOSIM of the whole community revealed significant differences 
in bacterial similarity as calculated by Sørensens similarity index however, this was not 
observed when Bray-Curtis similarity index was used. This result suggests that while the 
members of the bacterial community may be similar, bacterial abundances vary between 
genders. To investigate if the common or rare taxa groups were responsible for these 
changes ANOSIMs were carried on the partitioned data. This revealed no significant 
difference in the common group OTUs between females and males using either Sørensens 
or Bray-Curtis similarity indices. However importantly, when the rare group was considered 
both similarity indices revealed significant differences in bacterial community composition 
between genders.  
Similarity percentage analysis allowed the percentage contribution of OTUs to the female 
(mean age 28.7± SD 9.76, max 67, min 14.24) and male (mean age 30.7± SD 9.68, max 71, 
min 17.38) communities to be calculated. Pseudomonas aeruginosa was shown to contribute 
most to bacterial similarity; it was however shown to have a higher mean abundance in 
females than males. Interestingly Staphylococcus aureus, which was found to be the third 
biggest contributor to the whole community similarity (6.7%) and largest contributor to the 
rare group similarity (12.02%), were also found to have a larger mean abundance in females 
than males, suggesting that these recognised CF pathogens are more abundant in female 
CF patients. This relationship requires further investigation as it has been shown that co-
infection of P. aeruginosa and S. aureus may be related to worse disease outcomes (32). 
The relationship between gender and the bacterial community may be an important avenue 
for further study as it may signify the requirement for gender tailored antibiotic intervention.  
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A published study by Stressmann et al (2011) comparing the bacterial community between 2 
distinct CF centres, showed that while the common bacterial community was found to be 
similar between sites, samples collected from the US centre was significantly less diverse 
(15). The large number of samples and centres involved in this project allowed the 
investigation of between centres differences. By investigating diversity and composition at 
the metacommunity level across all study centres, this work could identify the effect of centre 
and geographic location on the bacterial community within the lung. Investigation of the 
whole community diversity alongside that of the common and rare groups revealed a 
significant difference in bacterial diversity in the whole and common groups, although the 
rare community showed only a significant change in the values of richness. However, while 
overall changes in diversity by centre are shown to be significantly different, post-hoc testing 
found few significant differences between centres. This suggests that while centre may be a 
contributing factor to bacterial diversity, differences in interpatient variation is likely to be 
more to account for more of the observed changes.  
Mantel tests showed community composition, as measured by Bray-Curtis similarity index, 
was significantly correlated with distance between centres. Showing that centres closer 
together geographically showed more similarity in community composition. To further 
investigate these changes ANOSIMs were carried out, using both Bray-Curtis and Sørensen 
indices of similarity, revealing significant changes in bacterial composition between centres. 
Despite the significant result of the Mantel tests, ANOSIMs on the whole community as well 
as the common and rare groups revealed significant differences between centres. In most 
cases this was irrespective of geographical distance. The common OTU group was found to 
be more conserved between centres than the rare group, suggesting that differences due to, 
centre, geographical distance or ethnic origin, were driven by the rare community. These 
results indicate that while geographical difference is a contributing factor to differences in the 
bacterial community, centre related differences such as treatment regimes also play a 
significant role in bacterial community composition.  
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 This study has revealed a range of clinical factors associated with differences in the 
bacterial community of the CF lung. The basic statistical analyses carried out here have 
provided an overview of the potentially important relationships which warrant further 
investigation. Previous studies have suggested that relationships between clinical factors 
such as, age, FEV1, CFTR genotype and gender could have potential clinical implications 
however, the sample sizes involved in these studies have failed to observe the true level of 
interpatient variation.  
This study is an initial investigation into a large and complex dataset, the size of which has 
never before been used in the exploration of the microbial community within the CF lung. As 
such, this data has the potential to be further mined as important clinical relationships are 
revealed. This study aimed to validate previously observed relationships between clinical 
factors and the bacterial community within the CF lung by testing them against this 
unparalleled dataset. While the size of this dataset provides unrivalled statistical power, it 
also adds levels of complexity to the analysis. Results from this study have so far revealed 
that no single clinical factor can explain the variance observed between patients.  
The size of this dataset, and the associated metadata collected alongside, provides the 
potential for a wide range of further investigations. Some of the future work on this data will 
include the use of more in depth and multivariate analyses in an attempt to explain the 
bacterial community within the lung and how this affects disease progression. On top of this, 
the role antibiotic regimes play in the bacterial community observed will be investigated to 
identify if particular antibiotic combinations result in better patient outcomes. In addition, 
further investigation into the role gender plays in bacterial community composition will be 
carried out. To gain a greater understanding of poor disease outcomes in female CF patients 
their bacterial community needs to be investigated further, particularly the presence of 
Pseudomonas aeruginosa and Staphylococcus aureus in the lower airways. This will be 
discussed more fully in Chapter 8. 
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6.6 Appendix  
Table A6.1 Species-level identities of detected bacterial taxa identified from 311 
sputum samples.  
Sputum collected from CF patients (n=292) and Non-CF controls (n=19). Given the length of 
the ribosomal sequences analysed (approx 350bp) these identities should be considered 
putative. Taxa partitioned as common are shown in bold.  
Class Family Taxon name 
Acidobacteria Acidobacteria Gp1 family incertae sedis Granulicella mallensis 
 
Acidobacteria Gp16 family 
incertae sedis Acidobacteria 
  Dehalococcoides ethenogenes  
  Paenibacillus taichungensis 
Actinobacteria Acidimicrobineae Aciditerrimonas ferrireducens 
 Actinomycetaceae Actinomyces 
  Actinomyces cardiffensis 
  Actinomyces dentalis 
  Actinomyces graevenitzii 
  Actinomyces hongkongensis 
  Actinomyces israelii  
  Actinomyces johnsonii  
  Actinomyces massiliensis 
  Actinomyces meyeri 
  Actinomyces naeslundii 
  Actinomyces odontolyticus 
  Actinomyces oris 
  Actinomyces radicidentis  
  Actinomyces viscosus 
  Arcanobacterium haemolyticum 
 Actinomycetales Micromonospora 
 Bifidobacteriaceae Alloscardovia omnicolens 
  Bifidobacterium animalis 
  Bifidobacterium breve 
  Bifidobacterium dentium 
  Bifidobacterium longum 
  Bifidobacterium subtile 
  Bombiscardovia coagulans 
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Table A6.1 Continued 
Class Family Taxon name 
  Parascardovia denticolens 
  Scardovia wiggsiae 
  Brevibacterium epidermidis 
  Brevibacterium massiliense 
  Brevibacterium otitidis 
  Brevibacterium sanguinis 
 Cellulomonadaceae Cellulomonas 
  Tropheryma whipplei 
 Conexibacteraceae Conexibacter woesei  
 Coriobacteriaceae Atopobium parvulum 
  Atopobium rimae 
  Cryptobacterium curtum 
  Olsenella uli 
 Corynebacteriaceae Corynebacterium afermentans 
  Corynebacterium amycolatum 
  Corynebacterium casei 
  Corynebacterium diphtheriae 
  Corynebacterium durum 
  Corynebacterium lipophiloflavum 
  Corynebacterium matruchotii 








  Corynebacterium ureicelerivorans 
  Corynebacterium variabilis 
  Turicella otitidis  
 Demequinaceae Demequina aestuarii 
 Dermacoccaceae Dermacoccus nishinomiyaensis 
  Kytococcus sedentarius 
 Dietziaceae Dietzia maris 
 Geodermatophilaceae Geodermatophilus  
 Intrasporangiaceae Janibacter 
  Knoellia melonis 
  Ornithinimicrobium murale 
  Phycicoccus 
 Microbacteriaceae Curtobacterium  
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Table A6.1 Continued 
Class Family Taxon name 
  Curtobacterium flaccumfaciens 
  Leifsonia bigeumensis 
  Leucobacter 
  Leucobacter albus  
  Leucobacter chromiiresistens 
  Microbacterium arborescens 
  Microbacterium sediminicola 
  Plantibacter flavus 
 Micrococcaceae Arthrobacter 
  Kocuria palustris 
  Kocuria rhizophila 
  Micrococcus luteus  
  Rothia dentocariosa 
  Rothia mucilaginosa 
 Micromonosporaceae Catellatospora bangladeshensis 
 Mycobacteriaceae Mycobacterium massiliense 
  Mycobacterium obuense 
 Nakamurellaceae Humicoccus flavidus 
 Nocardiaceae Gordonia terrae 
  Nocardia farcinica 
  Rhodococcus 
 Nocardioidaceae Nocardioides 
 Promicromonosporaceae Promicromonospora  
  Xylanibacterium ulmi 
 Propionibacteriaceae Brooklawnia massiliensis 
  Microlunatus phosphovorus 
  Propionibacterium acidifaciens 
  Propionibacterium acnes 
  Propionibacterium propionicum 
  Propionicimonas paludicola 
 Sanguibacteraceae Sanguibacter inulinus 
 Solirubrobacteraceae Patulibacter medicamentivorans 
 Streptomycetaceae Streptomyces  
 Thermomonosporaceae Thermomonospora  
Alphaproteobacteria Acetobacteraceae Acidomonas methanolica 
  Asaia 
  Granulibacter bethesdensis 
  Roseomonas mucosa 
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Table A6.1 Continued 
Class Family Taxon name 
  Roseomonas riguiloci 
 Beijerinckiaceae Methylocella palustris 
 Brucellaceae Bacillus malacitensis 
  Ochrobactrum intermedium 
 Caulobacteraceae Brevundimonas 
  Caulobacter fusiformis 
  Caulobacter vibrioides 
 Erythrobacteraceae Erythrobacter  
  Porphyrobacter 
 Hyphomicrobiaceae Devosia riboflavina 
  Rhodomicrobium vannielii 
  Shinella  
 Methylobacteriaceae Methylobacterium 
 Phyllobacteriaceae Shinella zoogloeoides 
 Rhodobacteraceae Leisingera aquaemixtae 
  Paracoccus alcaliphilus 
  Paracoccus aminophilus 
  Paracoccus aminovorans 
  Paracoccus denitrificans  
  Paracoccus homiensis 
  Paracoccus yeei 
  Rubellimicrobium mesophilum 
  Rubellimicrobium roseum  
 Rhodospirillaceae Azospirillum amazonense 
  Inquilinus limosus 
 Rhodospirillales Reyranella massiliensis 




  Sphingomonas 
 Xanthobacteraceae Orientia tsutsugamushi  
Bacilli Aerococcaceae Abiotrophia defectiva 
 Bacillaceae 1 Bacillus circulans 
  Bacillus longiquaesitum 
  Bacillus pumilus 
 
Bacillales Incertae Sedis 
XI Gemella bergeri 
  Gemella haemolysans 
  Gemella morbillorum 
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Table A6.1 Continued 
Class Family Taxon name 
  Gemella sanguinis 
  Exiguobacterium  
 Carnobacteriaceae Dolosigranulum pigrum 
  Granulicatella adiacens 
  Granulicatella elegans 
 Enterococcaceae Enterococcus 
  Enterococcus faecalis  
  Enterococcus faecium 
  Enterococcus malodoratus 
  Enterococcus moraviensis 
  Enterococcus saccharolyticus 
 Lactobacillaceae Lactobacillus acidophilus  
  Lactobacillus amylolyticus 
  Lactobacillus casei 
  Lactobacillus delbrueckii  
  Lactobacillus fermentum 
  Lactobacillus gasseri  
  Lactobacillus helveticus  
  Lactobacillus iwatensis 
  Lactobacillus kimbladii 
  Lactobacillus melliventris 
  Lactobacillus mucosae 
  Lactobacillus mucosae 
  Lactobacillus nantensis 
  Lactobacillus nasuensis 
  Lactobacillus oris 
  Lactobacillus plantarum 
  Lactobacillus rhamnosus 
  Lactobacillus salivarius 
  Lactobacillus vaginalis 
  Pediococcus acidilactici 
 Leuconostocaceae Fructobacillus 
 Listeriaceae Brochothrix thermosphacta 
 Planococcaceae Lysinibacillus fusiformis 
 Staphylococcaceae Staphylococcus aureus 
  Staphylococcus auricularis 
  Staphylococcus epidermidis 
  Staphylococcus pasteuri 
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Table A6.1 Continued 
Class Family Taxon name 
 Streptococcaceae Lactococcus lactis  
  Streptococcus 
  Streptococcus agalactiae 
  Streptococcus anginosus  
  Streptococcus australis 
  Streptococcus constellatus 
  Streptococcus cristatus 
  Streptococcus dysgalactiae 
  Streptococcus gordonii  
  Streptococcus infantis  
  Streptococcus intermedius  
  Streptococcus mitis  
  Streptococcus mutans 
  Streptococcus oralis 
  Streptococcus parasanguinis  
  Streptococcus pyogenes 
  Streptococcus salivarius  
  Streptococcus sobrinus 
Bacteroidetes Flavobacteriales Sediminibacter 
Bacteroidia Bacteroidaceae Bacteroides 
  Bacteroides acidifaciens 
 Bacteroidalesincertaesedis Phocaeicola abscessus 
 Porphyromonadaceae Butyricimonas faecihominis 
  Coprobacter fastidiosus 
  Dysgonomonas mossii 
  Odoribacter splanchnicus 
  Parabacteroides goldsteinii 
  Porphyromonas asaccharolytica 
  Porphyromonas bennonis 
  Porphyromonas catoniae  
  Porphyromonas endodontalis 
  Porphyromonas gingivalis 
  Porphyromonas macacae 
  Porphyromonas somerae  
  Prophorymonas catoniae 
  Tannerella forsythia  
 Prevotellaceae Alloprevotella rava 
  Gordonia jinhuaensis 
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Table A6.1 Continued 
Class Family Taxon name 
  Prevotella 
  Prevotella bivia 
  Prevotella buccae 
  Prevotella dentalis 
  Prevotella denticola  
  Prevotella enoeca 
  Prevotella fusca 
  Prevotella histicola 
  Prevotella intermedia  
  Prevotella loescheii 
  Prevotella melaninogenica 
  Prevotella micans 
  Prevotella multiformis 
  Prevotella nanceiensis  
  Prevotella nigrescens 
  Prevotella oralis 
  Prevotella oris  
  Prevotella oulorum 
  Prevotella pallens 
  Prevotella saccharolytica 
  Prevotella salivae  
  Prevotella scopos 
  Prevotella shahii 
  Prevotella tannerae 
  Prevotella veroralis 
 Rikenellaceae Alistipes shahii  
  Rikenella microfusus 
Betaproteobacteria Alcaligenaceae Achromobacter xylosoxidans 
  Alcaligenes faecalis 
  Bordetella petrii 
  Parapusillimonas granuli 
  Pusillimonas 
 Burkholderiaceae Burkholderia cepacia complex 
  Cupriavidus respiraculi 
  Ralstonia 
  Ralstonia mannitolilytica 
  Ralstonia pickettii  
 Comamonadaceae Acidovorax wautersii 
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Table A6.1 Continued 
Class Family Taxon name 
  Lautropia mirabilis 
  Ottowia  
  Ramlibacter tataouinensis 
  Variovorax paradoxus 
  Methylotenera versatilis 
 Neisseriaceae Eikenella corrodens  
  Kingella denitrificans 
  Kingella oralis  
  Neissaria flavescens 
  Neisseria bacilliformis 
  Neisseria elongata 
  Neisseria flavescens 
  Neisseria lactamica 
  Neisseria mucosa 
  Neisseria oralis 
  Neisseria pharyngis 
  Neisseria sicca 
 Oxalobacteraceae Herbaspirillum huttiense 
  Massilia aurea 
  Massilia timonae 
 Rhodocyclaceae Dechloromonas agitata 
  Methyloversatilis universalis  
  Propionivibrio  
 Sutterellaceae Sutterella parvirubra 
Clostridia Clostridiaceae 1 Clostridium paraputrificum  
 Clostridiales  Clostridiales  
 
Clostridiales Family XI. 
Incerta Sedis Peptoniphilus 
 
Clostridiales Family XIII. 
Incertae Sedis Eubacterium sulci 
  Mogibacterium timidum 
 
Clostridiales Incertae 
Sedis XI Anaerococcus 
  Parvimonas micra 
  Peptoniphilus lacrimalis  
  Peptoniphilus tyrrelliae 
 
Clostridiales Incertae 
Sedis XIII Mogibacterium diversum 
 Eubacteriaceae Eubacterium brachy 
  Eubacterium infirmum 
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Table A6.1 Continued 
Class Family Taxon name 
  Eubacterium nodatum 
  Eubacterium saphenum 
  Eubacterium uniforme 
 Incertae Sedis XI Peptoniphilus asaccharolyticus 
 Lachnospiraceae Butyrivibrio fibrisolvens 
  Butyrivibrio hungatei 
  Catonella morbi 
  Clostridium algidixylanolyticum 
  Clostridium clostridioforme 
  Clostridium hathewayi  
  Clostridium symbiosum 
  Clostridium xylanovorans 
  Eubacterium oxidoreducens 
  Howardella ureilytica 
  Johnsonella ignava 
  Lachnospiraceae 
  Moryella indoligenes 
  Oribacterium sinus 
  Shuttleworthia satelles 
 Peptococcaceae Peptococcus 
 Peptostreptococcaceae Clostridium metallolevans 
  Clostridium rectum 
  Eubacterium yurii 
  Filifactor alocis 
 Ruminococcaceae Clostridium methylpentosum 
  Clostridium orbiscindens 
  Faecalibacterium prausnitzii 
  Oscillibacter ruminantium 
  Ruminococcus 
Cyanobacteria Chroococcales Synechococcus elongatus 
Deferribacteres Deferribacteraceae Mucispirillum schaedleri 
Deltaproteobacteria Cystobacteraceae Cystobacter miniatus  
 Desulfobulbaceae Desulfobulbus 
 Desulfomicrobiaceae Desulfomicrobium orale 
 Polyangiaceae Chondromyces apiculatus 
  Sorangium cellulosum 
Epsilonproteobacteria Campylobacteraceae Campylobacter concisus 
  Campylobacter gracilis 
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Class Family Taxon name 
  Campylobacter mucosalis 
  Campylobacter rectus 
  Campylobacter showae 
  Campylobacter sputorum  
 Helicobacteraceae Sulfuricurvum kujiense 
Erysipelotrichia Erysipelotrichaceae Bulleidia extructa 
  Coprobacillus catenaformis 
  Erysipelothrix tonsillarum 
  Lactobacillus catenaformis 
  Solobacterium moorei 
Flavobacteria Cryomorphaceae Salinirepens amamiensis 
 Flavobacteriaceae Bergeyella zoohelcum  
  Capnocytophaga gingivalis 
  Capnocytophaga granulosa 
  Capnocytophaga haemolytica 
  Capnocytophaga leadbetteri 
  Capnocytophaga ochracea 
  Capnocytophaga sputigena 
  Chryseobacterium anthropi 
  Elizabethkingia miricola 
  Flavobacterium 
  Kocuria rosea 
  Myroides odoratus 
  Wautersiella falsenii  
  Myroides odoratimimus 
  Myroides profundi 
Fusobacteria Fusobacteriaceae Fusobacterium necrophorum  
  Fusobacterium nucleatum 
  Fusobacterium periodonticum 
 Leptotrichiaceae Leptotrichia buccalis 
  Leptotrichia goodfellowii 
  Leptotrichia hofstadii 
  Leptotrichia hongkongensis 
  Leptotrichia shahii 
  Leptotrichia trevisanii 
  Leptotrichia wadei 
  Sneathia sanguinegens 
  Streptobacillus moniliformis 
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Class Family Taxon name 
Gammaproteobacteria Aeromonadaceae Aeromonas 
 Cardiobacteriaceae Cardiobacterium hominis 
 Coxiellaceae Legionella spiritensis 
 Enterobacteriaceae Arsenophonus nasoniae 
  Erwinia rhapontici 
  Escherichia coli 
  Klebsiella oxytoca 
  Morganella morganii  
  Pantoea ananatis 
  Proteus mirablis 
  Providencia alcalifaciens 
  Providencia rettgeri 
  Serratia marcescens 
 
Gammaproteobacteria 
family incertae sedis Orbus hercynius 
  Orbus sasakiae 
  Psychromonas marina 
 Halomonadaceae Halomonas 
 Legionellaceae Legionella fairfieldensis 
 Moraxellaceae Alkanindiges illinoisensis 
  Enhydrobacter aerosaccus 
  Moraxella catarrhalis 
  Moraxella macacae 




  Aggregatibacter segnis 
  Haemophilus haemolyticus 
  Haemophilus influenzae 
  Haemophilus parahaemolyticus 
  Haemophilus parainfluenzae 
  Haemophilus sputorum 
 Pseudomonadaceae Pseudomonas aeruginosa 
 Sinobacteraceae Povalibacter uvarum 
 Xanthomonadaceae Ignatzschineria ureiclastica 
  Stenotrophomonas maltophilia 
  Thermomonas hydrothermalis 
  Xanthomonas 
Gemmatimonadetes Gemmatimonadaceae Gemmatimonas aurantiaca 
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Class Family Taxon name 
Ignavibacteria Ignavibacteriaceae Ignavibacterium album 
Mollicutes Mycoplasmataceae Mycoplasma faucium 
  Mycoplasma feliminutum 
  Mycoplasma salivarium 
Negativicutes Veillonellaceae Anaeroglobus geminatus 
  Centipeda periodontii  
  Dialister invisus 
   
  Dialister micraerophilus 
  Dialister pneumosintes 
  Megasphaera micronuciformis 
  Mitsuokella 
  Schwartzia succinivorans 
  Selenomonas 
  Selenomonas artemidis 
  Selenomonas dianae 
  Selenomonas flueggei 
  Selenomonas infelix 
  Selenomonas noxia  
  Selenomonas sputigena  
  Veillonella atypica 
  Veillonella dispar 
  Veillonella parvula 
Planctomycetacia Planctomycetaceae Gemmata obscuriglobus 
  Telmatocola sphagniphila 
Spartobacteria Spartobacteria family incertae sedis Chthoniobacter flavus 
Sphingobacteria Chitinophagaceae Chitinophaga 
  Chitinophaga niastensis  
  Sediminibacterium 
 Cytophagaceae Hymenobacter 
 Sphingobacteriaceae Pedobacter cryoconitis 
  Pedobacter heparinus 
  Sphingobacterium 
Spirochaetes Spirochaetaceae Treponema 
  Treponema amylovorum 
  Treponema denticola 
  Treponema maltophilum  
  Treponema putidum 
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Table A6.1 Continued 
Class Family Taxon name 
  Treponema socranskii 
  Treponema vincentii  
SR1 class incertae 
sedis SR1 family incertae sedis SR1 bacterium human oral taxon  
Synergistetes Synergistetes Synergistetes 
TM7 class incertae 
sedis TM7 family incertae sedis TM7 phylum sp. oral taxon 
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Table A6.2 Mantel test analyses for the investigation of autocorrelation. 
The P-values have been calculated using the distribution of the Mantel test statistic (r) 
estimated for 9999 permutations. N=152, n= 11476 pair wise comparisons between groups. 
Significant P-values are indicated in bold. A, Mantel tests carried out using a two tailed test, 
B, Mantel tests carried out using a lower tailed test 
A 
Matrix	  A	   Matrix	  B	   r	   P	  
Age	   BMI	   -­‐0.045	   <0.001	  
Age	   Clinical	  status	   -­‐0.037	   <0.001	  
Age	   Diabetes	   0.044	   <0.001	  
Age	   Pancreatic	   0.013	   0.168	  
Age	   Gender	   0.005	   0.559	  
Age	   liver	  disease	   0.012	   0.212	  
BMI	   Clinical	  status	   -­‐0.021	   0.027	  
BMI	   diabetes	   -­‐0.002	   0.829	  
BMI	   Liver	  disease	   0.097	   <0.001	  
BMI	   Pancreatic	   0.001	   0.947	  
Clinical	  status	   Diabetes	   -­‐0.001	   0.897	  
Clinical	  status	   Liver	  disease	   -­‐0.006	   0.564	  
Clinical	  status	   Pancreatic	   0.039	   <0.001	  
Diabetes	   Liver	  disease	   0.025	   0.008	  
Diabetes	   Pancreatic	   0.063	   <0.001	  
FEV1	   Age	   0	   0.965	  
FEV1	   Gender	   0.017	   0.071	  
FEV1	   BMI	   0.026	   0.005	  
FEV1	   Clinical	  status	   0.014	   0.142	  
FEV1	   Diabetes	   0.029	   0.002	  
FEV1	   Pancreatic	   0.011	   0.23	  
FEV1	   Liver	  disease	   0.062	   <0.001	  
Liver	  disease	   Pancreatic	   -­‐0.004	   0.644	  
Location	   BMI	   -­‐0.005	   0.616	  
Location	   Clinical	  status	   0.009	   0.352	  
Location	   Diabetes	   0.107	   <0.001	  
Location	   FEV1	   -­‐0.012	   0.216	  
Location	   Liver	  disease	   -­‐0.002	   0.878	  
Location	   Pancreatic	   0.255	   <0.001	  
Location	   Gender	   0.008	   0.401	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Table A6.2 Continued 
A  
Matrix	  A	   Matrix	  B	   r	   P	  
Gender	   BMI	   0.02	   0.038	  
Gender	   Diabetes	   0	   0.99	  
Gender	   Liver	  disease	   -­‐0.011	   0.237	  
Gender	   Pancreatic	   -­‐0.006	   0.541	  
Gender	   Clinical	  status	   0	   0.99	  
 
B 
Matrix	  A	   Matrix	  B	   r	   P	  
FEV1	   Liver	  disease	   0.062	   1	  
FEV1	   BMI	   0.026	   0.997	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Table A6.3 Comparison of community composition using analysis of similarity 
(ANOSIM) for each CFTR genotype. 
ANOSIM was carried out using both, A, Sørensen and, B, Bray-Curtis measures of similarity, 
for the whole, common and rare communities. Matrices below show R values in the lower 
half and P values on the upper. Significant R values indicate the samples within a group are 
more similar than would be expected by random chance, therefore the two groups can be 
considered significantly different. P values less than 0.05 were considered significant. 
Significant P values are highlight in green.   
A 
Whole	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.5548	   0.2777	  
Heterozygous	   -­‐0.002862	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.281	  
Other	   0.0397	   0.04064	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  
Common	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.3812	   0.5845	  
Heterozygous	   0.003042	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.6543	  
Other	   -­‐0.02109	   -­‐0.03657	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  
Rare	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.5336	   0.3389	  
Heterozygous	   -­‐0.002539	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.3181	  
Other	   0.0263	   0.03184	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  
B 
Whole	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.0379	   0.9763	  
Heterozygous	   0.02338	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.9972	  
Other	   -­‐0.1143	   -­‐0.1527	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  
Common	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.1385	   0.9709	  
Heterozygous	   0.01179	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.9919	  
Other	   -­‐0.1047	   -­‐0.1131	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	  
Rare	   Homozygous	   Heterozygous	   Other	  
Homozygous	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.2566	   0.5269	  
Heterozygous	   0.007679	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.6378	  
Other	   -­‐0.007451	   -­‐0.02893	   r	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	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7.1 Introduction 
It is well established that chronic lung infections are the main cause of morbidity and 
mortality in cystic fibrosis (CF) patients (1). In recent years, increased use of culture 
independent molecular technologies has enhanced our understanding of the complex and 
diverse polymicrobial community associated with CF lung infections (2-5). This improved 
understanding has lead to better patient management (6), however, there are still gaps in our 
understanding of how the microbial community relates to disease progression.  
Pulmonary symptoms in CF begin in early life, over time a combination of impaired 
mucociliary clearance, innate immune responses and microbial infection lead to a 
progressive loss of lung function (7). This gradual decline in pulmonary function is 
interspersed with periods of acute worsening of respiratory symptoms known as CF 
pulmonary exacerbations (CFPE) (8). These periods of CFPE are associated with more 
rapid disease progression and reduced survival, as well as a recognised reduction in quality 
of life and an increase in overall healthcare costs (9). 
Despite efforts, no strict guidelines are in place to describe when patients are experiencing a 
CFPE. This lack of consensus is mainly due to inconsistency in the symptoms experienced 
by CF individuals of different ages and disease state, thus making it challenging for 
paediatricians and adult physicians to come to an agreement (10). Although no consensus 
for a generally applicable definition has been reached, clinical features include; decreased 
exercise tolerance, increased cough, increased sputum production, shortness of breath, 
chest pain, absence from school or work, increased adventitial sounds on lung examination, 
decreased appetite or weight loss and a decline in lung function. Surprisingly a study by 
Rosenfeld et al (2001) revealed that a change in lung function showed little effect on the 
sensitivity or specificity of CFPE diagnosis, however, it is still widely relied upon as an 
indicator of worsening symptoms (11).  
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The dynamic nature of CF lung disease makes the identification of CFPE particularly 
challenging, ultimately it is the job of the treating clinician to determine if the patient is 
experiencing a CFPE and therefore requires intervention. CFPE are treated with aggressive 
antibiotic therapy, which in the majority of cases involves high dose intravenous (IV) 
antibiotics targeted at the most abundant organism within the lung; in many cases this is 
Pseudomonas aeruginosa (10).  
Efficient intervention is important, as it has been well established that CFPE have important 
negative effects on pulmonary function, with lung function tests failing to recover to baseline 
after treatment in one in four cases (12). However, Sanders et al (2012) found that quick 
efficient management of CFPE results in improved prognosis and increased likelihood of 
lung function recovery, thus underlining the need to efficiently recognise CFPE (12).  
To date the majority of studies carried out have involved cross-sectional sampling, where a 
single sample is taken from each patient within the study (2, 13, 14). These studies have 
been invaluable for investigating the microbial community within the lung, revealing high 
levels of microbial diversity and increasing our understanding of the correlations between the 
lung community and disease progression. Although extremely useful, these studies reveal 
little of the how community dynamics over time relates to clinical outcomes. For this reason 
more studies are being carried out using longitudinal sampling with multiple samples from 
each patient (5, 15-19).  By examining the microbial community over time, insights into how 
the community relates to factors that result in poor clinical outcomes, such as pulmonary 
exacerbation (18) and its treatment (15) can be investigated. 
Longitudinal studies provide useful information about how community changes relate to 
disease state and provide information on potential targets and biomarkers that could lead to 
more effective treatment options. In a 10 year study, Zhao et al (2011) using 16S rRNA gene 
pyrosequencing, revealed that bacterial community diversity within the CF lung can be 
maintained in over prolonged periods in patients with mild disease symptoms. However, in 
those with more progressive lung disease, diversity is found to decrease significantly over 
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time (5). Over the shorter scale of one year, Stressmann et al (2012) used terminal 
restriction fragment length polymorphism (T-RFLP) to reveal that the bacterial community 
was conserved over time and resistant to perturbations (16). 
These long term studies have provided valuable information about how changes in the 
bacterial community composition relate to disease state over time. However they give no 
indication of how perturbations within the lungs, such as CFPE, relate to patient well being in 
the short term. Studies by Fodor et al (2012) and Carmody et al (2013) used high throughput 
sequencing to investigate changes in bacterial community composition as a result of CFPE 
(15, 18). Both studies relied on paired samples (two samples obtained at defined times from 
the same patient), however while Fodor et al, (2012) examined the changes from initiation of 
treatment for CFPE to completion (15), Carmody et al (2013) compared baseline samples, 
before the onset of respiratory symptoms associated with CFPE to those samples taken 
when the exacerbation had been confirmed, but prior to the start of treatment (18). A study 
by Price et al (2013) attempted to address changes in the community over the entirety of a 
CFPE by collecting a single sample from each of the following periods; baseline, 
exacerbation, treatment and recovery. However, this study failed to recognise trends in the 
bacterial community over the course of the disease (19). Although these studies provided 
insights into changes in community composition, they were limited by the sampling strategy, 
which did not allow any indication of short term variation within the airway community to be 
accounted for. These studies highlight the need to examine community changes using 
multiple samples per clinical period in conjunction with detailed patient metadata.  
In order to address the knowledge gap identified by these studies, FLX Titanium 454 
pyrosequencing was used to examine changes in the bacterial community dynamics of 12 
patients, over the course of one year. During this period ten of the twelve patients were 
treated for a CFPE, multiple sputum samples were collected throughout the full cycle of 
CFPE and back to baseline. This full cycle approach has, as yet, not been explored and 
therefore this study provides novel insight into the changes in the bacterial community 
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dynamics between disease states. From this, patterns in the bacterial community over time 
could be identified, while detecting potential biomarkers for clinical exacerbations.   
 
7.2 Materials and methods 
7.2.1 Sample collection 
This study was undertaken with the local ethical approval from Southampton and South 
West Hampshire Research Ethics Committee (06/Q1704/24). Sputum samples were 
collected from 12 adult CF patients attending the Southampton General Hospital, 
Southampton, UK (Table 7.1). Subjects were selected due to their persistent production of 
sputum and history of CFPE. All patients were chronically colonised with Pseudomonas 
aeruginosa.   
Samples were collected from patients during periods of stability, defined as periods where 
patients were only receiving maintenance doses of antibiotics. During the study period 10 of 
the 12 patients were treated for a CFPE. The start and end of CFPE were identified by 
treating clinicians, and were defined for the purpose of this study as the period of time where 
patients received clinical intervention in the form of aggressive antibiotic treatment. 
Decisions to initiate treatment were based on worsening clinical symptoms (20), stabilisation 
or improvement of these symptoms lead to the termination of this treatment. Samples were 
retrospectively partitioned into 5 periods; 1a) Stable pre-CFPE, 2) 30 days prior to antibiotic 
treatment for CFPE, 3) period of time patients were receiving treatment for pulmonary 
exacerbation, 4) 30 days post treatment for CFPE, 1b) Stable post-CFPE.  
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Table 7.1 Clinical characteristics for individual patients 
Patient	   Age	  (Years)	   Gender	  
CFTR	  
genotype	   BMI	   Diabetes	   CFPE	  Antibiotics*	  
1	   30	   Male	   ΔF508/NK	   29	   No	   Ciprofloxacin	  PO	  
2	   45	   Female	   ΔF508/NK	   18.2	   Yes	   Colomycin	  IV	  +	  Tobramycin	  IV	  
3	   47	   Male	   ΔF508/NK	   19.9	   Yes	   	  
4	   22	   Female	   ΔF508/ΔF508	   18	   No	  
Cirprofloxacin	  PO,	  
then,	  Meropenem	  IV	  +	  
Amakacin	  IV	  
5	   55	   Male	   ΔF508/G58E	   23.9	   No	   Ceftazidime	  IV	  +	  Gentamicin	  IV	  
6	   21	   Female	   ΔF508/ΔF508	   20.3	   No	   Ciprofloxacin	  PO	  
7	   40	   Male	   ΔF508/ΔF508	   19.4	   Yes	   	  
8	   22	   Male	   ΔF508/ΔF508	   18.4	   Yes	   Meropenem	  IV	  +	  Colomycin	  IV	  
9	   17	   Female	   ΔF508/ΔF508	   22.5	   No	   Ceftazidime	  IV	  +	  Gentamicin	  IV	  
10	   24	   Female	   ΔF508/G542X	   21	   No	   Clarithromycin	  PO	  
11	   20	   Male	   ΔF508/ΔF508	   20.4	   No	   Ciprofloxacin	  PO	  +	  Metronidazole	  
12	   20	   Male	   ΔF508/ΔF508	   28.5	   No	   Ceftazidime	  IV	  +	  Gentamicin	  IV	  
Abbreviations: BMI, body mass index (kg /m2); CFTR, cystic fibrosis transmembrane 
conductance regulator; NK, genotype not known; * Antibiotics administered as intervention 
for a clinically defined CFPE; PO, Oral; IV, intravenous. 
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7.2.2 Clinical information 
Clinically relevant symptoms were monitored throughout the sampling period. Lung function 
was assessed using a Koko PeakPro home spirometer (Ferraris Cardiorespiratory, 
Louisville, CO, USA) at the time of each sample collection. Patients were also required to 
assess respiratory symptoms; cough, breathlessness, sputum production and general 
wellbeing, using a visual analogue scale (VAS) scored 0-100, with 0 being the worst and 100 
the best. 
7.2.3 DNA extraction and Pyrosequencing 
Samples were stored at -80°C until processing. A sterile scalpel was used to transfer 
approximately 250µl of frozen sputum into a 15ml centrifuge tube for a sputum wash to be 
performed, as described in Chapter 2.3.1. Washed sputum was then treated with propidium 
monoazide (PMA) using the method described in Chapter 2.3.2 prior to DNA extraction, 
Chapter 2.3.3 
7.2.4 Sample processing and sequence analysis 
The primers 338F (5'-ACTCCTACGGGAGGCAGCAG) and 926R (5'-
CCGTCAATTCMTTTRAGT) were used to perform bacterial Golay Barcode encoded FLX 
Titanium amplicon pyrosequencing following the method outlines in Chapter 2.4.1. 16S rRNA 
gene amplicons were initially generated using a one step PCR of 25 cycles using 
AccuPrimeTM Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA). 454 
pyrosequencing using the Lib-L kit was performed at the Wellcome Trust Sanger Institute, 
Hinxton, UK. 
As previously described in Chapter 2.7, resulting data was analysed using the Mothur 
sequencing analysis platform.  The sequence data reported in this paper have been 
deposited in the European Nucleotide Archive under Study Accession Numbers ERP005251 
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and ERP007059, and Sample Accession Numbers ERS421603 and ERS551400. The 
relevant barcode information for each sample is shown in Table A7.1.  
7.2.5 Statistical analysis 
All statistical analysis was performed in R version 3.1.1(2012-07-10) (21).  
Species were partitioned using a distribution abundance distribution, described by Magurran 
and Henderson (2003) (22). The most persistent and abundant species, those present in 
more that 75% of the total samples, were described as common, while all others were 
considered to be rare.  
The rate of species turnover between consecutive samples was calculated using the method 
described by Brown and Kodric-Brown (1977) (23).  
Analysis of similarity (ANOSIM) was used to assess the similarity between disease periods, 
using PAST (version 2.7) (24). This method uses the Bray-Curtis measure of similarity to 
assess the similarity within periods. Results were compared between periods to allow 
differences to be assessed. R values are on a scale of +1 to -1, values of +1 indicates the 
most similar samples are within the same period, while -1 indicates the most similar samples 
are outside the period. Significant R values indicate that the community similarities are more 
similar within the disease period and therefore can be considered significantly different.  
Similarity of Percentages (SIMPER) analysis was used to assess the contribution of each 
species to the observed similarity between disease periods, in order to identify those species 
that are important in creating the observed pattern of similarity using the Bray-Curtis 
measure of similarity. SIMPER analyses were performed as previously described by Clarke 
(1993) (25), using PAST (version2.7) (24). 
To analyse species level changes over the five disease periods, outlined above, mixed effect 
models (GLMMADMB) with negative binomial errors were used as data was found to be over 
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dispersed (data showed greater variability than would be expected based on a Poisson 
distribution). For each species the change in abundance, across all patients, was measured 
using the disease period as the fixed effect and variation between patients was accounted 
for by including patient as a random effect. The model fits the changes in abundance on the 
logit scale. The null hypothesis for each species was that there would be no change in 
species abundance between periods.  
 
7.3 Results 
Sputum samples were collected from 12 adult CF patients over the course of 12 months 
along with complementary clinical information (Table 7.1). The diversity and composition of 
bacterial communities was assessed using 16S rRNA gene pyrosequencing. A total of 237 
samples were sequenced resulting in a total of 386,002 bacterial sequences (mean± 
standard error/sample 1628±84, n=237), comprising 92 genera and 163 distinct Operational 
taxonomic units (OTUs) classified to species level (Table A7.2).  
In order to examine how bacterial community changes were associated with disease state, 
data was partitioned into distinct clinical periods, in line with those defined and used by Zhao 
et al (2012) (5) and Price et al (2013) (19). The data was partitioned into 5 clinical periods; 
1a) stable pre-CFPE (n=56, 1845±247), 2) 30 days prior to CFPE treatment (n=41,	  
1357±136), 3) treatment for clinical exacerbation (n=67, 1643±127), 4) 30 days post CFPE 
treatment (n=32, 1845±151), 1b) stable post-CFPE (n=41, 1449±212). In this study the 
course of a single exacerbation was followed allowing the addition of a fifth category, stable 
post-CFPE, to investigate the resistance of the bacterial community to perturbations within 
the system.  
During periods 1a, 2, 4 and 1b, patients received their standard doses of maintenance 
antibiotics. During period 3, defined as the period of treatment for CFPE, patients were 
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hospitalised and received increased antibiotic intervention, in the majority of cases through 
IV antibiotic treatment, see Table 7.1.  
Periods 2 and 4 were defined as 30 days pre- and post- antibiotic intervention. These 
periods were chosen to investigate how the bacterial community changed leading into and 
out of pulmonary exacerbation. Period 2 was chosen to investigate how the bacterial 
community changed in the run up to clinical intervention becoming necessary, while period 4 
was defined to investigate how the bacterial community recovered after antibiotic 
intervention. The 30 day period allowed any residual effect of antibiotic treatment to be 
completely removed from the system prior to the post CFPE baseline period. 
7.3.1 Partitioning OTUs 
A distribution abundance relationship (DAR) was used to partition the common, most 
persistent and abundant OTUs, and the rare, transient OTUs found in low abundance. The 
log OTU abundance was plotted against the sample persistence (the number of samples in 
which a particular OTU appears) showing a significant positive relationship, see Figure 7.1. 
This direct relationship between OTU persistence and abundance indicates a coherent 
metacommunity. OTUs present in more than 75% of the samples were considered common, 
all remaining OTUs were considered rare, Figure 7.1. Five OTUs were found to be present in 
more than 75% of the samples and were therefore considered to be common. These 
common OTUs derived from; Pseudomonas aeruginosa, Streptococcus pneumoniae, S. 
sanguinis group, Prevotella melaninogenica and Veillonella parvula, were found to add up to 
over 84% of the total sequences in this study (327,133 sequences). On the other hand, the 
rare group was comprised of 158 OTUs, and accounted for just over 15% of the total 
sequences (58,869 sequences).  
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Figure 7.1 The persistence and total abundance of bacteria taxa present in all 
longitudinal samples and at each of the five partitioned periods.  
Common taxa were defined as those that fell within the upper quartile (vertical line), all taxa 
that fell below the line were considered rare. All) The total from samples collected from the 
12 CF patients, irrespective of disease state, within the study (n=237, r2=0.7, F(1,182)=425.7, 
P<0.001). 1a) Stable pre-CFPE (n=56, r2=0.8, F(1,106)=429.3, P<0.001), 2) 30 days prior to 
antibiotic treatment (n=41, r2=0.8, F(1,121)=415.1, P<0.001), 3) period of time patients were 
receiving treatment for pulmonary exacerbation (n=67, r2=0.7, F(1,140)=363.3, P<0.001), 4) 30 
days post treatment (n=32, r2=0.8, F(1,86)=316.7, P<0.001), 1b) Stable post-CFPE (n=41, 
r2=0.7, F(1,92)=221.1, P<0.001) 
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When samples were divided up by clinical state and partitioned it was found that the 
Veillonella parvula and Prevotella melaninogenica OTUs fell below the upper quartile, 
resulting in those OTUs being considered rare during the treatment period (Figure 7.1, 3). 
Importantly however, these OTUs were found to return to the common group after the 
conclusion of the treatment period, Figure 7.1. All other OTUs were consistently partitioned 
into either the common or rare group.  
7.3.2 OTU turnover 
The rate of OTU turnover, the number of OTUs eliminated and replaced over time, was 
assessed based on for each patient over the study period using the Brown and Kordric-
Brown (1977) measure of species turnover, Figure 7.2 (23). Changes in the rate of OTU 
turnover were observed showing more variation in the periods surrounding and during 
treatment for CFPE. 
By partitioning the turnover data into 5 periods it was found that during period 1a and 1b the 
rate of OTU turnover was relatively consistent, this was particularly evident for patients 3 and 
7 who did not experience a CFPE over the study period, Figure 7.2. However, during periods 
2, 3 and 4 greater levels of variation in this rate were observed, meaning that no statistically 
significant trend was observed as changes in turnover rates were not consistent between 
individual patients. 
The turnover rates of the partitioned groups were plotted and displayed on Figure 7.1. This 
revealed that the rate of turnover of the common OTUs was much lower than the rare 
category. Most turnover of common OTUs occurred during period 2, 3 and 4 however, this 
was not the case for all patients. The rate of rare OTU turnover was greater than that 
observed for the common OTUs and showed high levels of variability. This suggests that the 
rare group members were driving the observed changes in the rate of community turnover 
over time.  
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Figure 7.2 Changes in the rate of OTUs turnover for each patient.  
Solid vertical lines indicate the start and end of treatment for CFPE, Dashed lines indicate 
the start and end of the 30 day period either side of the treatment period. 1a; stable pre-
CFPE, 2; 30 days prior to CFPE treatment, 3; treatment for clinical exacerbation, 4; 30 days 
post CFPE treatment, 1b; stable post-CFPE. Black line represents the total community 
turnover, green represents the common and blue the rare.  
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7.3.3 Analysis of similarities (ANOSIM) 
Analysis of similarity was used to determine how the community composition changed 
between the 5 disease periods using Bray-Curtis measure of similarity. ANOSIMs were 
carried out on the whole community and the common and rare groups (Table 7.3). No 
significant change was observed between disease periods within the whole or common 
communities. However, significant differences in the community composition of the rare 
community were seen between; period 1a (stable pre CFPE) and periods 3 (P=0.002) and 4 
(P=0.04), period 2 (30 days pre treatment) and period 4 (P=0.009) and 1b (P=0.04), period 4 
(30 days post treatment) was also significantly different from 1b (P=0.009). Importantly no 
significant difference in community composition was observed between the two stable 
periods, pre and post CFPE (P=0.5).  These results support the observations made 
previously when examining changes in the rate of OTU turnover.   
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Table 7.2 Comparison of community composition using analysis of similarity 
(ANOSIM) for each disease period. 
ANOSIM was carried out using Bray-Curtis measure of similarity, for the whole, common and 
rare communities. Matrices below show R values in the lower half and P values on the 
upper. Significant R values indicate the samples within a group are more similar than would 
be expected by random chance, therefore the two groups can be considered significantly 
different.  
P values less than 0.05 were considered significant. Significant P values are highlight in 
green.   
 
Whole	   1a	   2	   3	   4	   1b	  
1a	   R	  	  	  	  	  	  	  	  	  	  	  	  P	  	   0.21	   0.0919	   0.4133	   0.5622	  
2	   0.01194	   R	  	  	  	  	  	  	  	  	  	  	  P	   0.2757	   0.177	   0.342	  
3	   0.01848	   0.01222	   R	  	  	  	  	  	  	  	  	  	  P	   0.7783	   0.3957	  
4	   0.0003736	   0.01658	   -­‐0.03389	   R	  	  	  	  	  	  	  	  	  	  P	   0.1993	  
1b	   -­‐0.006949	   0.000646	   0.002817	   0.01431	   R	  	  	  	  	  	  	  	  P	  
	   	   	   	   	   	  
	   	   	   	   	   	  Common	   1a	   2	   3	   4	   1b	  
1a	   R	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.1909	   0.1428	   0.4776	   0.5337	  
2	   0.01142	   R	  	  	  	  	  	  	  	  	  	  	  P	   0.2592	   0.2117	   0.4807	  
3	   0.01162	   0.01288	   R	  	  	  	  	  	  	  	  	  	  	  	  P	   0.8338	   0.413	  
4	   -­‐0.005413	   0.01251	   -­‐0.03924	   R	  	  	  	  	  	  	  	  	  	  	  P	   0.1394	  
1b	   -­‐0.006063	   -­‐0.00388	   0.001393	   0.02168	   R	  	  	  	  	  	  	  	  	  	  P	  
	   	   	   	   	   	  
	   	   	   	   	   	  Rare	   1a	   2	   3	   4	   1b	  
1a	   R	  	  	  	  	  	  	  	  	  	  	  	  	  	  P	   0.1469	   0.0016	   0.0361	   0.5339	  
2	   0.02272	   R	  	  	  	  	  	  	  	  	  	  	  	  P	   0.9613	   0.0094	   0.0394	  
3	   0.05551	   -­‐0.04503	   R	  	  	  	  	  	  	  	  	  	  	  	  P	   0.3131	   0.2543	  
4	   0.07463	   0.07108	   0.01644	   R	  	  	  	  	  	  	  	  	  	  	  P	   0.0086	  
1b	   -­‐0.0041	   0.02845	   0.01742	   0.07378	   R	  	  	  	  	  	  	  	  	  	  	  	  P	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7.3.4 Similarity percentage (SIMPER) 
Similarity percentage (SIMPER) tables allow the investigation of the contribution of individual 
OTUs to the community similarity. Using the Bray-Curtis measure of similarity SIMPER 
tables were made to examine the contributions of OTUs from the whole (Table 7.4.1), 
common (Table 7.4.2) and rare (Table 7.4.3) communities, between each of the 5 disease 
periods. Table 7.4.1 indicates that P. aeruginosa contributed the most to the whole 
community similarity between all disease states; this was backed up by the result of the 
common groups (Table 7.4.2). Of the rare group, Porphyromonas catoniae was found to 
provide the biggest contribution to community similarity in all disease periods, with the 
exception of the comparison between the CFPE treatment period and 30days post-CFPE, 
where Fusobacterium nucleatum provided the largest contribution.  
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Table 7.3.1 Similarity of percentages (SIMPER) analysis of the bacterial dissimilarity (Bray-
Curtis) of the whole bacterial community between disease states. 
Given is the mean % abundance of sequences for each OTU across the periods they were 
observed to occupy. In addition, the average dissimilarity between periods is given. 
Percentage contribution is calculated from the mean contribution divided by the mean 
dissimilarity between periods. A) SIMPER analysis of the whole community between period 
1a and 2, B) SIMPER analysis of the whole community between period 2 and 3, C) SIMPER 
analysis of the whole community between period 3 and 4, D) SIMPER analysis of the whole 
community between period 4 and 1b, E) SIMPER analysis of the whole community between 
period 1a and 1b. *Indicates organisms partitioned as common; organisms in bold are 
considered to be recognised CF pathogens.  
A	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   2	  
	  
Pseudomonas	  aeruginosa*	   53.9	   49	   22.03	   37.44	   37.44	  
	  
Streptococcus	  pneumoniae*	   8.22	   12.9	   7.056	   11.99	   49.42	  
	  
Streptococcus	  sanguinis	  group*	   8.53	   9.5	   5.603	   9.521	   58.95	  
	  
Prevotella	  melaninogenica*	   9.35	   5.12	   5.128	   8.714	   67.66	  
	  
Porphyromonas	  catoniae	   4.91	   2.99	   3.142	   5.339	   73	  
	  
Veillonella	  parvula*	   1.21	   5.41	   2.605	   4.426	   77.42	  
	  
Fusobacterium	  nucleatum	   2.03	   2.76	   2.215	   3.763	   81.19	  
	  
Enterobacter	  cowanii	   0.0144	   2.51	   1.262	   2.144	   83.33	  
	  
Stenotrophomonas	  maltophilia	   2.37	   0.141	   1.225	   2.082	   85.41	  
	  
Prevotella	  enoeca	   0.559	   0.915	   0.7029	   1.194	   86.61	  
	  
Prevotella	  oris	   1.22	   0.315	   0.6859	   1.165	   87.77	  
	  
Staphylococcus	  aureus	   0.0172	   1.13	   0.5699	   0.9683	   88.74	  
	  
Bacteroides	  oleiciplenus	  	   0.784	   0.546	   0.5613	   0.9537	   89.7	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Table 7.3.1. Continued 
B	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







2	   3	  
	  
Pseudomonas	  aeruginosa*	   49	   57.2	   21.81	   37.33	   37.33	  
	  
Streptococcus	  pneumoniae*	   12.9	   12	   8.164	   13.97	   51.3	  
	  
Streptococcus	  sanguinis	  group*	   9.5	   3.37	   4.57	   7.823	   59.13	  
	  
Prevotella	  melaninogenica*	   5.12	   4.5	   3.452	   5.91	   65.04	  
	  
Veillonella	  parvula*	   5.41	   4.07	   3.387	   5.798	   70.84	  
	  
Enterobacter	  cowanii	   2.51	   3.95	   3.061	   5.239	   76.07	  
	  
Fusobacterium	  nucleatum	   2.76	   2.09	   2.259	   3.867	   79.94	  
	  
Porphyromonas	  catoniae	   2.99	   0.89	   1.726	   2.954	   82.9	  
	  
Staphylococcus	  aureus	   1.13	   1.66	   1.339	   2.293	   85.19	  
	  
Prevotella	  enoeca	   0.915	   1.04	   0.9239	   1.582	   86.77	  
	  
Achromobacter	  xylosoxidans	  	   0.19	   1.03	   0.5872	   1.005	   87.77	  
	  
Haemophilus	  parainfluenzae	   0.381	   0.828	   0.546	   0.9346	   88.71	  
	  
Barnesiella	  intestinihominis	   0.269	   0.844	   0.5298	   0.9069	   89.62	  
	  




	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







3	   4	  
	  
Pseudomonas	  aeruginosa*	   57.2	   61.9	   21.2	   38.84	   38.84	  
	  
Streptococcus	  pneumoniae*	   12	   9.4	   7.706	   14.12	   52.96	  
	  
Fusobacterium	  nucleatum	   2.09	   6.92	   4.206	   7.706	   60.67	  
	  
Prevotella	  melaninogenica*	   4.5	   3.53	   3.247	   5.949	   66.62	  
	  
Veillonella	  parvula*	   4.07	   4.2	   2.974	   5.45	   72.07	  
	  
Streptococcus	  sanguinis	  group*	   3.37	   3.37	   2.319	   4.249	   76.32	  
	  
Enterobacter	  cowanii	   3.95	   0.0414	   1.987	   3.64	   79.96	  
	  
Porphyromonas	  catoniae	   0.89	   3.15	   1.842	   3.374	   83.33	  
	  
Prevotella	  enoeca	   1.04	   1.84	   1.323	   2.424	   85.76	  
	  
Staphylococcus	  aureus	   1.66	   0.0042	   0.8324	   1.525	   87.28	  
	  
Achromobacter	  xylosoxidans	  	   1.03	   0.309	   0.6343	   1.162	   88.45	  
	  
Stenotrophomonas	  maltophilia	   0.904	   0.0233	   0.4585	   0.8402	   89.29	  
	  
Haemophilus	  parainfluenzae	   0.828	   0.116	   0.449	   0.8227	   90.11	  
	  
Barnesiella	  intestinihominis	   0.844	   0.0338	   0.4308	   0.7894	   90.9	  
 1 
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Table 7.3.1. Continued 
D	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







4	   1b	  
	  
Pseudomonas	  aeruginosa*	   61.9	   53.5	   20.4	   37.42	   37.42	  
	  
Streptococcus	  pneumoniae*	   9.4	   9.45	   6.589	   12.08	   49.5	  
	  
Fusobacterium	  nucleatum	   6.92	   3.94	   4.838	   8.872	   58.38	  
	  
Streptococcus	  sanguinis	  group*	   3.37	   9.44	   4.448	   8.157	   66.53	  
	  
Prevotella	  melaninogenica*	   3.53	   4.78	   3.238	   5.939	   72.47	  
	  
Porphyromonas	  catoniae	   3.15	   2	   2.154	   3.951	   76.42	  
	  
Veillonella	  parvula*	   4.2	   1.3	   2.133	   3.912	   80.34	  
	  
Prevotella	  enoeca	   1.84	   1.69	   1.539	   2.823	   83.16	  
	  
Stenotrophomonas	  maltophilia	   0.0233	   1.79	   0.8973	   1.646	   84.8	  
	  
Staphylococcus	  aureus	   0.0042	   1.76	   0.8823	   1.618	   86.42	  
	  
Neisseria	  mucosa	   0.155	   1.44	   0.766	   1.405	   87.83	  
	  
Nocardia	  cyriacigeorgica	   0.00775	   1.27	   0.6387	   1.171	   89	  
	  
Prevotella	  oris	   0.598	   0.742	   0.5766	   1.058	   90.06	  
	  




	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   1b	  
	  
Pseudomonas	  aeruginosa*	   53.9	   53.5	   21.43	   37.7	   37.7	  
	  
Streptococcus	  pneumoniae*	   8.22	   9.45	   5.889	   10.36	   48.06	  
	  
Streptococcus	  sanguinis	  group*	   8.53	   9.44	   5.508	   9.689	   57.75	  
	  
Prevotella	  melaninogenica*	   9.35	   4.78	   5.048	   8.879	   66.63	  
	  
Porphyromonas	  catoniae	   4.91	   2	   2.72	   4.785	   71.41	  
	  
Fusobacterium	  nucleatum	   2.03	   3.94	   2.717	   4.779	   76.19	  
	  
Stenotrophomonas	  maltophilia	   2.37	   1.79	   1.953	   3.436	   79.63	  
	  
Prevotella	  enoeca	   0.559	   1.69	   1.049	   1.846	   81.47	  
	  
Neisseria	  mucosa	   0.717	   1.44	   1.004	   1.766	   83.24	  
	  
Veillonella	  parvula*	   1.21	   1.3	   0.8938	   1.572	   84.81	  
	  
Staphylococcus	  aureus	   0.0172	   1.76	   0.8881	   1.562	   86.37	  
	  
Prevotella	  oris	   1.22	   0.742	   0.8703	   1.531	   87.91	  
	  
Nocardia	  cyriacigeorgica	   0.00321	   1.27	   0.6369	   1.12	   89.03	  
	  
Parvimonas	  micros	   0.333	   0.685	   0.4852	   0.8535	   89.88	  
	  
Bacteroides	  oleiciplenus	  	   0.784	   0.321	   0.476	   0.8373	   90.72	  
 1 
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Table 7.3.2 Similarity of percentages (SIMPER) analysis of the bacterial dissimilarity 
(Bray-Curtis) of the common taxa group between disease states. 
Given is the mean % abundance of sequences for each OTU across the periods they were 
observed to occupy. In addition, the average dissimilarity between periods is given. 
Percentage contribution is calculated from the mean contribution divided by the mean 
dissimilarity between periods. A) SIMPER analysis of the common group between period 1a 
and 2, B) SIMPER analysis of the common group between period 2 and 3, C) SIMPER 
analysis of the common group between period 3 and 4, D) SIMPER analysis of the common 
group between period 4 and 1b, E) SIMPER analysis of the common group between period 
1a and 1b. Organisms in bold are considered to be recognised CF pathogens. 
A	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   2	  
	  
Pseudomonas	  aeruginosa	   53.9	   49	   27.55	   51.44	   51.44	  
	  
Streptococcus	  pneumoniae	   8.22	   12.9	   8.933	   16.68	   68.11	  
	  
Streptococcus	  sanguinis	  
group	   8.53	   9.5	   7.075	   13.21	   81.32	  
	  
Prevotella	  melaninogenica	   9.35	   5.12	   6.701	   12.51	   93.83	  
	  




	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







2	   3	  
	  
Pseudomonas	  aeruginosa	   49	   57.2	   28.05	   52.72	   52.72	  
	  
Streptococcus	  pneumoniae	   12.9	   12	   10.4	   19.54	   72.26	  
	  
Streptococcus	  sanguinis	  
group	   9.5	   3.37	   5.866	   11.02	   83.28	  
	  
Veillonella	  parvula	   5.41	   4.07	   4.461	   8.383	   91.66	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Table 7.3.2. Continued 
C	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







3	   4	  
	  
Pseudomonas	  aeruginosa	   57.2	   61.9	   28.3	   57.46	   57.46	  
	  
Streptococcus	  pneumoniae	   12	   9.4	   9.852	   20	   77.46	  
	  
Prevotella	  melaninogenica	   4.5	   3.53	   4.152	   8.431	   85.89	  
	  
Veillonella	  parvula	   4.07	   4.2	   3.919	   7.957	   93.85	  
	  
Streptococcus	  sanguinis	  




	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







4	   1b	  
	  
Pseudomonas	  aeruginosa	   61.9	   53.5	   27.59	   56.28	   56.28	  
	  
Streptococcus	  pneumoniae	   9.4	   9.45	   8.492	   17.32	   73.61	  
	  
Streptococcus	  sanguinis	  
group	   3.37	   9.44	   5.907	   12.05	   85.66	  
	  
Prevotella	  melaninogenica	   3.53	   4.78	   4.211	   8.59	   94.25	  
	  




	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   1b	  
	  
Pseudomonas	  aeruginosa	   53.9	   53.5	   28.16	   54.87	   54.87	  
	  
Streptococcus	  pneumoniae	   8.22	   9.45	   7.685	   14.97	   69.84	  
	  
Streptococcus	  sanguinis	  
group	   8.53	   9.44	   7.275	   14.17	   84.02	  
	  
Prevotella	  melaninogenica	   9.35	   4.78	   6.892	   13.43	   97.44	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Table 7.3.3 Similarity of percentages (SIMPER) analysis of the bacterial dissimilarity 
(Bray-Curtis) of the rare taxa group between disease states. 
Given is the mean % abundance of sequences for each OTU across the periods they were 
observed to occupy. In addition, the average dissimilarity between periods is given. 
Percentage contribution is calculated from the mean contribution divided by the mean 
dissimilarity between periods. A) SIMPER analysis of the rare group between period 1a and 
2, B) SIMPER analysis of the rare group between period 2 and 3, C) SIMPER analysis of the 
rare group between period 3 and 4, D) SIMPER analysis of the rare group between period 4 
and 1b, E) SIMPER analysis of the rare group between period 1a and 1b. Organisms in bold 
are considered to be recognised CF pathogens 
A	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   2	  
	  
Porphyromonas	  catoniae	   4.91	   2.99	   17.67	   19.48	   19.48	  
	  
Fusobacterium	  nucleatum	   2.03	   2.76	   6.669	   7.352	   26.84	  
	  
Stenotrophomonas	  maltophilia	   2.37	   0.141	   5.237	   5.773	   32.61	  
	  
Enterobacter	  cowanii	   0.0144	   2.51	   4.923	   5.428	   38.04	  
	  
Prevotella	  oris	   1.22	   0.315	   3.649	   4.023	   42.06	  
	  
Bacteroides	  oleiciplenus	  	   0.784	   0.546	   3.486	   3.843	   45.9	  
	  
Megasphaera	  micronuciformis	   0.729	   0.352	   3.429	   3.78	   49.68	  
	  
Haemophilus	  parainfluenzae	   0.0138	   0.381	   2.926	   3.226	   52.91	  
	  
Gemella	  sanguinis	   0.183	   0.489	   2.905	   3.203	   56.11	  
	  
Capnocytophaga	  sputigena	   0.123	   0.506	   2.786	   3.071	   59.18	  
	  
Prevotella	  maculosa	   0.74	   0.255	   2.584	   2.849	   62.03	  
	  
Prevotella	  pallens	   0.471	   0.401	   2.427	   2.676	   64.71	  
	  
Staphylococcus	  aureus	   0.0172	   1.13	   2.413	   2.66	   67.37	  
	  
Prevotella	  nanceiensis	   0.305	   0.349	   2.09	   2.304	   69.67	  
	  
Neisseria	  mucosa	   0.717	   0.177	   2.064	   2.275	   71.95	  
	  
Granulicatella	  adiacens	   0.308	   0.199	   2.049	   2.259	   74.21	  
	  
Capnocytophaga	  granulosa	   0.17	   0.409	   2.043	   2.253	   76.46	  
	  
Prevotella	  enoeca	   0.559	   0.915	   1.722	   1.898	   78.36	  
	  
Oribacterium	  sinus	   0.257	   0.139	   1.593	   1.757	   80.12	  
	  
Achromobacter	  xylosoxidans	  	   0.028	   0.19	   1.323	   1.459	   81.57	  
	  
Prevotella	  loescheii	   0.283	   0.123	   1.251	   1.379	   82.95	  
	  
Nocardia	  cyriacigeorgica	   0.00321	   0.181	   1.243	   1.37	   84.32	  
	  
Parvimonas	  micros	   0.333	   0.521	   1.117	   1.232	   85.56	  
	  
Porphyromonas	  endodontalis	   0.416	   0.0559	   1.026	   1.132	   86.69	  
	  
Lachnoanaerobaculum	  orale	   0.218	   0.149	   0.9714	   1.071	   87.76	  
	  
Actinomyces	  odontolyticus	   0.282	   0.0664	   0.9427	   1.039	   88.8	  
	  
Barnesiella	  intestinihominis	   0.00679	   0.269	   0.7411	   0.8171	   89.62	  
	  
Prevotella	  nigrescens	   0.242	   0.112	   0.7262	   0.8007	   90.42	  
 1  
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Table 7.3.3 Continued 
B) SIMPER analysis of the rare group between period 2 (30 days prior to antibiotic treatment 
for CFPE) and 3 (Treatment) 
B	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







2	   3	  
	  
Porphyromonas	  catoniae	   2.99	   0.89	   11.28	   12.19	   12.19	  
	  
Enterobacter	  cowanii	   2.51	   3.95	   9.412	   10.17	   22.36	  
	  
Fusobacterium	  nucleatum	   2.76	   2.09	   6.643	   7.177	   29.53	  
	  
Haemophilus	  parainfluenzae	   0.381	   0.828	   4.675	   5.051	   34.58	  
	  
Staphylococcus	  aureus	   1.13	   1.66	   4.652	   5.026	   39.61	  
	  
Achromobacter	  xylosoxidans	  	   0.19	   1.03	   4.033	   4.357	   43.97	  
	  
Prevotella	  pallens	   0.401	   0.559	   3.035	   3.279	   47.25	  
	  
Prevotella	  enoeca	   0.915	   1.04	   2.904	   3.137	   50.38	  
	  
Capnocytophaga	  sputigena	   0.506	   0.0623	   2.851	   3.08	   53.46	  
	  
Gemella	  sanguinis	   0.489	   0.147	   2.801	   3.026	   56.49	  
	  
Barnesiella	  intestinihominis	   0.269	   0.844	   2.748	   2.968	   59.46	  
	  
Capnocytophaga	  granulosa	   0.409	   0.263	   2.61	   2.819	   62.28	  
	  
Prevotella	  nanceiensis	   0.349	   0.404	   2.494	   2.694	   64.97	  
	  
Megasphaera	  micronuciformis	   0.352	   0.196	   2.404	   2.598	   67.57	  
	  
Bacteroides	  oleiciplenus	  	   0.546	   0.183	   2.34	   2.528	   70.1	  
	  
Prevotella	  oris	   0.315	   0.347	   2.176	   2.351	   72.45	  
	  
Stenotrophomonas	  maltophilia	   0.141	   0.904	   2.135	   2.306	   74.75	  
	  
Neisseria	  mucosa	   0.177	   0.228	   1.901	   2.054	   76.81	  
	  
Prevotella	  maculosa	   0.255	   0.294	   1.856	   2.005	   78.81	  
	  
Granulicatella	  adiacens	   0.199	   0.0668	   1.5	   1.621	   80.43	  
	  
Nocardia	  cyriacigeorgica	   0.181	   0.00366	   1.283	   1.386	   81.82	  
	  
Oribacterium	  sinus	   0.139	   0.0538	   1.263	   1.365	   83.18	  
	  
Lachnoanaerobaculum	  orale	   0.149	   0.252	   1.144	   1.236	   84.42	  
	  
Prevotella	  loescheii	   0.123	   0.2	   0.9566	   1.033	   85.45	  
	  
Parvimonas	  micros	   0.521	   0.107	   0.7968	   0.8607	   86.31	  
	  
Prevotella	  nigrescens	   0.112	   0.114	   0.6742	   0.7283	   87.04	  
	  
Clostridium	  cellobioparum	   0.017	   0.192	   0.6735	   0.7276	   87.77	  
	  
Atopobium	  parvulum	   0.0605	   0.0537	   0.5502	   0.5944	   88.36	  
	  
Actinomyces	  odontolyticus	   0.0664	   0.0785	   0.5133	   0.5545	   88.92	  
	  
Haemophilus	  influenzae	   0.0569	   0.00545	   0.5119	   0.553	   89.47	  
	  
Clostridium	  lavalense	   0.066	   0.125	   0.4467	   0.4825	   89.95	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Table 7.3.3 Continued 
C) SIMPER analysis of the rare group between period 3 (treatment) and 4 (30 days post 
treatment for CFPE) 
C	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







3	   4	  
	  
Fusobacterium	  nucleatum	   2.09	   6.92	   11.65	   12.39	   12.39	  
	  
Porphyromonas	  catoniae	   0.89	   3.15	   11.09	   11.79	   24.19	  
	  
Achromobacter	  xylosoxidans	  	   1.03	   0.309	   5.699	   6.062	   30.25	  
	  
Enterobacter	  cowanii	   3.95	   0.0414	   5.65	   6.01	   36.26	  
	  
Haemophilus	  parainfluenzae	   0.828	   0.116	   4.529	   4.818	   41.08	  
	  
Prevotella	  enoeca	   1.04	   1.84	   4.412	   4.693	   45.77	  
	  
Barnesiella	  intestinihominis	   0.844	   0.0338	   3.267	   3.475	   49.25	  
	  
Capnocytophaga	  granulosa	   0.263	   0.336	   3.238	   3.444	   52.69	  
	  
Prevotella	  oris	   0.347	   0.598	   2.748	   2.923	   55.61	  
	  
Prevotella	  pallens	   0.559	   0.122	   2.705	   2.877	   58.49	  
	  
Staphylococcus	  aureus	   1.66	   0.0042	   2.653	   2.822	   61.31	  
	  
Neisseria	  mucosa	   0.228	   0.155	   2.499	   2.658	   63.97	  
	  
Prevotella	  maculosa	   0.294	   0.242	   2.438	   2.594	   66.56	  
	  
Capnocytophaga	  sputigena	   0.0623	   0.518	   2.262	   2.406	   68.97	  
	  
Prevotella	  nanceiensis	   0.404	   0.167	   2.183	   2.323	   71.29	  
	  
Gemella	  sanguinis	   0.147	   0.248	   2.093	   2.226	   73.52	  
	  
Stenotrophomonas	  maltophilia	   0.904	   0.0233	   1.942	   2.066	   75.58	  
	  
Megasphaera	  micronuciformis	   0.196	   0.156	   1.787	   1.901	   77.49	  
	  
Lachnoanaerobaculum	  orale	   0.252	   0.127	   1.526	   1.623	   79.11	  
	  
Granulicatella	  adiacens	   0.0668	   0.131	   1.485	   1.58	   80.69	  
	  
Bacteroides	  oleiciplenus	  	   0.183	   0.241	   1.392	   1.48	   82.17	  
	  
Sneathia	  sanguinegens	   0.163	   0.706	   1.102	   1.172	   83.34	  
	  
Prevotella	  loescheii	   0.2	   0.0527	   1.034	   1.1	   84.44	  
	  
Prevotella	  nigrescens	   0.114	   0.154	   1.014	   1.079	   85.52	  
	  
Oribacterium	  sinus	   0.0538	   0.0814	   0.6996	   0.7442	   86.26	  
	  
Atopobium	  parvulum	   0.0537	   0.0531	   0.6717	   0.7145	   86.98	  
	  
Actinomyces	  odontolyticus	   0.0785	   0.079	   0.6314	   0.6716	   87.65	  
	  
Clostridium	  cellobioparum	   0.192	   0	   0.6281	   0.6682	   88.32	  
	  
Haemophilus	  influenzae	   0.00545	   0.0212	   0.5675	   0.6036	   88.92	  
	  
Parvimonas	  micros	   0.107	   0.295	   0.4805	   0.5111	   89.43	  
	  
Pseudomonas	  fragi	   0.00966	   0	   0.38	   0.4042	   89.84	  
	  
Prevotella	  oralis	   0.137	   0.0829	   0.377	   0.401	   90.24	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Table 7.3.3 Continued 
D) SIMPER analysis of the rare group between period 4  (30 days post treatment for CFPE) 
and 1b (Stable post-CFPE) 
D	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







4	   1b	  
	  
Porphyromonas	  catoniae	   3.15	   2	   14.6	   15.95	   15.95	  
	  
Fusobacterium	  nucleatum	   6.92	   3.94	   13.11	   14.32	   30.27	  
	  
Prevotella	  enoeca	   1.84	   1.69	   4.462	   4.873	   35.14	  
	  
Achromobacter	  xylosoxidans	  	   0.309	   0.338	   4.239	   4.63	   39.77	  
	  
Nocardia	  cyriacigeorgica	   0.00775	   1.27	   4.105	   4.483	   44.25	  
	  
Granulicatella	  adiacens	   0.131	   0.446	   3.765	   4.112	   48.37	  
	  
Stenotrophomonas	  maltophilia	   0.0233	   1.79	   3.392	   3.704	   52.07	  
	  
Gemella	  sanguinis	   0.248	   0.54	   3.378	   3.689	   55.76	  
	  
Prevotella	  oris	   0.598	   0.742	   3.094	   3.379	   59.14	  
	  
Neisseria	  mucosa	   0.155	   1.44	   3.035	   3.315	   62.45	  
	  
Oribacterium	  sinus	   0.0814	   0.358	   2.458	   2.685	   65.14	  
	  
Staphylococcus	  aureus	   0.0042	   1.76	   2.185	   2.387	   67.53	  
	  
Bacteroides	  oleiciplenus	  	   0.241	   0.321	   2.16	   2.359	   69.88	  
	  
Capnocytophaga	  sputigena	   0.518	   0.0937	   2.059	   2.249	   72.13	  
	  
Prevotella	  maculosa	   0.242	   0.225	   1.97	   2.152	   74.29	  
	  
Capnocytophaga	  granulosa	   0.336	   0.0911	   1.794	   1.959	   76.24	  
	  
Haemophilus	  parainfluenzae	   0.116	   0.295	   1.669	   1.822	   78.07	  
	  
Actinomyces	  odontolyticus	   0.079	   0.247	   1.662	   1.815	   79.88	  
	  
Sneathia	  sanguinegens	   0.706	   0.49	   1.506	   1.644	   81.53	  
	  
Prevotella	  nanceiensis	   0.167	   0.221	   1.381	   1.508	   83.04	  
	  
Megasphaera	  micronuciformis	   0.156	   0.238	   1.378	   1.505	   84.54	  
	  
Parvimonas	  micros	   0.295	   0.685	   1.197	   1.307	   85.85	  
	  
Atopobium	  parvulum	   0.0531	   0.102	   1.119	   1.222	   87.07	  
	  
Prevotella	  nigrescens	   0.154	   0.493	   1.086	   1.186	   88.26	  
	  
Prevotella	  denticola	   0.0059	   0.135	   0.9884	   1.08	   89.33	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Table 7.3.3 Continued 
E) SIMPER analysis of the rare group between period 1a (Stable pre-CFPE) and 1b (Stable 
post-CFPE) 
E	  
	   	   	   	   	   	  
	   Taxon	  	  
%	  Mean	  







1a	   1b	  
	  
Porphyromonas	  catoniae	   4.91	   2	   16.61	   18.35	   18.35	  
	  
Fusobacterium	  nucleatum	   2.03	   3.94	   8.157	   9.008	   27.36	  
	  
Stenotrophomonas	  maltophilia	   2.37	   1.79	   7.242	   7.998	   35.35	  
	  
Prevotella	  oris	   1.22	   0.742	   4.451	   4.915	   40.27	  
	  
Granulicatella	  adiacens	   0.308	   0.446	   3.744	   4.135	   44.4	  
	  
Nocardia	  cyriacigeorgica	   0.00321	   1.27	   3.696	   4.082	   48.49	  
	  
Neisseria	  mucosa	   0.717	   1.44	   3.25	   3.589	   52.07	  
	  
Bacteroides	  oleiciplenus	  	   0.784	   0.321	   3.107	   3.431	   55.51	  
	  
Gemella	  sanguinis	   0.183	   0.54	   3.045	   3.362	   58.87	  
	  
Prevotella	  enoeca	   0.559	   1.69	   3.042	   3.36	   62.23	  
	  
Achromobacter	  xylosoxidans	  	   0.028	   0.338	   2.668	   2.946	   65.17	  
	  
Prevotella	  maculosa	   0.74	   0.225	   2.551	   2.818	   67.99	  
	  
Oribacterium	  sinus	   0.257	   0.358	   2.506	   2.768	   70.76	  
	  
Megasphaera	  micronuciformis	   0.729	   0.238	   2.393	   2.643	   73.4	  
	  
Staphylococcus	  aureus	   0.0172	   1.76	   2.237	   2.47	   75.87	  
	  
Actinomyces	  odontolyticus	   0.282	   0.247	   1.832	   2.023	   77.89	  
	  
Prevotella	  pallens	   0.471	   0.156	   1.654	   1.827	   79.72	  
	  
Prevotella	  nanceiensis	   0.305	   0.221	   1.431	   1.58	   81.3	  
	  
Parvimonas	  micros	   0.333	   0.685	   1.307	   1.443	   82.74	  
	  
Atopobium	  parvulum	   0.0627	   0.102	   1.167	   1.288	   84.03	  
	  
Porphyromonas	  endodontalis	   0.416	   0.072	   1.108	   1.223	   85.26	  
	  
Prevotella	  nigrescens	   0.242	   0.493	   1.081	   1.193	   86.45	  
	  
Prevotella	  denticola	   0.0533	   0.135	   1.036	   1.145	   87.59	  
	  
Capnocytophaga	  granulosa	   0.17	   0.0911	   0.977	   1.079	   88.67	  
	  
Lachnoanaerobaculum	  orale	   0.218	   0.122	   0.9638	   1.064	   89.74	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7.3.5 Mixed effect models 
Despite observing no significant changes in the core group by disease period (Table 7.3), 
SIMPER analysis revealed possible changes in the percentage contribution of individual 
OTUs within the core group. To investigate how the abundance of individual OTUs changed 
between disease periods mixed effect models were used. These models allow the inclusion 
of both fixed (disease period) and random effects (Patient) allowing the variation between 
patients to be accounted for within the model. The five taxa partitioned into the common 
group were modelled to examine how the relative abundance of these changed over the 5 
disease periods, Figure 7.3.  
As shown in Figure 7.3, there was no significant difference in the proportional abundance of 
P. aeruginosa prior, or during intervention for CFPE. A significant increase was observed in 
the proportional abundance of P. aeruginosa (100%) after the treatment period (period 4) 
however, this returned to baseline after the 30 day period. No significant change in the 
proportional abundance of S. pneumonia was observed over the five disease periods. A 
significant decrease in the proportional abundance of S. sanguinis group (82%) and P. 
melaninogenica (59%) was observed during the treatment period (3). However, V. parvula 
was found to show a significant increase in proportional abundance prior to the start of 
treatment (264%). The proportional abundance remained significantly higher for period 3 
(129%) and 4 (400%), with a slight decrease being observed during treatment.  
SIMPER analysis indicated the percentage contribution of P. catoniae, the most 
proportionally abundant of the rare group, decreased during the treatment period. This was 
also supported by the results of the mixed effect modelling, which revealed the proportional 
abundance of P. catoniae significantly decreased (60%) during the treatment period, before 
recovery leading into the post CFPE stable period. 
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Figure 7.3 Trends in the relative abundance of bacterial taxa with change in disease 
period.  
Parameters are extracted from mixed-effects models based on 237 samples from 12 
patients. 1a) Stable pre-CFPE, 2) 30 days prior to antibiotic treatment, 3) period of time 
patients were receiving treatment for pulmonary exacerbation, 4) 30 days post treatment, 1b) 
Stable post-CFPE. ** P<0.001, *=P<0.05. ‡ indicates OTU was partitioned as rare.  
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7.4 Discussion 
Spatial studies have informed our understanding of the bacterial community within the CF 
lung, revealing a complex and highly variable system. However, in order to understand the 
progressive nature of CF lung disease and how this relates to changes in bacterial 
community dynamics, it is important to investigate how the community changes over time. 
Several recent studies have been published that attempt to understand the bacterial 
community dynamics within the CF lung (5, 15-19). While these investigations have provided 
valuable information, they have several limitations, typically, they have relied on point 
samples to be representative of a given disease state (e.g. baseline or exacerbation), which 
fails to account for variation in microbiota structure and composition within a disease period. 
By collecting samples and associated metadata at more frequent intervals this study was 
able to not only account for variation within the bacterial community over time but also 
investigate how this relates to changes in disease state.         
Despite efforts to investigate change in the bacterial community due to CFPE, the findings of 
studies by Fodor et al (2012) Carmody et al (2013) Price et al (2013) and Zhao et al (2012), 
were limited (5, 15, 18, 19). Fodor et al (2012) and Carmody et al (2013) compared paired 
samples from patients, leading into or during treatment for CFPE (15, 18). While Fodor et al 
(2012) showed no significant change in the bacterial density or composition from the start to 
the end of treatment for CFPE (15), Carmody et al (2013) revealed that changes in the 
bacterial community, from baseline leading into CFPE was highly variable depending on 
bacterial diversity and composition (18). While these studies are informative they have been 
shown to have inherent limitations. Carmody et al (2013) state the limitations of their study, 
including the frequency of the sample collection, which failed to allow fluctuations in the 
airway microbiota to be accounted for (18). On top of this, both these studies fail to 
investigate bacterial changes across an entire CFPE, concentrating instead on the treatment 
period and lead in respectively, they fail to address the issues of how treatment effects the 
bacterial community and if the community returns to its baseline state post treatment. 
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Studies by Zhao et al (2012) and Price et al (2013), aimed to examine changes in the 
bacterial community over the course of an exacerbation using the “BETR” classification; 
baseline (B), exacerbation prior to treatment (E), treatment (T) and into recovery (R) (5, 19). 
While Zhao et al, 2012, used these clearly defined parameters of each disease period (5), 
Price et al (2013) failed to clearly define the recovery period, simply collecting samples at the 
next routine quarterly visit (19). These studies provided a more complete picture of changes 
in the bacterial community over the course of CFPE. However, Zhao et al (2012) failed to 
follow a single exacerbation from start to finish for any given patient and therefore revealed 
little about specific changes in the bacterial community (5). Whereas Price et al (2013) 
examined changes in community composition over a single exacerbation, revealing a stable 
bacterial community this study. Even so, this work neglected to account for the fluctuations in 
the community identified previously (19).  
In order to address how the bacterial community changes from baseline and across the full 
cycle of CFPE back to baseline, which has not been previously studied, samples were 
collected from CF patients over the course of a year. This collection regimen included 
several samples collected when patients were considered to be stable as well as multiple 
samples that were collected leading into, during and out of a CFPE, giving a more complete 
picture of the exacerbation event. The collection of multiple samples allows a more complete 
assessment of short term variation within the community, therefore allowing true shifts in the 
bacterial community composition to be observed.  
It has been well established in previous studies that the metacommunity within the CF lung 
shows a distinct divide between common and locally abundant species and those that are 
rare or transient (3, 26). As explained in Chapter 3.4, such studies used a Poisson 
distribution to establish the core-satellite groups within the community. However, due to the 
tendency for this analysis to assign some species with low persistence but uniform 
abundance as core, a more intuitive approach based on the positive persistence abundance 
relationship was employed. This approach partitioned only the species appearing in more 
than 75% of the samples into the common group. Partitioning all samples revealed five 
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species common OTUs; Pseudomonas aeruginosa, Streptococcus pneumonia, S. sanguinis 
group, Prevotella melaninogenica and Veillonella parvula. This common group was found to 
account for the majority of the sequence abundance. However, the majority of diversity was 
accounted for by the rare group. Interestingly, over the five clinical periods the common 
group was found to be relatively stable, with only V. parvula   and P. melaninogenica falling 
into the rare group during the treatment period. However, none of the members of the rare 
group were found to move into the core.   
As expected, bacterial community turnover within the lung was never completely stable 
however, rates of OTU turnover were found to be more consistent over the stable periods, 
and show more variation surrounding, and throughout the treatment for CFPE. Changes in 
species richness were hypothesised to drive the changes in the rate of turnover. To explore 
this further the turnover rates for the common and rare taxa were calculated. While the 
common OTUs were found to be conserved over the study period, the much more diverse, 
rare group was found to be highly variable, driving the turnover rates observed in the whole 
community.  
The Bray-Curtis measure of similarity was used to compare changes in community 
composition over the study period, allowing a quantitative measure of similarity to be 
calculated. Over the five clinical periods, no change in similarity was observed when either 
the whole community or common group were examined. However, significant differences 
were seen within the rare group. Importantly these changes occurred leading into, during 
and out of CFPE. However, no significant differences in similarity between the stable 
periods, pre and post CFPE were observed. These findings underline the importance of 
partitioning the data, as the contribution of the rare taxa to community composition would be 
neglected without this distinction. If partitioning had been carried out by Stressmann et al 
(2012), more variation in the community composition may have been observed (16).   
Failure of the common group to show any significant change over the study period indicates 
resistance of that group to perturbations within the lung. Resistance of ecological 
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communities to change is defined as the degree to which a microbial community can resist 
change as a result of community perturbations (27). The abundance of these common taxa 
results in this pattern of resistance being reflected in the whole community, and as a result 
masks changes in the rare group. While the common group shows resistance to 
perturbations the data suggests that the rare group shows resilience. Resilience of 
ecological communities to change is defined as the rate at which the microbial community 
composition returns to the baseline after perturbation (27). This resilience indicates that over 
the short term the bacterial community within the lung can, despite the influence of CFPE 
and interventions, recover to the previous baseline community composition. These findings 
are reflected in the results observed when examining rates of taxa turnover. 
There are two plausible explanations of how the rare taxa can return to baseline after the 
initiation of CFPE and treatment. The first is that species recolonise the lung through 
immigration from the upper airways and/or oral cavity, the second is that populations of rare 
taxa are not totally eradicated by antibiotic intervention and have fallen below the detection 
threshold, thereby allowing the species to re-establish after the termination of antibiotic 
intervention. It is probable that both of these explanations will be the case for different rare 
taxa. 
From the community level analysis it is clear that the common group shows high resistance 
to community perturbations. However, the changes in individual species influence on 
percentage dissimilarity indicated that subtle changes in the abundance of individual species 
could be occurring. In order to investigate this mixed effect models, with a negative binomial 
error structure, were used to examine how individual species from the common group were 
affected by perturbation at the population level. The most persistent of the rare species 
group was included also in this analysis due to their high abundance, observed in the 
persistence abundance plots, along with the high percentage contribution to community 
similarity, shown in the SIMPER analysis.  
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Infection with P. aeruginosa has been highlighted by numerous studies to be a key factor in 
poor clinical outcomes and is one of the main targets for treatment. It is therefore surprising 
that its abundance remained high across all clinical periods, even showing a significant 
increase in abundance after the treatment period. While the relative abundance from high 
throughput sequencing data of a given taxa may not be considered strictly quantitative, Price 
et al (2013) clearly demonstrated a highly significant correlation for P. aeruginosa between 
the results of qPCR analysis and sequencing data (19). Therefore, coupled with the PMA 
treatment, ruling out artefacts of cell death as a result of antibiotic intervention, confidence 
can be taken that this represents a true reflection of the P. aeruginosa population over all 
disease periods. One possible explanation for the increase in abundance of P. aeruginosa 
observed after the conclusion of treatment is that antibiotic treatment has lead to a reduction 
in the abundance of other taxa, thereby allowing P. aeruginosa to take advantage of newly 
available niche space. Even so, the abundance in P. aeruginosa returns to baseline after the 
30 day post treatment period, due to the resilience of members of the rare group.    
Similarly, no change in the abundance of Streptococcus pneumoniae was observed over the 
disease period. However, members of the Streptococcus sanguinis group were found to 
significantly decrease during the treatment period. This abundance only returned to baseline 
after the 30 day post treatment period, suggesting that the initiation of treatment is having an 
effect on the abundance of the members of the Streptococcus sanguinis group but that the 
group is resilient and is able to re-establish and return to previous baseline abundance.  
This resilience of individual taxa to CFPE is also observed when examining the changes in 
Porphyromonas catoniae, Prevotella melaninogenica and Veillonella parvula. However, while 
the abundance of Porphyromonas catoniae simply decreases significantly during treatment 
and then returns to baseline levels, the abundance of Prevotella melaninogenica and V. 
parvula significantly changed prior to the initiation of intervention. During the lead in to 
exacerbation, a significant decrease in the abundance of Prevotella melaninogenica was 
observed, while a significant increase was seen in V. parvula. While both these taxa are 
resilient and return to baseline during the 30 day period after the conclusion of treatment 
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period, the significant changes observed prior to the start of exacerbation makes them 
potential biomarkers of disease state.  
The lack of a generally applicable definition of CFPE is a major problem for the timely 
treatment of exacerbations. Work by Sanders et al (2010) has already established that in 
many cases patients suffering from CFPE will fail to return to baseline lung function following 
treatment however, earlier identification, and therefore treatment, can improve patient 
outcomes and increase the likelihood of lung function recovery (28). This failure to recover 
lung function after CFPE, despite the return of the bacterial community to baseline, may be a 
result to incremental lung damage due to inflammatory responses and not be associated 
directly with the bacterial community. The advances in DNA based technologies has 
promoted their use in molecular diagnostics allowing disease associated biomarkers to be 
used to identify, predict and monitor changes in infections (29). The identification of 
biomarkers for CFPE could be a potentially important route to improve the identification and 
therefore outcomes for CF patients.  
Two potential biomarkers for disease state, Prevotella melaninogenica and Veillonella 
parvula, were identified due to their significant change from baseline prior to the start of 
antibiotic intervention. While both these species may be useful, the large (264%) increase in 
the abundance of V. parvula observed in this study make it the more promising of the two 
species. More detailed work into this area is required to examine the potential of these 
species for use as a diagnostic tool. Development of targeted qPCR based analysis is 
required to check the efficacy of these species as a molecular diagnostic tool for detecting 
the onset of CFPE.  
Here, examination of changes in the bacterial community across the entire span of CFPE 
has revealed valuable insight into how the bacterial community reacts to perturbations within 
the lung. While the common species are found to be resistant, the rare are resilient to CFPE 
perturbations. Examination at the common species group level has not only revealed 
potentially two novel biomarkers for changes in disease state but has also revealed that key 
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recognised CF pathogen P. aeruginosa is, in essence, unaffected by a change in disease 
state. 
While the resistance and resilience of the common and rare group is of concern with regards 
to treatment, of particular concern to clinicians will be the lack of substantial change in P. 
aeruginosa.  As antibiotics administered in response to the worsening symptoms associated 
with CFPE are predominantly targeted at P. aeruginosa. These findings suggest that 
clinicians may need to re-examine intervention regimens. From a fundamental perspective 
the bacterial community may not be the whole story. The wider microbial community needs 
to be considered through investigations into the roles of bacteria, fungi and respiratory 
viruses, alongside markers of host immune response. Studies of this nature could reveal the 
underlying cause or causes of CFPE. It may well be the case that there is no consistent 
factor (infection or host) across CFPE, within or between patients.  
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7.6 Appendix  
Table A7.1 The raw sequence data reported in this Chapter have been deposited in the 
European Nucleotide Archive short read database  
Study Accession Numbers ERP005251 and ERP007059, and Sample Accession Numbers 
ERS421603 and ERS551400. A list of barcodes used and their associated samples are 
shown below.  
Barcode Sputum ID Sample No Patient Date Exacerbation 
CAACTCATCGTA 01_006 6 1 14-Jun-06 1 
TACTACATGGTC 01_031 31 1 08-Sep-06 1 
ATGACCATCGTG 01_055 55 1 27-Oct-06 1 
AGAGTCCTGAGC 01_075 75 1 18-Dec-06 1 
ACTATTGTCACG 01_078 78 1 03-Jan-07 2 
AGAACACGTCTC 01_081 81 1 10-Jan-07 2 
AGCACACCTACA 01_084 84 1 17-Jan-07 2 
AGCTCTCAGAGG 01_087 87 1 24-Jan-07 2 
AGTCTCGCATAT 01_089 89 1 26-Jan-07 3 
ATCGATCTGTGG 01_091 91 1 28-Jan-07 3 
ATAGGCGATCTC 01_093 93 1 30-Jan-07 3 
AGTTCTACGTCA 01_095 95 1 02-Feb-07 3 
TAGTGCTGCGTA 01_096 96 1 03-Feb-07 3 
CAAGATCGACTC 01_097 97 1 05-Feb-07 3 
ATGTGCACGACT 01_099 99 1 07-Feb-07 3 
ATGCCTGAGCAG 01_100 100 1 09-Feb-07 3 
GTCGCTGTCTTC 01_101 101 1 12-Feb-07 3 
AGTTCAGACGCT 01_112 112 1 19-Mar-07 4 
ATCCTCAGTAGT 01_114 114 1 21-Mar-07 5 
ATAGCTCCATAC 01_116 116 1 26-Mar-07 5 
TAGTCGTCTAGT 01_117 117 1 28-Mar-07 5 
ACATCACTTAGC 02_003 3 2 07-Jun-06 1 
ACGGTGAGTGTC 02_020 20 2 12-Jul-06 1 
AGGCTACACGAC 02_022 22 2 24-Jul-06 1 
ACTCGATTCGAT 02_051 51 2 06-Oct-06 1 
TAGCACACCTAT 02_061 61 2 30-Oct-06 1 
CATATACTCGCA 02_073 73 2 27-Nov-06 1 
AGTTCTACGTCA 02_084 84 2 22-Dec-06 1 
ACTTGTAGCAGC 02_090 90 2 12-Jan-07 1 
AGTGAGAGAAGC 02_095 95 2 24-Jan-07 2 
ATAATCTCGTCG 02_098 98 2 31-Jan-07 2 
ATATCGCTACTG 02_101 101 2 07-Feb-07 2 
ATCGCGGACGAT 02_103 103 2 12-Feb-07 2 
ATCTTAGACTGC 02_106a 106 2 16-Feb-07 3 
GTCTTCGTCGCT 02_108 108 2 18-Feb-07 3 
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Table A7.1 Continued 
Barcode Sputum ID Sample No Patient Date Exacerbation 
ATGCGTAGTGCG 02_109a 109 2 19-Feb-07 3 
ATGTGTCGACTT 02_111 111 2 21-Feb-07 3 
TAGCGACATCTG 02_112 112 2 22-Feb-07 3 
AGTGCGATGCGT 02_115 115 2 25-Feb-07 3 
ATACACGTGGCG 02_118 118 2 28-Feb-07 3 
ATATGCCAGTGC 02_122 122 2 07-Mar-07 4 
ATCGCTCGAGGA 02_125 125 2 14-Mar-07 4 
ATGACTCATTCG 02_128 128 2 21-Mar-07 4 
AGATGTTCTGCT 02_131 131 2 28-Mar-07 5 
ACTAGCTCCATA 02_137 137 2 16-Apr-07 5 
CATCATGAGGCT 02_153 153 2 25-May-07 5 
TACCGCTAGTAG 03_017 17 3 17-Jul-06 1 
ATTCTGTGAGCG 03_030 30 3 16-Aug-06 1 
TAGACTGTACTC 03_040 40 3 18-Sep-06 1 
ATCTACTACACG 03_054 54 3 20-Oct-06 1 
ATGTCACCGTGA 03_063 63 3 17-Nov-06 1 
TAGCGGATCACG 03_072 72 3 08-Dec-06 1 
GTCTCTCTACGC 03_085 85 3 15-Jan-07 1 
AGAGTAGCTAAG 03_110 110 3 19-Mar-07 1 
GTTCGCGTATAG 03_135 135 3 25-May-07 1 
GTTGACGACAGC 05_002 2 4 14-Jul-06 1 
TACGGTATGTCT 05_012 12 4 07-Aug-06 1 
AGCTATCCACGA 05_014 14 4 30-Aug-06 2 
ACGATGCGACCA 05_016 16 4 04-Sep-06 2 
AGATCTCTGCAT 05_018 18 4 06-Sep-06 2 
ACTGTGACTTCA 05_021 21 4 13-Sep-06 3 
ACTACGTGTGGT 05_023 23 4 15-Sep-06 3 
ACGCGATACTGG 05_024 24 4 17-Sep-06 3 
ACATGTCACGTG 05_026 26 4 19-Sep-06 3 
ACACGAGCCACA 05_028 28 4 21-Sep-06 3 
AGTCACATCACT 05_030 30 4 23-Sep-06 3 
AGCGTAGGTCGT 05_034 34 4 27-Sep-06 3 
AGATCGGCTCGA 05_036 36 4 29-Sep-06 3 
ACTGTCGAAGCT 05_038 38 4 01-Oct-06 3 
ACTACAGCCTAT 05_040 40 4 03-Oct-06 3 
ACGCAACTGCTA 05_041 41 4 04-Oct-06 3 
TACACACATGGC 05_044 44 4 09-Oct-06 3 
ACACATGTCTAC 05_045 45 4 11-Oct-06 3 
AGTAGTATCCTC 05_047 47 4 13-Oct-06 3 
AGCGCTGATGTG 05_049 49 4 15-Oct-06 3 
AGATACACGCGC 05_051 51 4 17-Oct-06 3 
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Table A7.1 Continued 
Barcode Sputum ID Sample No Patient Date Exacerbation 
ACTGTACGCGTA 05_053 53 4 19-Oct-06 3 
ACGTTAGCACAC 05_055 55 4 21-Oct-06 3 
ACGATGCGACCA 05_060 60 4 27-Oct-06 4 
ACATCACTTAGC 05_062 62 4 01-Nov-06 4 
ACACACTATGGC 05_065 65 4 08-Nov-06 4 
AGTACTGCAGGC 05_068 68 4 15-Nov-06 4 
AATCGTGACTCG 05_079 79 4 01-Dec-06 5 
ATACGTCTTCGA 05_088 88 4 08-Jan-07 5 
AGAACACGTCTC 05_098 98 4 05-Feb-07 5 
GTTAGAGCACTC 05_112 112 4 01-Mar-07 5 
ACGTTAGCACAC 05_125 125 4 28-Mar-07 5 
AGCACACCTACA 05_130 130 4 27-Apr-07 5 
AACTGTGCGTAC 05_138 138 4 21-May-07 5 
ATGCCTGAGCAG 05_139 139 4 23-May-07 5 
TACATCACCACA 06_006 6 5 26-Jul-06 1 
ACGCTATCTGGA 06_021 21 5 13-Sep-06 1 
ACAGAGTCGGCT 06_030 30 5 13-Oct-06 1 
ATCGTACAACTC 06_061 61 5 10-Jan-07 1 
AGCATATGAGAG 06_067 67 5 29-Jan-07 1 
AGTCTACTCTGA 06_072 72 5 12-Feb-07 1 
AGTCCATAGCTG 06_079 79 5 28-Feb-07 2 
ACACGGTGTCTA 06_081 81 5 05-Mar-07 2 
ATCACTAGTCAC 06_082 82 5 09-Mar-07 2 
ACATTCAGCGCA 06_083 83 5 14-Mar-07 2 
ACGCGCAGATAC 06_086a 86 5 20-Mar-07 2 
ACTTGTAGCAGC 06_087 87 5 21-Mar-07 3 
AGATGTTCTGCT 06_089 89 5 23-Mar-07 3 
AGCTCCATACAG 06_090 90 5 24-Mar-07 3 
ACACTAGATCCG 06_094 94 5 28-Mar-07 3 
ACCACATACATC 06_096 96 5 30-Mar-07 3 
ACCACATACATC 06_100 100 5 13-Apr-07 4 
ACGCTATCTGGA 06_102 102 5 18-Apr-07 4 
ACTATTGTCACG 06_112 112 5 30-May-07 5 
ACGAGTGCTATC 06_125 125 5 09-Jul-07 5 
TAAGCGCAGCAC 07_015 15 6 06-Sep-06 1 
TAGCGACATCTG 07_036 36 6 13-Oct-06 1 
AGCGACTGTGCA 07_053 53 6 22-Nov-06 2 
AGAGTAGCTAAG 07_056 56 6 29-Nov-06 2 
ACTGACAGCCAT 07_059 59 6 06-Dec-06 2 
ACGTGAGAGAAT 07_062 62 6 12-Dec-06 2 
ACAGTGCTTCAT 07_065 65 6 15-Dec-06 3 
CATGGCTACACA 07_066 66 6 17-Dec-06 3 
AATCAGTCTCGT 07_067 67 6 18-Dec-06 3 
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Table A7.1 Continued 
Barcode Sputum ID Sample No Patient Date Exacerbation 
AGGTGTGATCGC 07_068 68 6 19-Dec-06 3 
AGCCATACTGAC 07_071 71 6 27-Dec-06 4 
ACTCTTCTAGAG 07_073 73 6 05-Jan-07 4 
AGAGCAAGAGCA 07_075 75 6 10-Jan-07 4 
TACTAATCTGCG 07_077 77 6 15-Jan-07 4 
ATCTGAGCTGGT 07_085 85 6 02-Feb-07 5 
CATGAGTGCTAC 07_094 94 6 23-Feb-07 5 
ATGCGTAGTGCG 07_122 122 6 20-Apr-07 5 
TAACTCTGATGC 07_137 137 6 30-May-07 5 
TAGTCGTCTAGT 08_022 22 7 18-Sep-06 1 
TAACAGTCGCTG 08_033 33 7 18-Oct-06 1 
TAGAGAGAGTGG 08_086 86 7 02-Mar-07 1 
TAGATAGCAGGA 08_097 97 7 28-Mar-07 1 
TACTTACTGCAG 08_109 109 7 30-Apr-07 1 
GTGTCTACATTG 08_121 121 7 01-Jun-07 1 
ACAGTTGCGCGA 09_005 5 8 31-Jul-06 1 
ACTGATCCTAGT 09_009 9 8 09-Aug-06 1 
ACACTAGATCCG 09_017 17 8 30-Aug-06 1 
AGTACTGCAGGC 09_027 27 8 22-Sep-06 1 
AAGAGATGTCGA 09_047 47 8 27-Oct-06 1 
ATGGCAGCTCTA 09_055 55 8 15-Nov-06 2 
ATTATCGTGCAC 09_061 61 8 29-Nov-06 2 
TAGCGGATCACG 09_064 64 8 06-Dec-06 2 
AGTGGATGCTCT 09_066 66 8 08-Dec-06 3 
ATACAGAGCTCC 09_068 68 8 10-Dec-06 3 
ATCACGTAGCGG 09_071 71 8 12-Dec-06 3 
ATCGTACAACTC 09_075 75 8 17-Dec-06 3 
ATGAGACTCCAC 09_076 76 8 18-Dec-06 4 
ATGGCGTGCACA 09_078 78 8 22-Dec-06 4 
ATTCTGTGAGCG 09_080 80 8 03-Jan-07 4 
TAGCTCGTAACT 09_082 82 8 08-Jan-07 4 
AGTGTCACGGTG 09_085 85 8 15-Jan-07 4 
AGTAGTATCCTC 09_087 87 8 22-Jan-07 5 
GTCTCATGTAGG 09_120 120 8 21-Mar-07 5 
TAGTGTGCTTCA 09_133 133 8 08-Apr-07 5 
ACCTCGATCAGA 09_156 156 8 17-May-07 5 
AGTCTCGCATAT 09_160 160 8 31-May-07 5 
ACGTACTCAGTG 09_163 163 8 06-Jun-07 5 
AGCAGTCGCGAT 09_303 303 8 27-Jun-07 5 
ATGTGTCGACTT 10_001 1 9 16-Aug-06 1 
CATATCGCAGTT 10_063 63 9 05-Jan-07 1 
ACAGCAGTGGTC 10_067 67 9 15-Jan-07 1 
CATCGTATCAAC 10_083 83 9 21-Feb-07 1 
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Table A7.1 Continued 
Barcode Sputum ID Sample No Patient Date Exacerbation 
TAGTGCTGCGTA 10_124 124 9 21-May-07 1 
GTTGTATACTCG 10_130 130 9 06-Jun-07 1 
ACCTCGATCAGA 10_138 138 9 25-Jun-07 2 
ACGTACTCAGTG 10_141 141 9 02-Jul-07 2 
ACTCGCACAGGA 10_144 144 9 09-Jul-07 2 
AGAGAGCAAGTG 10_147 147 9 15-Jul-07 3 
AGCATATGAGAG 10_149 149 9 17-Jul-07 3 
AGGCTACACGAC 10_150 150 9 18-Jul-07 3 
AAGCTGCAGTCG 10_153 153 9 23-Jul-07 3 
ACAGCTAGCTTG 10_157 157 9 01-Aug-07 4 
ACCTGTCTCTCT 10_160 160 9 08-Aug-07 4 
ACGTCTGTAGCA 10_162 162 9 13-Aug-07 4 
ATGAGACTCCAC 11_006 6 10 18-Sep-06 1 
CAACTCATCGTA 11_025 25 10 01-Nov-06 2 
ATACAGAGCTCC 11_027 27 10 06-Nov-06 2 
ATGTCACCGTGA 11_028 28 10 08-Nov-06 2 
ATGCAGCTCAGT 11_032 32 10 17-Nov-06 2 
ATCTGAGCTGGT 11_035 35 10 24-Nov-06 2 
ATCCGATCACAG 11_036 36 10 25-Nov-06 3 
ATACTCACTCAG 11_040 40 10 29-Nov-06 3 
AGTTAGTGCGTC 11_041 41 10 30-Nov-06 3 
TAGGTATCTCAC 11_045 45 10 04-Dec-06 3 
CAACTATCAGCT 11_046 46 10 05-Dec-06 3 
ATGTACGGCGAC 11_051 51 10 13-Dec-06 4 
ATGCACTGGCGA 11_055 55 10 22-Dec-06 4 
ATCTCTGGCATA 11_057 57 10 03-Jan-07 4 
TACAGTCTCATG 11_113 113 10 09-Apr-07 5 
GTGATAGTGCCG 11_127 139 10 09-May-07 5 
ATGATCGAGAGA 11_154 154 10 13-Jul-07 5 
GTCTATCGGAGT 11_163 163 10 15-Aug-07 5 
ATCTGGTGCTAT 12_002 2 11 08-Oct-06 1 
AGTGGATGCTCT 12_023 23 11 14-Nov-06 1 
ACTCAGATACTC 12_037 37 11 10-Jan-07 2 
AGCGAGCTATCT 12_038 38 11 11-Jan-07 2 
AGACGTGCACTG 12_040 40 11 17-Jan-07 2 
AGCAGCACTTGT 12_042 42 11 21-Jan-07 2 
AGCTTGACAGCT 12_046 46 11 31-Jan-07 2 
AACTGTGCGTAC 12_048 48 11 02-Feb-07 3 
ACAGAGTCGGCT 12_050 50 11 04-Feb-07 3 
ACCGCAGAGTCA 12_051 51 11 05-Feb-07 3 
ACGGTGAGTGTC 12_054 54 11 08-Feb-07 3 
ACTCGATTCGAT 12_056 56 11 10-Feb-07 3 
AGACTGCGTACT 12_058 58 11 12-Feb-07 3 
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Table A7.1 Continued 
Barcode Sputum ID Sample No Patient Date Exacerbation 
AGCAGTCGCGAT 12_061 61 11 15-Feb-07 3 
AGGACGCACTGT 12_064 64 11 22-Feb-07 4 
AAGAGATGTCGA 12_066 66 11 28-Feb-07 4 
ACTGTACGCGTA 12_067 67 11 01-Mar-07 4 
ACAGCAGTGGTC 12_069 69 11 07-Mar-07 4 
ATCACGTAGCGG 12_082 82 11 23-Mar-07 5 
ACACACTATGGC 12_083 83 11 15-Apr-07 5 
ACTCGCACAGGA 12_108 108 11 06-Jun-07 5 
ACCGCAGAGTCA 12_110 110 11 27-Sep-07 5 
AGTGTCACGGTG 12_115 115 11 10-Oct-07 5 
ACGCGCAGATAC 13_002 2 12 06-Oct-06 1 
AGTTCAGACGCT 13_011 11 12 27-Oct-06 1 
TACGTGTACGTG 13_038 38 12 20-Dec-06 1 
AGACTGCGTACT 13_051 51 12 24-Jan-07 1 
GTGGCGATACAC 13_060 60 12 14-Feb-07 1 
ATACGTCTTCGA 13_068 68 12 05-Mar-07 2 
ATCACTAGTCAC 13_071 71 12 12-Mar-07 2 
ATCCTCAGTAGT 13_072 72 12 14-Mar-07 2 
ATCTACTACACG 13_074 74 12 19-Mar-07 2 
ATGATCGAGAGA 13_077 77 12 26-Mar-07 2 
ATGGTCTACTAC 13_079 79 12 28-Mar-07 3 
CAACACGCACGA 13_081 81 12 30-Mar-07 3 
TAGCTGAGTCCA 13_083 83 12 01-Apr-07 3 
AGTGTTCGATCG 13_086 86 12 04-Apr-07 3 
AGCTCTCAGAGG 13_090 90 12 18-Apr-07 4 
ATACTATTGCGC 13_091 91 12 20-Apr-07 4 
ATCAGGCGTGTG 13_094 94 12 27-Apr-07 4 
ACGTGCCGTAGA 13_099 99 12 11-May-07 5 
TACGATGACCAC 13_106 106 12 30-May-07 5 
ATGGTCTACTAC 13_113 113 12 11-Jun-07 5 
ACATTCAGCGCA 13_142 142 12 17-Aug-07 5 
ACACGGTGTCTA 13_149 149 12 05-Sep-07 5 
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Table A7.2 Species-level identities of detected bacterial taxa identified from 237 
sputum samples collected from CF patients.  
Given the length of the ribosomal sequences analysed, these identities should be considered 
putative. Ae denotes aerobe and An, Anaerobe. Only strict anaerobes were classified as 
anaerobes, whereas aerobes, facultative anaerobes, and microaerophiles were classified as 
aerobes. 
Class Family Taxon name Common or Rare 
Anaerobe
/ Aerobe 
Actinobacteria Actinomycetaceae Actinobaculum massiliense Rare Ae 
  Actinomyces graevenitzii Rare Ae 
  Actinomyces naeslundii Rare Ae 
  Actinomyces odontolyticus Rare Ae 
 Bifidobacteriaceae Scardovia inopinata Rare Ae 
 Coriobacteriaceae Atopobium parvulum Rare An 
 Corynebacteriaceae Corynebacterium durum Rare Ae 
  Corynebacterium matruchotii Rare Ae 
  
Corynebacterium 
tuberculostearicum Rare Ae 
 Microbacteriaceae Microbacterium paraoxydans Rare Ae 
 Micrococcaceae Arthrobacter tumbae Rare An 
  Rothia mucilaginosa Rare Ae 
 Nocardiaceae Nocardia cyriacigeorgica Rare An 
 Propionibacteriaceae Propionibacterium acidifaciens Rare An 
  Propionibacterium acnes Rare An 
  Propionibacterium propionicum Rare Ae 
Alphaproteobacteria Brucellaceae Ochrobactrum anthropi Rare Ae 
 Caulobacteraceae Brevundimonas vesicularis Rare Ae 
 Rhodobacteraceae Paracoccus yeei Rare Ae 
 Sphingomonadaceae Sphingobium amiense Rare An 
  Sphingomonas paucimobilis Rare An 
Bacilli Aerococcaceae Abiotrophia defectiva Rare Ae 
 Bacillaceae Bacillus subtilis Rare Ae 
  Gemella sanguinis Rare Ae 
 Carnobacteriaceae Granulicatella adiacens Rare Ae 
 Lactobacillaceae Lactobacillus casei Rare Ae 
  Lactobacillus delbrueckii Rare Ae 
  Lactobacillus frumenti Rare Ae 
  Lactobacillus johnsonii Rare Ae 
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Table A7.2 Continued 
Class Family Taxon name Common or Rare 
Anaerobe
/ Aerobe 
  Lactobacillus salivarius Rare Ae 
 Staphylococcaceae Staphylococcus aureus Rare Ae 
 Streptococcaceae Streptococcus agalactiae Rare An 
  Streptococcus mutans Rare An 
  Streptococcus pneumoniae Common An 
  Streptococcus sanguinis group Common An 
Bacteroidia Bacteroidaceae Bacteroides acidofaciens Rare An 
  Bacteroides cellulosilyticus Rare An 
  Bacteroides intestinalis Rare An 
  Bacteroides oleiciplenus Rare An 
  Bacteroides uniformis Rare An 
 Porphyromonadaceae Barnesiella intestinihominis Rare An 
  Odoribacter laneus Rare an 
  Paludibacter propionicigenes Rare An 
  Parabacteroides distasonis Rare Ae 
  Parabacteroides goldsteinii Rare Ae 
  Porphyromonas catoniae Rare An 
  Porphyromonas endodontalis Rare An 
  Porphyromonas somerae Rare An 
  Tannerella forsythia Rare An 
 Prevotellaceae Prevotella bivia Rare An 
  Prevotella buccae Rare An 
  Prevotella copri Rare An 
  Prevotella denticola Rare An 
  Prevotella enoeca Rare An 
  Prevotella histicola Rare An 
  Prevotella loescheii Rare An 
  Prevotella maculosa Rare An 
  Prevotella melaninogenica Common An 
  Prevotella nanceiensis Rare An 
  Prevotella nigrescens Rare An 
  Prevotella oralis Rare An 
  Prevotella oris Rare An 
  Prevotella oulorum Rare An 
  Prevotella pallens Rare An 
  Prevotella paludivivens Rare An 
  Prevotella shahii Rare An 
  Prevotella tannerae Rare An 
 Rikenellaceae Alistipes finegoldii Rare An 
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Table A7.2 Continued 
Class Family Taxon name Common or Rare 
Anaerobe
/ Aerobe 
Betaproteobacteria Alcaligenaceae Achromobacter xylosoxidans Rare Ae 
  Advenella mimigardefordensis Rare Ae 
 Burkholderiaceae Burkholderia cepacia complex Rare Ae 
  Lautropia mirabilis Rare Ae 
  Ralstonia mannitolilytica Rare Ae 
 
Burkholderiales incertae 
sedis Aquabacterium fontiphilum Rare Ae 
 Comamonadaceae Comamonas testosteroni Rare Ae 
  Curvibacter lanceolatus Rare Ae 
  Delftia acidovorans Rare Ae 
 Neisseriaceae Kingella oralis Rare Ae 
  Neisseria mucosa Rare Ae 
  Neisseria oralis Rare Ae 
 Sutterellaceae Parasutterella excrementihominis Rare An 
Clostridia Clostridiaceae Anaerococcus octavius Rare An 
  Clostridium aerotolerans Rare An 
  Clostridium aldenense Rare An 
  Clostridium algidixylanolyticum Rare An 
  Clostridium bolteae Rare An 
  Clostridium celerecrescens Rare An 
  Clostridium cellobioparum Rare An 
  Clostridium clostridioforme Rare An 
  Clostridium hathewayi Rare An 
  Clostridium indolis Rare An 
  Clostridium lavalense Rare An 
  Clostridium orbiscindens Rare An 
  Clostridium papyrosolvens Rare  
  Clostridium piliforme Rare An 
  Clostridium populeti Rare An 
  Clostridium proteoclasticum Rare An 
  Clostridium scindens Rare An 
  Clostridium subterminale Rare An 
  Clostridium sufflavum Rare An 
  Clostridium tertium Rare An 
  Finegoldia magna Rare An 
  Mogibacterium neglectum Rare An 
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Table A7.2 Continued 
Class Family Taxon name Common or Rare 
Anaerobe
/ Aerobe 
  Parvimonas micros Rare An 
  Peptoniphilus lacrimalis Rare An 
 Eubacteriaceae Eubacterium brachy Rare An 
  Eubacterium sulci Rare An 
  Eubacterium ventriosum Rare An 
 Lachnospiraceae Anaerostipes butyraticus Rare An 
  Blautia obeum Rare An 
  Catonella morbi Rare An 
  Howardella ureilytica Rare An 
  Lachnoanaerobaculum orale Rare An 
  Oribacterium sinus Rare An 
  Robinsoniella peoriensis Rare An 
  Shuttleworthia satelles Rare An 
  Stomatobaculum longum Rare An 
 Peptococcaceae Peptococcus niger Rare An 
 Peptostreptococcaceae Peptostreptococcus stomatis Rare An 
 Ruminococcaceae Pseudoflavonifractor capillosus Rare Ae 
  Ruminococcus flavefaciens Rare An 
Deltaproteobacteria Bdellovibrionaceae Vampirovibrio chlorellavorus Rare Ae 
Epsilonproteobacteria Campylobacteraceae Campylobacter concisus Rare Ae 
  Campylobacter curvus Rare Ae 
  Campylobacter showae Rare Ae 
Erysipelotrichia Erysipelotrichaceae Eubacterium cylindroides Rare An 
Flavobacteria Flavobacteriaceae Capnocytophaga granulosa Rare Ae 
  Capnocytophaga ochracea Rare Ae 
  Capnocytophaga sputigena Rare Ae 
  Chryseobacterium indologenes Rare Ae 
Fusobacteria Fusobacteriaceae Fusobacterium necrophorum Rare An 
  Fusobacterium nucleatum Rare An 
 Leptotrichiaceae Leptotrichia buccalis Rare Ae 
  Sneathia sanguinegens Rare Ae 
Gammaproteobacteria Cardiobacteriaceae Cardiobacterium valvarum Rare Ae 
 Enterobacteriaceae Enterobacter cowanii Rare Ae 
  Proteus mirabilis Rare Ae 
  Yersinia frederiksenii Rare Ae 
 Moraxellaceae Acinetobacter johnsonii Rare Ae 
  Acinetobacter lwoffii Rare Ae 
  Moraxella nonliquefaciens Rare Ae 
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Table A7.2 Continued 
Class Family Taxon name Common or Rare 
Anaerobe
/ Aerobe 
  Moraxella osloensis Rare Ae 
 Pasteurellaceae Haemophilus influenzae Rare Ae 
  Haemophilus parainfluenzae Rare Ae 
 Pseudomonadaceae Pseudomonas aeruginosa Common Ae 
  Pseudomonas fragi Rare Ae 
  Pseudomonas pseudoalcaligenes Rare Ae 
 Xanthomonadaceae Stenotrophomonas maltophilia Rare An 
Mollicutes Mycoplasmataceae Mycoplasma hominis Rare Ae 
  Mycoplasma salivarium Rare An 
Negativicutes Veillonellaceae Anaeroglobus geminatus Rare An 
  Dialister invisus Rare Ae 
  Dialister micraerophilus Rare Ae 
  Dialister pneumosintes Rare Ae 
  Megasphaera micronuciformis Rare An 
  Schwartzia succinivorans Rare An 
  Selenomonas artemidis Rare An 
  Selenomonas noxia Rare An 
  Veillonella parvula Common An 
  Veillonella ratti Rare An 
Sphingobacteria Chitinophagaceae Sediminibacterium salmoneum Rare Ae 
 Sphingobacteriaceae Sphingobacterium spiritivorum Rare Ae 
Spirochaetes Spirochaetaceae Treponema denticola Rare Ae 
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Chronic respiratory infections are the main cause of morbidity and mortality in individuals 
suffering from cystic fibrosis. Improvements in the treatments available for CF has increased 
the median predicted survival age of these patients to 41.1 years of age (1). However, in 
order to increase this further a much greater understanding of the microbial community 
associated with this disease is required. The use of culture independent technologies in 
recent years has revealed a complex and diverse bacterial community within the CF lung, 
yet it is still unclear how this community is related to clinical outcomes.  
The main aim of this dissertation was to investigate the relationship between the bacterial 
community within the CF lung and host related clinical factors. By examining these 
relationships it was anticipated that this work would uncover potentially important factors that 
may influence treatment regimes and ultimately improve prognosis. This was achieved 
through high throughput sequencing of the bacterial community extracted from CF sputum. 
In this chapter the findings generated throughout this project will be discussed in relation to 
their potential impact on CF research.  
 
8.1 Reducing bias 
The aim of every researcher is to gain an unbiased representation of their chosen study 
system. It is possible to introduce bias at every level of sampling; from sample collection and 
storage, to DNA extraction, PCR and sequencing. As such, in order to be confident in the 
observed results efforts must be made to both understand and reduce the effect of potential 
bias. Consequently, throughout this study standard procedures including; extraction controls, 
both positive and negative PCR controls and reagent controls were included in every study 
and sequencing run (2). While these measures controlled for contamination during 
sequencing these actions alone would not account for all areas of potential bias; the most 
prevalent perhaps being the presences of extracellular DNA and sample handling.  
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8.1.1 Extracellular DNA 
The presence of extracellular DNA within the CF lung is inevitable due to immune responses 
and the continual administration of antibiotics, as well as the lack of ability to clear mucus 
from the airways. As a result, PMA was identified by Rogers et al (2008) as a potentially 
important method of reducing the impact of this extracellular DNA when investigating the 
bacterial community within the CF lung (3). Chapter 3 supports the findings of Roger et al 
(2013), confirming that failure to account for the presence of extracellular DNA or DNA from 
dead or damaged cells can result in a misrepresentation of the bacterial community either by 
an under or over estimation of the bacterial diversity (4).  
The use of PMA was also found to have significantly affected the abundance of common 
organisms, in particular the recognised CF pathogen Pseudomonas aeruginosa. These 
results show that failure to treat samples with PMA prior to culture independent analysis may 
result in the masking of important changes within the community. This in turn could lead to 
misrepresentative data and consequentially effect treatment decisions.  As a result of these 
findings, PMA treatment was used throughout this project.  
In Chapter 7, the use of PMA was particularly important as it allowed an unbiased overview 
of the effect of perturbations on the bacterial community within the lung. Without the use of 
PMA the impact of antibiotic treatment may have been masked by the amplification of non-
viable DNA from bacteria killed as a result of aggressive intervention. Consequently, studies 
such as that carried out by Fodor et al (2012), which failed to include PMA treatment, may 
have missed important changes in the overall community structure with antibiotic intervention 
for CFPE (5).    
8.1.2 Sample handling 
From the investigation of CF lung infections by culture based microbiology of sputum, it has 
been recognised that the storage and handling of clinical samples is vital to obtaining a 
representative depiction of the bacterial community (6). While studies have been undertaken 
to determine the optimal storage and transport of sputum for culture, few have investigated 
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the impact of sample handling prior to the use of culture independent techniques. As moves 
are made towards the introduction of these techniques for clinical diagnostics it is becoming 
more important than ever that samples are handled appropriately allowing the most accurate 
representation of the true bacterial community to be achieved (7).  
Due to the practicalities involved with processing samples for culture independent analysis 
samples are collected and stored at -80°C until processing. This ensures rapid stabilisation 
of the bacterial community from the time of freezing and for as long as necessary. In Chapter 
4, the bacterial community within sputum samples, frozen at intervals over a 72 hour period 
was assessed revealing significant changes the abundance of anaerobic taxa after storage 
at room temperature for more than 12 hours. Therefore, recommendations were made that 
respiratory samples should be stabilised to -80°C within 12 hours of collection in order to 
avoid significant changes in bacterial community composition.  
Obtaining large sample sets of respiratory samples with associated metadata is a huge 
undertaking both for researchers and clinicians. Consequently, the use of previously 
collected samples for multiple studies can provide a more practical option. As such, many 
clinics are collating large detailed biobanks of samples for research purposes. While these 
biobanks represent a wealth of potential information for researchers investigating a wide 
range of factors relating to CF lung infections they represent another avenue of bias.  
Once stored at -80°C, common practice dictated that sputum may be defrosted and 
subsampled once, after which they should no longer be refrozen and sub-sampled at a later 
date without occurring significant changes to the microbial community. However, no studies 
actually examined this relationship. By carrying out 6 freeze thaw cycles on sputum samples 
from eight patients, changes in the bacterial community as a result of these cycles were 
assessed in Chapter 5. No change in the whole bacterial community similarity was observed 
over 6 freeze-thaw cycles however, after 4 cycles the rare community fell below the level 
expected for within sample variation. As such sub-sampling should be carried out a 
maximum of 3 times in order to obtain an accurate representation of the bacterial community 
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within the respiratory tract. In the case of large volumes of sputum a more practical solution 
would be to aliquot the sample avoiding unnecessary freeze-thaw cycles. 
Chapters 3, 4 and 5, by assessing areas of potential bias, allowed the identification of 
guidelines for the storage and treatment of sputum samples prior to DNA based analysis. 
These guidelines directed clinicians and researchers to store samples as soon as possible 
after collection (within a 12 hour window) to only allow minimal freeze-thaw cycles when sub-
sampling sputum and to include PMA treatment in the processing of all sputum samples. 
These clearly researched guidelines provided strong evidence that the results presented in 
this thesis were a true, unbiased representation of the bacterial community.  
 
8.2 Understanding the metacommunity through data partitioning  
The idea of the metacommunity was first introduced into the analysis of bacterial 
communities within the CF lung by van der Gast et al (2011). By partitioning the bacterial 
community into the most common and abundant taxa, and those that are rare and transient, 
it became possible to uncover how the community was effected by a variety of factors. 
Throughout this work partitioning of the bacterial community has been used to identify 
patterns and determine the taxa responsible for the changes observed. Across all studies the 
use of partitioning revealed potentially important factors relating to the bacterial community 
that would have been missed had this partitioning not been implemented, this was 
particularly true of the rare OTUs.  
When considering the reduction of bias in the initial chapters discussed previously, failure to 
partition the bacterial community would have resulted in less conserved estimates of time to 
freezing and a failure to identify any change in the community over the 6 freeze-thaw cycles. 
This could have important consequences for future studies, where rare bacterial taxa may 
have been misrepresented within the community.  
The importance of partitioning data when analysing the bacterial community in relation to 
clinical factors was identified in the results of Chapters 6 and 7. For example in Chapter 6, 
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had partitioning not been undertaken the relationship between the bacterial community and 
gender would not have been identified. While this relationship requires further investigation, 
the identification of a bacterial community relationship with gender could be of enormous 
value in the treatment of CF lung disease. Further, when considering the bacterial 
community over the course of an exacerbation, partitioning of OTUs provided valuable 
insight into the dynamics of the bacterial community. It was shown that rate of species 
turnover was driven by the rare taxa, while patterns in community composition were 
controlled by the common organisms. Partitioning the data in this study allowed patterns of 
resilience in the rare to be revealed, a relationship unobserved by other studies. 
 
8.3 Relating bacterial community to clinical factors on a large 
scale 
Several relationships have been observed relating interpatient differences in the bacterial 
community to clinical factors however, the studies presenting these findings have lacked 
statistical power due the small sample sizes involved. For example both Delhaes et al (2012) 
and van der Gast et al (2011) identified a significant relationship between bacterial diversity 
and lung function however this relationship was based on the bacterial community of 4 and 
14 patients respectively (8, 9). Using bacterial community data from 292 individual CF 
patients previously described relationships, such as that between FEV1 (Forced expiratory 
volume in 1 second) and bacterial diversity, were examined to determine if these 
relationships were genuine or simply an artefact of the limited sample size used in these 
studies.  
Due to the huge size and complexity of the dataset investigated in Chapter 6, this thesis 
aimed to highlight preliminary findings. Consequently, throughout this section further work 
that could be undertaken to explore the relationships exposed by this study further are 
discussed.  
8.3.1 Bacterial diversity and lung function 
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As explained to above, a significant relationship between lung function and the bacterial 
community has previously been revealed (8, 9). Through the investigation of this relationship 
using a much larger dataset it was revealed that while a significant relationship is present 
between bacterial diversity and FEV1, the interpatient variation observed was such that the 
variance explained by this relationship was low. A significant correlation between bacterial 
community composition and lung function was also observed using Mantel tests, while partial 
Mantel tests revealed correlation between lung function and community composition when 
controlling for clinical status (stable or experiencing a CFPE), BMI and liver disease. A 
significant correlation between the rare taxa composition and FEV1 was also found when 
controlling for clinic location.  
Understanding the relationship between the bacterial community and lung function is 
important as FEV1 is considered to be the best predictor for mortality in CF individuals (10). 
As a decrease in lung function is associated with poor clinical outcomes, it is important to 
understand how this prognosis is related to the bacterial community and other clinical 
factors. By understanding this relationship it may be possible to identify risk factors to 
reduced lung function and treat patients accordingly. Further work on this area would involve 
the use of detailed multivariate analysis, where FEV1 and the 4 related clinical factors, 
identified using partial mantel testing, are used as explanatory variables. Additional 
investigation into the effect of individual bacterial taxa on the clinical factors may also reveal 
important relationships relating to disease outcomes.    
In addition to the relationships identified above, variation in the relationship between diversity 
and FEV1, could be further explained by investigating the relationship between the bacterial 
diversity, lung function and treatment regimes. This analysis could not only include 
investigation into the effect of antibiotic treatment regimes but also the effect of different 
methods for the administration as well as other treatments including, steroids and 
mucolytics.  
8.3.2 CFTR genotype and the bacterial community 
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CFTR (CF transmembrane regulator) genotype has been suggested as a potentially 
important factor in disease progression with some mutations found to correlate with more 
severe disease than others (11). In accordance with the knowledge of mutation frequency, at 
least one gene showed the ΔF508 mutation in the majority of patients, alongside this a large 
variation in other mutations were observed. As a result 3 groups were outlined; ΔF508 
homozygotes, ΔF508 heterozygotes and other mutations. However, only ANOSIM revealed 
a significant difference in community composition between patients with homozygous and 
heterozygous ΔF508 mutations (P=0.03).  
While this is not compelling evidence for genotype based differences in bacterial community, 
it does not rule out the relationship. By partitioning the ΔF508 heterozygotes into those 
associated with the severe CF phenotype and those associated with a milder phenotype, 
potential differences in the bacterial community could be uncovered.  
8.3.3 The gender gap and the bacterial community 
A so called gender gap has historically been observed been CF individuals, with females 
showing significantly worse prognosis than males (12, 13). Although this gap has become 
less pronounced more recently (14), an investigation was carried out to understand if the 
bacterial community was a factor in the disparity between genders. This analysis revealed 
that female patients had significantly lower bacterial diversity; while ANOSIM revealed a 
significant difference in the community composition of the rare taxa. Further analysis of the 
organisms responsible for the disparity between females and males revealed that the 
recognised CF pathogens Pseudomonas aeruginosa and Staphylococcus aureus had a 
higher mean abundance in female patients.  
The relationship between the bacterial community and gender warrants further investigation 
to explore the potential reasons for the differences in community diversity and composition 
observed. Firstly, the relationship between P. aeruginosa and S. aureus mean abundance 
and gender requires further study. It has been previously shown that co-infection with these 
organisms is associated with poor prognosis (15, 16), therefore examination of this 
relationship could potentially reveal an important reason for the gender gap. In addition, a 
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more in depth study of how the rare communities differ between genders may provide other 
potentially important species which contribute to the prognosis of females.  
 
8.3.4 The bacterial community by CF centre 
The relationship between the bacterial community and CF centres is complex and 
multifaceted involving geographic location, treatment regimes employed and environment 
surrounding the centre catchment area (e.g. urban or rural). As a result differences between 
CF centres are difficult to elucidate. In an attempt to identify any differences in the bacterial 
community between centres, bacterial diversity and community composition were explored. 
Although differences in bacterial diversity were observed, post-hoc testing revealed these 
differences were not consistent or ubiquitous between centres, rather they were more likely 
to be an artefact of interpatient variation than true differences between centres.  
Mantel test results suggested that patients from CF centres closer in geographic distance 
would show more similar bacterial communities. However, ANOSIM showed little evidence 
that this was the case. Even so it did reveal that the common taxa were more conserved 
between sites than those considered to be rare. These data suggested therefore that it is the 
rare community that drives differences by centre or geographical location. Further study 
would be required to determine if these transient organisms are associated with the 
surrounding environment of the centre.  
 
8.4 Bacterial community dynamics as a result of pulmonary 
exacerbation 
CF pulmonary exacerbations (CFPE) are associated with more rapid disease progression, 
aggressive antibiotic treatment and hospital stays, making them both medically and 
economically important phenomena (17). Using longitudinal sampling the bacterial 
community within the CF lung was examined over the full course of a CFPE; from baseline, 
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leading into exacerbation, treatment, leading out and back to baseline. This full cycle 
approach allowed both the lead in and the recovery to be examined for the first time.  
This study observed that the changes in the bacterial community were associated with 
changes in rare taxa. This was highlighted when investigating rates of species turnover as 
well as community composition over the study period. The rare group was shown to 
significantly change leading into, throughout and leading out of treatment for CFPE. It was 
also found to return to baseline levels within the 30 days after treatment had ceased, 
indicating resilience within the rare group.  
Taxa partitioned in the common group were found to be resistant to changes due to CFPE 
treatment however, when the relative abundance of these OTUs were examined individually 
key taxa, Prevotella melaninogenica and Veillonella parvula, were identified as potential 
biomarkers for CFPE. V. parvula was considered to be the most appropriate organism for 
further investigation due to the increase in abundance of this OTU prior to the initiation of 
treatment for CFPE.  
The association between CFPE and disease progression is a major concern in CF research, 
therefore the identification of CFPE is hugely important. With no consensus as to the clinical 
symptoms which indicate the start of CFPE, clinicians are required to make an antibiotic 
intervention judgement call based on worsening health. It is known that rapid intervention 
with antibiotic treatment results in the return of lung function to baseline states (18), however 
without a clear understanding of what causes a CFPE the initiation of rapid intervention is 
challenging. The identification of biomarkers for disease state could be the answer to this 
issue. By introducing a rapidly testable parameter for clinicians to identify a CFPE, a 
reduction in the use of unnecessary intervention could result. This in itself could provide one 
of the most important recent developments in CF therapy.    
The potential importance of these biomarkers (in particular V. parvula due to its rapid 
increase in abundance prior to the antibiotic treatment) cannot be underestimated. To 
investigate the potential of V. parvula, further work is required over the course of CFPE, this 
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includes using qPCR to track this organism, allowing a truly quantitative indication of the 
bacterial abundance, as well as large scale screening.  
 
8.5 Conclusions  
This thesis examined the bacterial community ecology within the CF lung through the use of 
next generation sequencing technologies (Roche 454 and Illumina MiSeq). This work was 
carried out in two sections, the first examined the importance of reducing bias in order to 
obtain the most representative depiction of the bacterial community. The results from the 
initial work were used to underpin work carried out in the second half of this project, which 
focused on the relationship between the bacterial community and clinical factors.  
Conclusions that can be drawn from this dissertation include; 
• The use of PMA is required to obtain a true picture of the bacterial community within 
the CF lung. 
• Sputum samples should be stored at -80°C within 12 hours of collection to avoid 
significant changes in the bacterial community. 
• Sputum samples for culture independent analysis should go through no more than 3 
freeze-thaw cycles to avoid significant changes in the rare taxa. 
• FEV1 is not a reliable indicator of bacterial diversity due to the levels of interpatient 
variation seen in CF patients. 
• Significant differences are observed in the rare bacterial community between 
females and males. 
• The common bacterial taxa are conserved between CF centres, however differences 
in the rare taxa are correlated with geographical distance.  
• Over the course of a pulmonary exacerbation the common bacterial taxa show 
resistance while the rare taxa show resilience.  
• Veillonella parvula has the potential to be a bioindicator of CFPE.  
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Through validated sampling methods this study has revealed several factors which have 
potential to inform treatment and improve prognosis. However, further research is 
required to investigate the full extent of this potential.   
 
8.6 Future work 
This project aimed to provide a greater understanding of the bacterial community within the 
CF lung. The complexity of the bacterial community throughout this investigation has 
informed the conclusion that while the bacterial community plays an important role in disease 
progression, assessment of the wider microbial diversity is required in order to understand 
CF lung disease progression more fully. Several studies have been published examining 
both bacteria and fungi within the CF lung (8, 19), however, no study to date has 
encompassed the whole microbiota including the bacterial, fungal and viral communities.  
Although a wider more microbial based assessment of the CF lung is important, there is also 
a real requirement for a more multi-disciplinary approach to assessing how the microbial 
community relates to disease state. By combining microbial data with immunological data as 
well as clinical metadata, real insight into the complexities of infection can be uncovered. 
Further, the use of metatranscriptomics to investigate gene function could potentially 
uncover important insights into microbial activates as well as diversity in response to 
perturbations within the lung.   
In order to gain meaningful data from studies of this nature, there is a requirement for large 
sample sets, to account for the degree of individual patient variation between individual 
patients. There is also a pressing need for the data sets to not just include adult patients but 
also young children (<10 years of age). Further, there is a need for large, longitudinal studies 
which sample patients over long periods, throughout times of stability and over the course of 
CFPE.  
Despite the pressing need for studies of this nature and size to be carried out, the 
organisation and time involved in collecting samples for these sorts of investigations would 
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be a huge commitment for any research group, most likely requiring several collaborating 
research centres and CF clinics in order to obtain the sample sizes required. Despite the 
work involved, CF research groups have to move towards studies of this nature in order to 
fully understand CF disease progression and ultimately it treatment.  
It must not be overlooked that CF makes up a very small percentage of the lower respiratory 
tract infections (LRTI) worldwide. LRTI and chronic obstructive pulmonary disease (COPD) 
are currently estimated by the world health organisation (WHO) to result in around 6.2 million 
deaths worldwide (3.1 million LRTI, 3.1 million COPD) (20). These numbers are staggering 
and underline the requirement for this type of research to be applied to a much wider range 
of pulmonary diseases, for example; COPD, bronchiectasis, bronchitis and severe asthma. 
Techniques and approaches presented throughout this thesis are already being applied to 
the bacterial communities of individuals with bronchiectasis and bronchitis (21, 22). The 
application of the knowledge gained in the study of CF to other respiratory disease has 
enormous potential to increase our understanding of lung disease and as a result reduce the 
associated mortality.  
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